Mini-gene therapy
By using recombinant adeno-associated viral vectors encoding CEP290 fragments and targeted inhibitory nucleic acids, the treatment problem of cilia, especially CEP290-associated ocular cilia, was solved, and significant improvement of cilia function and long-term rescue effect were achieved.
Patent Information
- Application Number
- CN202080037863.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-01-29
- Filing Date
- 2020-05-19
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2040-05-19
AI Technical Summary
Existing gene therapy methods are difficult to effectively treat cilia, especially due to the problems of large-size gene limitations and off-target effects, especially the lack of effective treatments for ophthalmic cilia associated with CEP290.
A recombinant adeno-associated virus (rAAV) vector encoding a CEP290 fragment was developed to bind inhibitory nucleic acids targeting endogenous gene variants associated with the disease for delivery to the subject's eyes to rescue cilia function.
By delivering CEP290 fragments, photoreceptor function and cilia length are significantly improved, providing a potential treatment for CEP290-related ophthalmic cilia, demonstrating rescue effects for up to 14 weeks.
Smart Images

Figure CN114206353B_ABST
Abstract
Description
[0001] Related applications
[0002] This application claims the benefit of U.S. Provisional Application Serial No. 62 / 967,521, filed January 29, 2020, 62 / 850,405, filed May 20, 2019, and 62 / 899,601, filed September 12, 2019, pursuant to 35 USC §119(e), the entire contents of which are incorporated herein by reference.
[0003] Government support
[0004] This invention was completed with government support under grant numbers EY029050, NS076991, AI100263, and HL131471 granted by the National Institutes of Health in the United States. The government holds certain rights to this invention.
[0005] background
[0006] Ciliopathies represent a group of diseases and conditions characterized by abnormal formation or function of cilia. For example, ocular ciliopathies can lead to retinal degeneration, vision loss, and / or blindness. Leber congenital amaurosis (LCA) associated with CEP290 is one of the most common and severe degenerative retinal diseases. However, there is currently no treatment or cure. Typically, the large size of cilia-related genes, such as the CEP290 gene (~8kb), limits the development of successful therapies using conventional adeno-associated virus (AAV) vector-mediated gene delivery methods, as the carrier size exceeds the ~4700bp packaging limit of rAAV. The use of genome editing (e.g., CRISPR / Cas9 methods) and antisense oligonucleotides may have off-target effects and is generally only applicable to one type of mutation in cilia-related genes. Therefore, novel compositions and methods are needed for the treatment of ciliopathies. Summary of the Invention
[0007] This disclosure relates to compositions and methods for delivering minigenes to a subject. Therefore, this disclosure is in part based on gene therapy vectors, such as viral (e.g., rAAV) vectors, which comprise one or more gene fragments (e.g., minigenes) encoding a therapeutic gene product (e.g., a protein or peptide). In some aspects, the gene therapy vector also comprises one or more repressive nucleic acids that target endogenous gene variants (e.g., mutants) (e.g., genes associated with cilia) related to a disease or condition. In some embodiments, the one or more repressive nucleic acids do not silence gene expression of the gene product encoded by the minigene. In some embodiments, methods are provided for treating cilia (e.g., ocular cilia), such as conditions and diseases characterized by mutations or deletions of cilia-related genes (e.g., the CEP290 gene associated with Leber's congenital amaurosis (LCA)).
[0008] Therefore, in some aspects, this disclosure relates to an isolated nucleic acid comprising a transgene encoding a CEP290 fragment having the amino acid sequence shown in any one of SEQ ID NO: 10-19 or 36.
[0009] In some embodiments, the CEP290 fragment is encoded by a nucleic acid having the sequence shown in any one of SEQ ID NO: 20-29 and 34-35. In some embodiments, the CEP290 fragment is encoded by a nucleic acid having the sequence shown in SEQ ID NO: 29 or 34. In some embodiments, the nucleic acid encodes a CEP290 protein fragment comprising amino acids 1-200 and 580-1180 of human CEP290. In some embodiments, the nucleic acid encodes a CEP290 protein fragment comprising amino acids 1-200 and 580-1180 of SEQ ID NO: 1. In some embodiments, the nucleic acid encodes a CEP290 protein fragment comprising the amino acid sequence shown in SEQ ID NO: 19 or composed of the amino acid sequence shown in SEQ ID NO: 19.
[0010] In some embodiments, the CEP290 fragment is encoded by a nucleic acid having the sequence shown in SEQ ID NO: 35. In some embodiments, the nucleic acid encodes a CEP290 protein fragment comprising amino acids 1-380 and 580-1180 of human CEP290. In some embodiments, the nucleic acid encodes a CEP290 protein fragment comprising amino acids 1-380 and 580-1180 of SEQ ID NO: 1. In some embodiments, the nucleic acid encodes a CEP290 protein fragment comprising the amino acid sequence shown in SEQ ID NO: 36 or composed of the amino acid sequence shown in SEQ ID NO: 36.
[0011] In some embodiments, the transgene also includes a promoter. In some embodiments, the promoter is the CB6 promoter, the CBA promoter, or a tissue-specific promoter. In some embodiments, the tissue-specific promoter is an eye-specific promoter. In some embodiments, the eye-specific promoter is the retinoschisin promoter, the K12 promoter, the rhodopsin promoter, the rod-specific promoter, the cone-specific promoter, the rhodopsin kinase promoter (e.g., the GRK1 promoter), or the interphotoreceptor retinoid-binding protein proximal (IRBP) promoter.
[0012] In some implementations, the transgene also includes introns (e.g., chicken β-actin introns, synthetic introns, MBL introns, etc.). In some implementations, the intron is located between the promoter and a small gene (e.g., MiniCEP290) encoding the transgene sequence.
[0013] In some embodiments, the transgene is flanked by an adeno-associated virus (AAV) inverted terminal repeat (ITR). In some embodiments, the AAV ITR is an AAV2ITR or a variant thereof, such as a ΔITR or an mTR ITR.
[0014] In some aspects, this disclosure provides vectors comprising isolated nucleic acids as described herein. In some embodiments, the vector is a plasmid.
[0015] In some respects, this disclosure relates to host cells containing isolated nucleic acids or vectors as described herein.
[0016] In some embodiments, this disclosure provides a recombinant adeno-associated virus (rAAV) comprising: a capsid protein; and, isolated nucleic acid as described herein.
[0017] In some embodiments, the capsid protein is an AAV8 capsid protein or an AAV5 capsid protein. In some embodiments, the capsid protein is an AAV8 capsid protein or a variant thereof. In some embodiments, the capsid protein is an AAV5 capsid protein or a variant thereof. In some embodiments, the capsid protein comprises the amino acid sequence shown in SEQ ID NO: 9.
[0018] In some implementations, rAAV is a self-complementary AAV (scAAV).
[0019] In some embodiments, rAAV is formulated for delivery to the eye. In some embodiments, rAAV is formulated for subretinal delivery. In some embodiments, rAAV comprises one or more of the CEP290 fragment and AAV8 or AAV5 capsid protein described herein. In some embodiments, rAAV comprises (i) a nucleic acid sequence encoding the CEP290 fragment, said CEP290 fragment comprising the amino acid sequence shown in SEQ ID NO: 19 or 34, effectively linked to a rhodopsin kinase (RK) promoter; and (ii) the rAAV8 or AAV5 capsid protein. In some embodiments, rAAV is formulated for subretinal delivery.
[0020] In some aspects, this disclosure provides a composition comprising rAAV as described herein and a pharmaceutically acceptable excipient. In some embodiments, the composition comprises a plurality of rAAVs. In some embodiments, each of the plurality of rAAVs encodes a different CEP290 fragment.
[0021] In some aspects, this disclosure provides a method for treating ocular cilia in a subject in need, the method comprising administering to the subject suffering from ocular cilia a therapeutically effective amount of an isolated nucleic acid, rAAV, or composition as described herein.
[0022] In some embodiments, ocular cilia are associated with a mutation or deletion of the subject's CEP290 gene. In some embodiments, the mutation in the CEP290 gene is an intron mutation, nonsense mutation, frameshift mutation, missense mutation, or any combination thereof. In some embodiments, mutations or deletions of CEP290 lead to retinal degeneration, photoreceptor degeneration, retinal dysfunction, and / or loss of vision.
[0023] In some implementations, ocular cilia disease is Leber congenital amaurosis (LCA), Joubert syndrome, Bardet-Biedl syndrome, Meckel syndrome, Usher syndrome, Nephronophthisis, or Senior- Syndrome (Senior- In some implementations, ocular cilia is Leber's congenital amaurosis (LCA). In some implementations, such as retinitis pigmentosa (RP), the severity of ocular cilia is modified by CEP290.
[0024] In some embodiments, the subject is a person characterized by one or more CEP290 mutations occurring at location c.2991+1655 (e.g., one or more mutations in the CEP290 gene). In some embodiments, at least one mutation is A1655G.
[0025] In some embodiments, administration of the isolated nucleic acid, rAAV, or composition results in the delivery of the CEP290 fragment (e.g., a transgene encoding the CEP290 fragment) to the subject's eye. In some embodiments, administration is performed via injection. In some embodiments, injection includes subretinal or intravitreal injection. In some embodiments, administration is a local application to the subject's eye. In some embodiments, administration is via subretinal administration.
[0026] In some embodiments, an effective amount (e.g., administration of an effective amount of isolated nucleic acid (messenger RNA), isolated CEP290 fragment protein, rAAV, or a combination thereof) results in photoreceptor (PR) function (e.g., an increase in PR function as measured by ERG). In some embodiments, the effective amount (e.g., administration of an effective amount of isolated nucleic acid (messenger RNA), isolated CEP290 fragment protein, rAAV, or a combination thereof) results in photoreceptor (PR) function (e.g., an increase in PR function as measured by ERG) lasting up to 14 weeks. Brief description of the attached diagram
[0028] Figure 1 A schematic diagram of the full-length CEP290 gene, representing the locations of different protein-protein interaction domains, is shown.
[0029] Figure 2A The data shows data involving wild-type (WT) and Cep290. rd16 Microscopic data of the number and length of cilia in mouse embryonic fibroblasts (MEFs) from mice whose serum was starved for 24 hours (for cilia growth) and then stained with an anti-acetylated α-tubulin antibody (cilia marker). The images below depict cilia at higher magnification. Figure 2B The study showed a statistically significant reduction in cilia length in mutant MEF.
[0030] Figure 3The image shows Cep290 cells transfected with a construct encoding GFP or GFP-CEP290, followed by staining with ARL13b (a ciliary marker) and γ-tubulin. rd16 MEF. A significant increase in ciliary length was observed in cells expressing full-length CEP290. The GFP-encoded construct was used as a negative control. **: p < 0.001.
[0031] Figure 4A A schematic diagram of the human CEP290 protein and its deletion variants is shown. Muscle-tail: Myosin tail homology domain. Other protein-protein interaction domains are not shown. Figure 4B Showing the use Figure 4A Immunoblot analysis of mouse fibroblasts transiently transfected with the construct described in [the original text] using an anti-GFP antibody. Specific protein bands were detected (indicated by arrows), indicating that the deletion variant was stably expressed in the cells.
[0032] Figure 5A The image shows the effects of GFP, γ-tubulin, and ARL13B antibody on Cep290 cells transiently transfected with plasmids encoding full-length (FL) CEP290 and specified variants. rd16 Immunostaining of fibroblasts. Cell nuclei were stained with DAPI. Longer arrows indicate basal / cilia localization of proteins, while shorter arrows mark diffuse staining. Figure 5B Displayed using ImageJ quantization Figure 5A Cilia length of cells (n>200) described in the figure. *: p<0.001. ns: not significant.
[0033] Figure 6A The image shows Cep290 cells transiently transfected with a plasmid encoding a specified variant of GFP alone or a GFP fusion using an anti-GFP antibody. rd16 Immunoblot analysis performed on fibroblasts. Arrows point to protein products of expected size. Molecular mass markers are shown in kDa. Figure 6B Immunostaining of cells using antibodies against GFP and ARL13B (cilia marker) is shown. Cell nuclei are stained with DAPI. Arrows indicate the basal / cilia localization of proteins. Figure 6C The image shows the ciliary length of cells (n>200) quantized using ImageJ. *: p<0.001.
[0034] Figures 7A-7B The miniCEP290 was displayed. 580-1180 Its physiological rescue potential within the body. Figure 7A Display Cep290 rd16Mice were injected subretinally with the specified miniCEP290 or GFP at the P0 / P1 stage, and analyzed by ERG 3 weeks post-injection. Age-matched uninjected WT or Cep290 mice were also included. rd16 (Library) mice were used as controls for ERG. ERG a-waves are indicated by arrows, and b-waves by arrows. Data represent analyses of at least 6 mice. ***: p < 0.0001; ns: not significant. Figure 7B The scotopic a-wave and b-wave amplitudes of mice that underwent subretinal injection with the specified miniCEP290 or GFP at the P0 / P1 stage and were analyzed by ERG 3 weeks post-injection are shown.
[0035] Figures 8A-8D The miniCEP290 was displayed. 580-1180 Rescue of the in vivo morphology of photoreceptors. Figure 8A Display DAPI staining using the specified miniCEP290. 580-1180 or GFP-injected Cep290 rd16 Retina. Figure 8B The results of evaluation using miniCEP290 via ultrathin sections are shown. 580-1180 or GFP-injected Cep290 rd16 Retina. ONL (outer nuclear layer) is marked with vertical lines. WT retinal slices are shown for comparison. INL: Inner nuclear layer. Figure 8C It was shown that miniCEP290 was injected. 580-1180 Cep290 rd16 Increased RDS expression was detected in mice. GFP staining was used to label the injection region. Figure 8D The Cep290 indicated that the specified miniCEP290 was injected. rd16 Frozen sections of mouse retina were stained with GFP (injection area), rhodopsin (RHO; rod cell specific; or M-opsin (MOP; cone cell specific) antibody, and DAPI (nucleus). These sections were prepared after injection of miniCEP290. 580-1180 Outer segment (OS)-rich opsin staining was detected in the retina. This was observed after injection of miniCEP290. 2037-2479 A sharp decrease in opsin expression was detected in the retina. ONL: outer nuclear layer; INL: inner nuclear layer; GCL: ganglion cell layer.
[0036] Figure 9 Other implementation schemes of the CEP290 small gene are shown.
[0037] Figure 10The image shows Cep290 cells transiently transfected with plasmids encoding individual GFP or GFP fusion variants, quantified using ImageJ with anti-GFP antibodies (n>200). rd16 Fibroblast ciliary length.
[0038] Figure 11 The image shows Cep290 obtained by subretinal injection of the specified miniCEP290 or GFP at the P0 / P1 stage and analyzed by ERG 3 weeks post-injection. rd16 Mice. Age-matched uninjected WT or Cep290 mice. rd16 (Library) mice were used as controls for ERG. ERG a-waves are indicated by arrows, and b-waves by arrows. Data represent analyses of at least 6 mice. ***: p < 0.0001; ns: not significant.
[0039] Figure 12 The scotopic a-wave and b-wave amplitudes are shown in mice that received subretinal injection of the specified miniCEP290 or GFP at the P0 / P1 stage and were analyzed by ERG at 3 weeks post-injection. Scotopic (a-wave and b-wave) and photopic b-wave analyses of injected mice at 4 and 5 weeks post-injection are shown and compared with ERG at 3 weeks. Age-matched uninjected WT and GFP-injected Cep290 mice are also included. rd16 Mice were used as controls.
[0040] Figure 13 The scotopic a- and b-wave amplitudes are shown in 10-day-old mice that received subretinal injection of the specified miniCEP290 construct (GRK-580-1180). ERG was recorded at specified days post-injection.
[0041] Figure 14 The a- and b-wave amplitudes of photopic vision are shown in 10-day-old mice that received subretinal injection of the specified miniCEP290 construct (GRK-580-1180). ERG was recorded at the specified number of days post-injection.
[0042] Figure 15 Micrographs of rd16 mouse embryonic fibroblasts transiently transfected with cDNA encoding a specified small gene and GFP are shown.
[0043] Figure 16 The data show the ciliary length measurements of rd16 mouse embryonic fibroblasts transiently transfected with a small gene encoding a specified protein and GFP cDNA.
[0044] Figures 17A-17D The scotopic and photopic amplitudes of the CB6-promoter driving the specified small gene were shown, which was injected subretinally into 10-day-old rd16 mice. Figure 17A The amplitude of the dark-view alpha wave is shown. Figure 17B The amplitude of the photopic b-wave is shown. Figure 17C The amplitude of the dark-view b-wave is shown. Figure 17D The ERG of rd16 mice injected with CB6-1-200-580-1180 miniCEP290 is shown. ERG was recorded at specified days post-injection and compared with others.
[0045] Figure 18 This is a schematic diagram depicting another small CEP290 gene.
[0046] Figure 19 Representative data from an ERG analysis of rhodopsin kinase (RK) promoter-driven miniCEP290-580-1180 expression in subretinal mice are presented. The rescue effect persisted for more than 10 weeks post-injection.
[0047] Figure 20 Representative data from an ERG analysis of rhodopsin kinase (RK) promoter-driven miniCEP290-1181-2479 expression in subretinal injected mice are presented. The rescue effect persisted for up to 8.5 weeks post-injection.
[0048] Figure 21 Representative data from an ERG analysis of rhodopsin kinase (RK) promoter-driven miniCEP290-580-1180 / 1800-2479 expression in subretinal mice are presented. The rescue effect persisted for up to 5.5 weeks post-injection.
[0049] Figure 22 Representative data from an ERG analysis of rhodopsin kinase (RK) promoter-driven expression of miniCEP290-1181-1695 / 1966-2479 in mice injected under the retina are shown.
[0050] Figure 23 Representative data from an ERG analysis of rhodopsin kinase (RK) promoter-driven miniCEP290-1-200 / 580-1180 expression in subretinal mice are presented. The rescue effect persisted for more than 14 weeks post-injection.
[0051] Figures 24A-24C Data from the morphological analysis of the rhodopsin kinase (RK) promoter driving miniCEP290-1-200 / 580-1180 are shown: the small gene is delivered subretinally to Cep290 along with AAV8 at the P10 stage. rd16 Mice. The analysis was performed at 9 weeks of age. Figure 24AThe miniCEP290-1-200 / 580-1180 immunofluorescence assay shows the injected retinal region (GFP; the longer arrow). Figure 24B The data shown indicate improved rhodopsin (longer arrows) following delivery of miniCEP290-1-200 / 580-1180. The shorter arrows do not show GFP expression (non-transduction) and therefore exhibit undetectable rhodopsin expression. Figure 24C Nuclear staining data are shown, indicating that there are more nuclear layers in the outer nuclear layer (ONL) region in the miniCEP290-1-200 / 580-1180-transduced region (longer arrows and longer vertical lines) compared to the untransduced region (shorter arrows and shorter vertical lines).
[0052] Figures 25A-25C The codon-optimized miniCEP290 construct is shown. Figure 25A The miniCEP290(1-200 / 580-1180) construct with different promoters and introns is shown. Figure 25B The miniCEP290(1-380 / 580-1180) construct with different promoters and introns is shown. Figure 25C Representative data for the codon-optimized miniCEP290 (1-200 / 580-1180) construct, packaged in an AAV5 capsid and injected subretinally into mice at the P10 stage, are presented. Mice were then analyzed by ERG (scotopic and photopic) at specified ages. Invention Details
[0054] In some aspects, this disclosure relates to compositions and methods that can be used to treat certain genetic diseases, such as monogenic diseases, cilia, etc. Monogenic diseases are diseases caused by the abnormal expression or function of a single allele of a gene. Examples of monogenic diseases include, but are not limited to, thalassemia, sickle cell anemia, hemophilia, cystic fibrosis, Tay-Sachs disease, Fragile X syndrome, Huntington's disease, etc. Cilia are genetic diseases that affect the expression or function of cellular cilia, such as ocular cilia. Examples of ciliary disorders include, but are not limited to, Alstrom syndrome, Bardet-Biedl syndrome, Joubert syndrome, Merckel syndrome, nephronophthisis, orofaciodigital syndrome, Senior-Locken syndrome, polycystic kidney disease, primary ciliary dyskinesia, and situs inversus.
[0055] This disclosure is based in part on isolated nucleic acids, vectors (e.g., plasmids, rods, etc.) and gene therapy vectors, such as viral (e.g., rAAV) vectors, which contain one or more gene fragments (e.g., small genes) encoding therapeutic gene products such as proteins or peptides, and optionally one or more repressive nucleic acids targeting endogenous gene variants (e.g., mutants) associated with diseases or conditions (e.g., genes associated with cilia).
[0056] Gene therapy vectors can be viral vectors (e.g., lentiviral vectors, adeno-associated virus vectors, etc.), plasmids, closed-ended DNA (e.g., ceDNA), etc. In some embodiments, the gene therapy vector is a viral vector. In some embodiments, the expression cassette encoding a small gene is flanked by one or more viral replication sequences, such as lentiviral long terminal repeats (LTRs) or adeno-associated virus (AAV) inverted terminal repeats (ITRS).
[0057] As used herein, a “minigene” refers to an isolated nucleic acid sequence encoding a recombinant peptide or protein, wherein one or more non-essential elements of the corresponding gene encoding the naturally occurring peptide or protein have been removed and the peptide or protein encoded by the minigene retains the function of the corresponding naturally occurring peptide or protein. A “therapeutic minigene” refers to a minigene encoding a peptide or protein that can be used to treat genetic diseases, such as human centrosomal protein 290 (CEP290), dystrophin, dysferlin, factor VIII, amyloid precursor protein (APP), tyrosinase (Tyr), etc. Minigenes are known in the art and described, for example, by the following: Karpati and Acsadi (1994) Clin Invest Med 17(5):499-509; Plantier et al. (2001) Thromb Haemost. 86(2):596-603; and Xiao et al. (2007) World J. Gastroenterol. 13(2):244-9.
[0058] Typically, the isolated nucleic acid encoding a small gene (e.g., a therapeutic small gene) is truncated by about 10% to about 99% (e.g., about 10%, about 15%, about 20%, about 25%, about 30%, about 40%, about 50%, about 60%, about 70%, about 75%, about 80%, about 90%, about 99%, etc.) relative to the nucleic acid sequence encoding the corresponding naturally occurring wild-type protein. For example, in some embodiments, the small gene encoding a CEP290 protein fragment is truncated by about 76% (e.g., containing about 24% of the nucleic acid sequence) compared to the wild-type CEP290 gene.
[0059] Some aspects of this disclosure relate to isolated nucleic acids comprising transgenic components encoding one or more CEP290 fragments. A “fragment” refers to a protein encoded by at least two discontinuous nucleotide sequence portions that are within a reading frame of each other and encode a functional protein. The CEP290 fragment may contain one or more domains corresponding to a portion of a CEP290 protein (e.g., SEQ ID NO: 1), such as one or more of a CP110-binding domain (or a portion thereof), an NPHP5-binding domain (or a portion thereof), a RAB8A-binding domain (or a portion thereof), a microtubule (MT)-binding domain (or a portion thereof), and an RPGR-binding domain (or a portion thereof). In some embodiments, the CP110-binding domain corresponds to amino acid positions 1-579 of the wild-type CEP290 protein (e.g., SEQ ID NO: 1). In some embodiments, the NPHP5-binding domain corresponds to amino acid positions 580-880 of the wild-type CEP290 protein (e.g., SEQ ID NO: 1). In some embodiments, the RAB8A binding domain corresponds to amino acid positions 580-1695 of the wild-type CEP290 protein (e.g., SEQ ID NO: 1). In some embodiments, the MT binding domain corresponds to amino acid positions 1696-1966 of the wild-type CEP290 protein (e.g., SEQ ID NO: 1). In some embodiments, the RPGR binding domain corresponds to amino acid positions 1966 to 2479 of the wild-type CEP290 protein (e.g., SEQ ID NO: 1).
[0060] In some embodiments, the isolated nucleic acid encodes the CEP290 fragment, said CEP290 fragment comprising the amino acid sequence shown in any one of SEQ ID NOs: 10-19 and 36. In some embodiments, the isolated nucleic acid comprises the nucleic acid sequence shown in any one of SEQ ID NOs: 20-29 and 34-35. In some embodiments, the isolated nucleic acid comprises a nucleic acid sequence having at least 70%, 80%, 90%, 95%, or 99% identity with the nucleic acid sequence shown in any one of SEQ ID NOs: 20-29 and 34-35.
[0061] In some embodiments, the nucleic acid encodes a CEP290 protein fragment corresponding to amino acids 1-200 and 580-1180 of human CEP290. In some embodiments, the nucleic acid encodes a CEP290 fragment comprising amino acids 1-200 and 580-1180 of SEQ ID NO: 1. In some embodiments, the isolated nucleic acid comprises the nucleic acid sequence shown in SEQ ID NO: 29 or 34. In some embodiments, the nucleic acid encodes a CEP290 fragment corresponding to the amino acid sequence shown in SEQ ID NO: 19.
[0062] In some embodiments, the nucleic acid encodes a CEP290 protein fragment corresponding to amino acids 1-380 and 580-1180 of human CEP290. In some embodiments, the nucleic acid encodes a CEP290 fragment comprising amino acids 1-380 and 580-1180 of SEQ ID NO: 1. In some embodiments, the isolated nucleic acid comprises the nucleic acid sequence shown in SEQ ID NO: 35. In some embodiments, the nucleic acid encodes a CEP290 fragment corresponding to the amino acid sequence shown in SEQ ID NO: 36.
[0063] In some embodiments, the nucleic acid sequence encoding the CEP290 fragment is codon-optimized. In some embodiments, the codon-optimized CEP290 fragment is encoded by the nucleic acid sequence shown in SEQ ID NO: 34 or 35. In some embodiments, the codon-optimized nucleic acid sequence encodes the CEP290 small gene comprising the amino acid sequence shown in SEQ ID NO: 19 or 36.
[0064] In some embodiments, the nucleic acid comprises an expression cassette containing a sequence (e.g., a nucleic acid sequence encoding the amino acid sequence shown in SEQ ID NO: 29 or 34) that is effectively linked to a promoter (e.g., a rhodopsin kinase (RK) promoter). In some embodiments, the expression cassette is flanked by an adeno-associated virus (AAV) inverted terminal repeat (ITR). In some embodiments, the ITR is an AAV2ITR. In some embodiments, the nucleic acid is capsidated by one or more AAV capsid proteins. In some embodiments, the one or more AAV capsid proteins are AAV8 or AAV5 capsid proteins.
[0065] In some aspects, this disclosure relates to isolated nucleic acids (e.g., vectors, such as viral vectors) comprising expression cassettes, said expression cassettes comprising a first isolated nucleic acid sequence encoding a therapeutic small gene and a second isolated nucleic acid sequence encoding one or more repressive nucleic acids, wherein the expression cassettes are flanked by viral replication sequences, and wherein one or more repressive nucleic acids do not bind to the isolated nucleic acid encoding the therapeutic small gene.
[0066] In some aspects, this disclosure relates to AAV-mediated delivery of a CEP290 gene fragment lacking the “M region” (e.g., a fragment encoding the CEP290 protein) to cells (e.g., eye cells) of a subject suffering from a disease or condition characterized by a mutation or deletion of the CEP290 gene, which restores or improves cilia length and rescues or improves photoreceptor function. This finding is surprising, given previous disclosures, such as US 2016 / 0185832, which describes the “M region” of the CEP290 gene as essential for mediating microtubule localization and cilia formation. In some embodiments, the embodiment section of this disclosure describes a domain (e.g., a fragment) of the CEP290 protein that retains function in photoreceptors and can be delivered using conventional AAV vectors.
[0067] Therefore, in some aspects, this disclosure provides an isolated nucleic acid comprising: a first region comprising a first adeno-associated virus (AAV) inverted terminal repeat (ITR) sequence or a variant thereof; and a second region comprising a transgene encoding a CEP290 protein fragment, wherein the CEP290 protein fragment does not contain amino acid positions 1695 to 1966 of SEQ ID NO:1.
[0068] In some aspects, this disclosure provides an isolated nucleic acid comprising: a first region comprising a first adeno-associated virus (AAV) inverted terminal repeat (ITR) sequence or a variant thereof; and a second region comprising a transgene encoding a CEP290 protein fragment, wherein the CEP290 protein fragment comprises at least 500 consecutive amino acids of SEQ ID NO: 1. In some embodiments, the at least 500 consecutive amino acids comprise or consist of sequences selected from SEQ ID NO: 2, 3, and 4.
[0069] In some embodiments, the second region does not contain amino acid positions 1695 to 1966 of SEQ ID NO: 1. In some embodiments, the transgene contains no more than 1120 consecutive amino acids of SEQ ID NO: 1.
[0070] In some embodiments, the transgene comprises amino acid positions 580 to 1695 of SEQ ID NO: 1. In some embodiments, the CEP290 protein fragment encoded by the transgene comprises the sequence shown in SEQ ID NO: 2. In some embodiments, the CEP290 protein fragment encoded by the transgene comprises amino acid positions 580 to 1180 of SEQ ID NO: 1, or amino acid positions 1181 to 1695 of SEQ ID NO: 1. In some embodiments, the CEP290 protein fragment encoded by the transgene comprises or consists of the sequence shown in SEQ ID NO: 3 or 4. In some embodiments, the CEP290 protein fragment encoded by the transgene comprises amino acid positions 1 to 200 of SEQ ID NO: 1 and amino acid positions 580 to 1180 of SEQ ID NO: 1 (or consists of). In some embodiments, the CEP290 protein fragment encoded by the transgene comprises the sequence shown in SEQ ID NO: 29 or 34, or consists of the sequence shown in SEQ ID NO: 29 or 3. It should be understood that the CEP290 protein fragment delivered by the transgene can be translated into a single fusion protein containing two or more fragments, or as a separate polypeptide.
[0071] In some embodiments, the transgene comprises or consists of nucleic acid sequences selected from SEQ ID NO: 5, 6 and 7.
[0072] In some implementations, the gene therapy vector further comprises one or more repressive nucleic acids that do not silence the gene expression of the gene product encoded by the small gene but silence the gene expression of the endogenous protein corresponding to the wild-type or disease-associated variant of the protein encoded by the small gene. For example, in some embodiments, the gene therapy vector comprises a small gene encoding a CEP290 protein fragment and one or more repressive nucleic acids (e.g., dsRNA, siRNA, shRNA, miRNA, amiRNA, etc.), which inhibit the expression of endogenously expressed CEP290 (e.g., CEP290 mutants selected from c.2991+1655A>G, c.2249T>G, c.7341dupA, c.2118_2122dupTCAGG, c.3814C>T, c.679_680delGA, c.265dupA, c.180+1G?T, c.1550delT, c.4115_4116delTA, c.4966G>T, and c.5813_5817delCTTTA), but does not inhibit the expression of the CEP290 fragment encoded by the small gene. Those skilled in the art will also understand that, in some implementations, one or more repressive nucleic acids may be administered to the subject separately from the gene therapy construct, the repressive nucleic acid inhibiting the expression of endogenously expressed CEP290 but not the expression of CEP290 fragments encoded by small genes.
[0073] In some aspects, the CEP290 fragment is encoded by messenger RNA. In other aspects, the CEP290 fragment is a protein delivered to the affected cells. In some embodiments, one or more CEP290 fragments are delivered to the affected cells via a nanoparticle- or microsphere-based delivery system. In some embodiments, the nanoparticle- or microsphere-based delivery system is formulated to penetrate the affected cells, for example, by incorporating a cell-permeable peptide (cpp) sequence into the CEP290 fragment or the delivery system (e.g., nanoparticles).
[0074] Treatment of ocular cilia
[0075] Some aspects of this invention relate to transgenes encoding certain proteins (e.g., fragments of human CEP290) that, upon delivery to a subject, effectively promote the growth of ocular cilia (e.g., cilia of photoreceptors) and the rescue of photoreceptor structure and function in the subject. Therefore, in some embodiments, the methods and compositions described in this disclosure can be used to treat ocular cilia disorders associated with mutations or deletions in the CEP290 gene, such as Leber's congenital amaurosis (LCA), Joubert syndrome, Bardet-Biedl syndrome, Meckel syndrome, Usher syndrome, and Senior- Syndrome.
[0076] As used herein, “treat” or “treating” refers to (a) the prevention or delay of ocular cilia disorders associated with mutations or deletions in the CEP290 gene (e.g., Leber congenital amaurosis (LCA), Joubert syndrome, Bardet-Biedl syndrome, Meckel syndrome, Usher syndrome, or Senior- (a) to reduce the onset of oculicilopathy associated with mutations or deletions of the CEP290 gene; (b) to reduce the severity of oculicilopathy associated with mutations or deletions of the CEP290 gene; (c) to reduce or prevent the development of characteristic symptoms of oculicilopathy associated with mutations or deletions of the CEP290 gene; and (d) and / or to prevent the exacerbation of characteristic symptoms of oculicilopathy associated with mutations or deletions of the CEP290 gene. Signs and symptoms of oculicilopathy associated with mutations or deletions of the CEP290 gene include, for example, photoreceptor degeneration, impaired photoreceptor function, and cell death.
[0077] This disclosure provides a method for delivering a transgene (e.g., a gene encoding the CEP290 protein or a fragment thereof) to a subject. The method typically involves administering to the subject an effective amount of isolated nucleic acid encoding a fragment of the CEP290 protein, or an rAAV containing nucleic acid for expressing the CEP290 protein fragment.
[0078] The human CEP290 gene consists of 52 exons that encode a protein of ~290 kDa (2479 amino acids). In some embodiments, the human CEP290 gene encodes a protein comprising the amino acid sequence shown in SEQ ID NO: 1 and as described in GenBank accession number (NP_079390.3). In some embodiments, the human CEP290 gene (e.g., NCBI reference sequence: NM_025114.3) comprises the sequence shown in SEQ ID NO: 8.
[0079] CEP290 is a multidomain protein containing numerous coiled-coil domains distributed throughout its length. Furthermore, CEP290 contains membrane and microtubule-binding domains as well as a myosin-tail homologous domain. Typically, CEP290 is primarily located in the centrosome and transition zone of primary cilia, and in the central cytoreceptor (CC) of photoreceptors. Previous publications have observed that the domains of CEP290 that localize the protein to the centrosome (e.g., the “M region” of the CEP290 gene, as described in US 2016 / 0185832) are essential for mediating microtubule localization and cilia formation. In some embodiments, the “M region” refers to amino acid residues 1695 to 1966 of human CEP290, as described in US 2016 / 0185832.
[0080] Some aspects of this disclosure are based in part on the surprising finding that certain CEP290 fragments lacking the “M” region, when expressed in subjects in need, mediate effective rescue of ciliary formation and photoreceptor rescue, for example, via administration of a viral vector (e.g., rAAV).
[0081] Therefore, in some aspects, this disclosure provides a transgenic protein fragment encoding the CEP290 protein fragment, wherein the CEP290 protein fragment does not contain amino acid positions 1695 to 1966 of SEQ ID NO: 1 (e.g., the region containing the "M" region). "CEP protein fragment" refers to a portion of the CEP290 protein containing amino acids from positions 2 to 2479 (e.g., any integer between 2 and 2479). In some embodiments, the CEP protein fragment contains a continuous amino acid portion of CEP290 (e.g., amino acids 580 to 1180). In some embodiments, the CEP protein fragment contains one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) discontinuous amino acid portions of CEP290 (e.g., amino acids 1 to 10, 580 to 1180, and 1967 to 2470). In some embodiments, the CEP protein fragment contains a methionine (M) amino acid residue at its N-terminus.
[0082] In some embodiments, the CEP290 protein fragment comprises at least 500 consecutive amino acids of SEQ ID NO: 1. For example, in some embodiments, the CEP290 protein fragment comprises (or consists of) amino acids 580 to 1695, or amino acids 580 to 1180, or amino acids 1181 to 1695 of CEP290 (e.g., SEQ ID NO: 1). In some embodiments, the at least 500 consecutive amino acids comprise or consist of sequences selected from SEQ ID NO: 2, 3, and 4.
[0083] In some embodiments, the CEP290 protein comprises amino acids 480 to 579 of CEP290 (e.g., SEQ ID NO: 1). In some embodiments, the CEP290 protein fragment comprises amino acids 480 to 580 of CEP290 (e.g., SEQ ID NO: 1). In some embodiments, the CEP290 protein comprises amino acids 480 to 880 of CEP290 (e.g., SEQ ID NO: 1). In some embodiments, the CEP290 protein comprises amino acids 580 to 880 of CEP290 (e.g., SEQ ID NO: 1). In some embodiments, the CEP290 protein comprises amino acids 580 to 1180 of CEP290 (e.g., SEQ ID NO: 1). In some embodiments, the CEP290 protein comprises amino acids 1181 to 1695 of CEP290 (e.g., SEQ ID NO: 1). In some embodiments, the CEP290 protein comprises amino acids 1181 to 1966 of CEP290 (e.g., SEQ ID NO: 1). In some embodiments, the CEP290 protein comprises amino acids 1181 to 2479 of CEP290 (e.g., SEQ ID NO: 1). In some embodiments, the CEP290 protein comprises amino acids 1696 to 1966 of CEP290 (e.g., SEQ ID NO: 1). In some embodiments, the CEP290 protein comprises amino acids 1966 to 2479 of CEP290 (e.g., SEQ ID NO: 1). In some embodiments, the CEP290 protein comprises amino acids 1800 to 2479 of CEP290 (e.g., SEQ ID NO: 1). In some embodiments, the CEP290 fragment comprises two or more of the aforementioned fragments (e.g., 2, 3, 4, 5, 6, or more). In some embodiments, the CEP290 fragment comprises two or more (e.g., 2, 3, 4, 5, 6 or more) of the aforementioned fragments that are not consecutive in SEQ ID NO: 1. In some embodiments, the CEP290 protein fragment comprises or consists of the amino acid sequence shown in any one of SEQ ID NO: 10-19. In some embodiments, the CEP290 protein comprises amino acids 1-200 and 580-1180 of human CEP290. In some embodiments, the CEP290 protein comprises amino acids 1-200 and 580-1180 of SEQ ID NO: 1. In some embodiments, the CEP290 protein comprises the amino acid sequence shown in SEQ ID NO: 19. In some embodiments, the CEP290 protein is encoded by the nucleic acid sequence shown in SEQ ID NO: 29 or 34. In some embodiments, the CEP290 protein comprises amino acids 1-380 and 580-1180 of human CEP290.In some embodiments, the CEP290 protein comprises amino acids 1-380 and 580-1180 of SEQ ID NO: 1. In some embodiments, the CEP290 protein comprises the amino acid sequence shown in SEQ ID NO: 36. In some embodiments, the CEP290 protein is encoded by the nucleic acid sequence shown in SEQ ID NO: 35.
[0084] In some embodiments, this disclosure provides a transgenic material comprising a nucleic acid (e.g., isolated nucleic acid) encoding a CEP290 protein fragment. In some embodiments, the transgenic material comprises or consists of a nucleic acid sequence selected from SEQ ID NO: 5, 6, and 7. In some embodiments, the transgenic material comprises or consists of a nucleic acid sequence selected from any one of SEQ ID NO: 20-29.
[0085] In some embodiments, the transgene encoding the CEP290 fragment described in this disclosure mediates ciliary growth and photoreceptor rescue, and can therefore be used to treat ciliopathy, such as ocular ciliopathy. Generally, "ciliopathy" refers to a disease or condition characterized by a defect (or lack) in protein function that results in abnormal formation or function of cilia in the cells of a subject. "Ocular ciliopathy" is a ciliopathy in which abnormal formation or function of cilia occurs in the ocular cells of a subject (e.g., rod cells, cone cells, photoreceptor cells, etc.) and typically results in retinal degeneration, vision loss, and blindness. Examples of ciliopathy include, but are not limited to, early-onset developmental abnormalities such as Meckel Gruber syndrome and Joubert syndrome, and relatively late-onset diseases such as Bardet-Biedl syndrome, Senior-Loken syndrome, and Usher syndrome. In some embodiments, retinal dystrophy (e.g., due to ocular ciliopathy) is more commonly presented in a non-syndromic manner.
[0086] In some implementations, ocular cilia disease is Leber's congenital amaurosis (LCA). Generally, LCA is a clinically and genetically heterogeneous disease characterized by early-onset, severe retinal degeneration that begins at birth or between 5 and 7 years of age. In some implementations, LCA is LCA1, LCA2, LCA3, LCA4, LCA5, LCA6, LCA7, LCA8, LCA9, LCA10, LCA11, LCA12, LCA13, LCA14, LCA15, LCA16, or LCA17. In some implementations, LCA is LCA10 (e.g., LCA associated with one or more mutations in the CEP290 gene). Typically, one or more mutations in CEP290 account for >26% of LCA (LCA10; OMIM611755). In some implementations, LCA is characterized by the absence of the CEP290 gene in the subject. Typically, CEP290 mutations leading to LCA can be intron mutations, nonsense mutations, frameshift mutations, missense mutations, or any combination thereof. Examples of LCA-related CEP290 gene mutations include, but are not limited to, c.2991+1655A>G, c.2249T>G, c.7341dupA, c.2118_2122dupTCAGG, c.3814C>T, c.679_680delGA, c.265dupA, c.180+1G? T, c.1550delT, c.4115_4116delTA, c.4966G>T, and c.5813_5817delCTTTA, as described, for example, in den Hollander et al. (2006) Am J Hum Genet. 79(3): 556-561. In some embodiments, the mutation in CEP290 is a deep intron mutation, such as at position c.2991+1655A. In some embodiments, the deep intron mutation is c.2991+1655A>G. In some embodiments, the severity of ocular cilia is altered by the CEP290 mutation. For example, as described in Rao et al. (2016). Hum Mol Genet, 25(10):2005-2012. The deletion and / or mutation of the CEP290 gene in a subject (e.g., a subject with or suspected of having cilia associated with a deletion or mutation in the CEP290 gene) can be identified from samples obtained from the subject (e.g., DNA samples, RNA samples, blood samples, or other biological samples) by any method known in the art. For example, in some embodiments, nucleic acids (e.g., DNA, RNA, or a combination thereof) are extracted from a biological sample obtained from the subject and subjected to nucleic acid sequencing to identify mutations in the CEP290 gene.Examples of nucleic acid sequencing technologies include, but are not limited to, Maxam-Gilbert sequencing, pyrosequencing, chain termination sequencing, massively parallel characterization, single-molecule sequencing, nanopore sequencing, and Illumina sequencing. In some implementations, mutations or deletions in the CEP290 gene are detected indirectly, for example, by quantifying CEP290 protein expression (e.g., by Western blotting) or function (e.g., by analyzing ciliary growth, structure, function, etc.), or by direct DNA sequencing and comparing the obtained sequence with a control DNA sequence (e.g., wild-type CEP290 DNA sequence).
[0087] In some aspects, this disclosure provides a method for treating ocular cilia in a subject of need, the method comprising administering to the subject suffering from ocular cilia a therapeutically effective amount of an isolated nucleic acid or rAAV as described in this disclosure. In some embodiments, the administration is subretinal.
[0088] The “effective amount” of a substance is an amount sufficient to produce the desired effect. In some embodiments, the effective amount of isolated nucleic acid (e.g., isolated nucleic acid containing a transgene encoding a fragment of the CEP290 protein as described herein) is an amount sufficient to transfect (or infect, in the case of rAAV-mediated delivery) a sufficient number of target cells in the subject’s target tissue. In some embodiments, the target tissue is ocular tissue (e.g., photoreceptor cells, rod cells, cone cells, retinal ganglion cells, retinal cells, retinal pigment epithelial cells, etc.). In some embodiments, the effective amount of isolated nucleic acid (e.g., which may be delivered via rAAV) may be an amount sufficient to have a therapeutic benefit in the subject, such as increasing or supplementing the expression of a target gene or protein (e.g., CEP290) to improve one or more symptoms of the subject’s disease (e.g., symptoms of ocular cilia, such as LCA), such as light perception, photoreceptor function (electroretinography), and structural retina. The effective amount will depend on a variety of factors, such as the subject’s species, age, weight, health status, and the tissue to be targeted, and therefore can vary with the subject and tissue, as described elsewhere in this disclosure.
[0089] isolated nucleic acids
[0090] In some aspects, this disclosure provides isolated nucleic acids that can be used to express human CEP290 or fragments thereof. A “nucleic acid” sequence refers to a DNA or RNA sequence. In some embodiments, the proteins and nucleic acids of this disclosure are isolated. As used herein, the term “isolated” means artificially produced. As used herein with respect to nucleic acids, the term “isolated” means: (i) amplified in vitro by, for example, polymerase chain reaction (PCR); (ii) produced by clonal recombination; (iii) purified, for example, by lysis and gel electrophoresis; or (iv) synthesized by, for example, chemical synthesis. An isolated nucleic acid is a nucleic acid that is readily manipulated using recombinant DNA techniques well known in the art. Thus, a nucleotide sequence contained in a vector, wherein the 5′ and 3′ restriction sites are known, or whose polymerase chain reaction (PCR) primer sequences have been disclosed, is considered isolated, but a nucleic acid sequence present in its natural host in its native state is not. Isolated nucleic acids may be substantially purified, but are not required to be. For example, nucleic acids isolated within a cloning or expression vector are impure because they may constitute only a small percentage of the material in the cell in which they reside. However, such nucleic acids are isolated, as the term is used herein, because they are readily manipulated using standard techniques known to those skilled in the art. As used herein with respect to proteins or peptides, the term "isolated" refers to proteins or peptides that have been isolated from their natural environment or artificially produced (e.g., through chemical synthesis, through recombinant DNA technology, etc.).
[0091] Those skilled in the art will also recognize that conserved amino acid substitutions can be performed to provide functionally equivalent variants or homologs of capsid proteins. In some aspects, this disclosure includes sequence alterations that result in conserved amino acid substitutions. As used herein, a conserved amino acid substitution refers to an amino acid substitution that does not alter the relative charge or size characteristics of the protein to which the substitution is performed. Variants can be prepared according to methods of altering polypeptide sequences known to those skilled in the art, such as those found in references that document such methods, e.g., *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, FMAusubel, et al., eds., John Wiley & Sons, Inc., New York. Conserved amino acid substitutions include substitutions between amino acids in the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D. Therefore, conserved amino acid substitutions can be performed on the amino acid sequences of the proteins and peptides disclosed herein.
[0092] The isolated nucleic acid of the present invention can be a recombinant adeno-associated virus (AAV) vector (rAAV vector). In some embodiments, the isolated nucleic acid as described in this disclosure comprises a region containing a first adeno-associated virus (AAV) inverted terminal repeat (ITR) sequence or a variant thereof (e.g., a first region). The isolated nucleic acid (e.g., a recombinant AAV vector) can be packaged into a capsid protein and administered to a subject and / or delivered to selected target cells. A “recombinant AAV (rAAV) vector” typically consists of at least a transgene and its regulatory sequences, as well as 5' and 3' AAV inverted terminal repeat sequences (ITRs). As disclosed elsewhere herein, the transgene may comprise one or more regions encoding one or more proteins (e.g., human CEP290 or fragments thereof). The transgene may also comprise regions encoding, for example, miRNA binding sites and / or expression control sequences (e.g., poly-A tails), as described elsewhere in this disclosure.
[0093] Typically, the ITR sequence is approximately 145 bp in length. Preferably, a substantially complete sequence encoding the ITR is used in the molecule, although minor modifications to these sequences are permitted. The ability to modify these ITR sequences is within the scope of the art (see, for example, texts such as Sambrook et al., "Molecular Cloning. A Laboratory Manual", 2nd ed., Cold Spring Harbor Laboratory, New York (1989); and K. Fisher et al., J Virol., 70:520 532 (1996), etc.). One example of such a molecule used in this invention is a transgene-containing "cis-acting" plasmid, wherein the selected transgene sequence and the associated regulatory element are flanked by 5' and 3' AAV ITR sequences. In some embodiments, one or more additional nucleotide sequences are found between the transgene and the 5' and / or 3' AAV ITR sequences. The AAV ITR sequence can be obtained from any known AAV, including currently identified mammalian AAV types. In some embodiments, the isolated nucleic acid (e.g., an rAAV vector) comprises at least one ITR having a serotype selected from AAV1, AAV2, AAV5, AAV6, AAV6.2, AAV7, AAV8, AAV9, AAV10, AAV11, and variants thereof. In some embodiments, the isolated nucleic acid comprises a region encoding an AAV2 ITR (e.g., a first region).
[0094] In some embodiments, the isolated nucleic acid further includes a region containing a second AAV ITR (e.g., a second region, a third region, a fourth region, etc.). In some embodiments, the second AAV ITR has a serotype selected from AAV1, AAV2, AAV5, AAV6, AAV6.2, AAV7, AAV8, AAV9, AAV10, AAV11, and variants thereof. In some embodiments, the second ITR is a mutant ITR lacking a functional terminal resolution site (TRS). The term "lacking a terminal resolution site" can refer to an AAV ITR containing a mutation (e.g., a sense mutation, such as a nonsynonymous mutation or a missense mutation) that negates the function of the terminal resolution site (TRS) of the ITR, or a truncated AAV ITR (e.g., a ΔTRS ITR) lacking a nucleic acid sequence encoding a functional TRS. Without being bound by any particular theory, rAAV vectors containing ITRs lacking functional TRS generate self-complementary rAAV vectors, such as those described in McCarthy (2008) Molecular Therapy 16(10):1648-1656.
[0095] In addition to the major elements identified above for the recombinant AAV vector, the vector also includes conventional control elements that are efficiently linked to the transgenic element in a manner that allows transcription, translation, and / or expression in cells transfected by the vector or infected by a virus generated by this invention. As used herein, "efficiently linked" sequences include expression control sequences linked to the target gene and expression control sequences that act in a trans or spaced manner to control the target gene. Expression control sequences include appropriate transcription initiation, termination, promoter, and enhancer sequences (e.g., Nrl-responsive elements, CRX-responsive elements, RET-1, etc.); effective RNA processing signals, such as splicing and polyadenylation (polyA) signals; sequences stabilizing cytoplasmic mRNA; sequences that enhance translation efficiency (i.e., Kozak concordant sequences); sequences that enhance protein stability; and sequences that enhance the secretion of the encoded product when needed. Many expression control sequences, including native, constitutive, inducible, and / or tissue-specific promoters, are known in the art and are available for use.
[0096] As used herein, when nucleic acid sequences (e.g., coding sequences) and regulatory sequences are covalently linked in a manner that brings the expression or transcription of the nucleic acid sequence under the influence or control of the regulatory sequence, they are referred to as effectively linked. If the nucleic acid sequence is to be translated into a functional protein, if a promoter in the 5′ regulatory sequence is induced to cause transcription of the coding sequence, and if the nature of the link between the two DNA sequences does not (1) lead to the introduction of a frameshift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein, then the two DNA sequences are referred to as effectively linked. Thus, if a promoter region is able to influence the transcription of the DNA sequence, thereby allowing the resulting transcript to be translated into the desired protein or polypeptide, then the promoter region is effectively linked to the nucleic acid sequence. Similarly, when two or more coding regions are linked in a manner that allows transcription from a common promoter to cause the expression of two or more proteins already translated within a reading frame, they are effectively linked. In some embodiments, effectively linked coding sequences produce fusion proteins. In some embodiments, effectively linked coding sequences produce functional RNA (e.g., miRNA).
[0097] A promoter is a DNA sequence that is recognized by the cell's synthetic machinery or introduced synthetic machinery and is required to initiate the specific transcription of a gene. The phrases "effectively positioned," "under control," or "under transcriptional control" mean that the promoter is in the correct position and orientation relative to the nucleic acid to control the initiation of RNA polymerase and gene expression.
[0098] For nucleic acids encoding proteins, polyadenylated sequences are typically inserted after the transgene sequence and before the 3′AAV ITR sequence. The rAAV constructs available in this disclosure may also contain introns desired to be located between the promoter / enhancer sequence and the transgene. One possible intron sequence is derived from SV-40 and is referred to as the SV-40 T intron sequence. Another vector element that can be used is the internal ribosome entry site (IRES). IRES sequences are used to generate more than one polypeptide from a single gene transcript. IRES sequences will be used to generate proteins containing more than one polypeptide chain. The selection of these and other common vector elements is routine, and many such sequences are available [see, for example, Sambrook et al., and the references cited therein, for example, on pages 3.18, 3.26 and 16.17, 16.27, and Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1989]. In some implementations, the foot-and-mouth disease virus 2A sequence is included in a multiprotein; this is a small peptide (approximately 18 amino acids in length) that has been shown to mediate the cleavage of the multiprotein (Ryan, MD et al., EMBO, 1994; 4:928-933; Mattion, NM et al., J Virology, November 1996; p.8124-8127; Furler, S et al., Gene Therapy, 2001; 8:864-873; and Halpin, C et al., The Plant Journal, 1999; 4:453-459). The cleavage activity of the 2A sequence has previously been demonstrated in artificial systems including plasmids and gene therapy vectors (AAV and retroviruses) (Ryan, MD et al., EMBO, 1994; 4:928-933; Mattion, NM et al., J Virology, November 1996; p.8124-8127; Furler, S et al., Gene Therapy, 2001; 8:864-873; and Halpin, C et al., The Plant Journal, 1999; 4:453-459; de Felipe, P et al., Gene Therapy, 1999; 6:198-208; de Felipe, P et al., Human Gene Therapy, 2000; 11:1921-1931; and Klump, H et al.). al., GeneTherapy, 2001; 8:811-817).
[0099] Examples of constitutive promoters include, but are not limited to, the retrotranscribed Rous sarcoma virus (RSV) LTR promoter (optionally with an RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with a CMV enhancer) [see, for example, Boshart et al., Cell, 41:521-530 (1985)], the SV40 promoter, the dihydrofolate reductase promoter, the β-actin promoter, the glycerol phosphokinase (PGK) promoter, and the EF1α promoter [Invitrogen]. In some embodiments, the promoter is the CB6 promoter. In some embodiments, the transgene comprises a CB6 promoter effectively linked to the nucleic acid sequence described in any one of SEQ ID NO: 5-7, 20-29, and 34-35. In some embodiments, the promoter is an enhanced chicken β-actin promoter. In some embodiments, the promoter is the U6 promoter. In some embodiments, the promoter is the chicken β-actin (CBA) promoter. In some embodiments, the transgene comprises a CBA promoter that is effectively linked to the nucleic acid sequence shown in any one of SEQ ID NOs: 5-7, 20-29, and 34-35. In some embodiments, a longer version of the CB promoter is used. In some embodiments, the longer version of the CB promoter enhances the expression of the transgene.
[0100] Inducible promoters allow for the regulation of gene expression and can be regulated by exogenously provided compounds, environmental factors such as temperature, or the presence of specific physiological states, such as the acute phase, a specific differentiation state of the cell, or only in replicating cells. Inducible promoters and inducible systems are available from a variety of commercial sources, including but not limited to Invitrogen, Clontech, and Ariad. Many other systems have been described, and those skilled in the art can readily select from these systems. Examples of inducible promoters regulated by exogenously provided promoters include the zinc-inducible sheep metallothionine (MT) promoter, the dexamethasone (Dex)-inducible mouse mammary tumor virus (MMTV) promoter, the T7 polymerase promoter system (WO 98 / 10088); the ecdysone insect promoter (No et al., Proc. Natl. Acad. Sci. USA, 93:3346-3351 (1996)), the tetracycline inhibitory system (Gossen et al., Proc. Natl. Acad. Sci. USA, 89:5547-5551 (1992)), the tetracycline inducible system (Gossen et al., Science, 268:1766-1769 (1995), see also Harvey et al. The inducible promoters include those from Wang et al., Curr. Opin. Chem. Biol., 2:512-518 (1998) and Wang et al., Gene Ther., 4:432-441 (1997) and rapamycin inducible promoters (Magari et al., J. Clin. Invest., 100:2865-2872 (1997)). Other types of inducible promoters that may be useful in this context are those that are regulated by specific physiological states such as temperature, acute phase, specific differentiation state of the cell, or only in replicating cells.
[0101] In another embodiment, a natural promoter of the transgene will be used. A natural promoter may be preferred when it is desired that the expression of the transgene mimic natural expression. A natural promoter can be used when the expression of the transgene must be regulated temporally or developmentally, or in a tissue-specific manner, or in response to a specific transcriptional stimuli. In a further embodiment, other natural expression control elements, such as enhancer elements, polyadenylation sites, or Kozak concordant sequences, may also be used to mimic natural expression.
[0102] In some embodiments, the regulatory sequence confers tissue-specific gene expression capability. In some cases, the tissue-specific regulatory sequence binds to a tissue-specific transcription factor that induces transcription in a tissue-specific manner. Such tissue-specific regulatory sequences (e.g., promoters, enhancers, etc.) are well known in the art. In some embodiments, the tissue-specific promoter is an eye-specific promoter. Examples of eye-specific promoters include, but are not limited to, the retinal schistosome promoter, the K12 promoter, the rhodopsin promoter, rod-cell-specific promoters, cone-cell-specific promoters, rhodopsin kinase promoters, the GRK1 promoter, the interretinal retinol-binding protein proximal (IRBP) promoter, retinal pigment epithelium-specific promoters (e.g., RPE65, Best1, etc.), and opsin promoters (e.g., red opsin promoters, blue opsin promoters, etc.). In some embodiments, the transgene comprises an IRBP promoter effectively linked to the nucleic acid sequence shown in any one of SEQ ID NO: 5-7, 20-29, and 34-35.
[0103] In some embodiments, the transgene comprises a rhodopsin kinase promoter effectively linked to the nucleic acid sequence shown in SEQ ID NO: 29 or 34. In some embodiments, the transgene comprises a rhodopsin kinase promoter effectively linked to the nucleic acid sequence encoding amino acids 1-200 and 580-1180 of human CEP290. In some embodiments, the transgene comprises a rhodopsin kinase promoter effectively linked to the nucleic acid sequence encoding amino acids 1-200 and 580-1180 of SEQ ID NO: 1. In some embodiments, the transgene comprises a rhodopsin kinase promoter effectively linked to the nucleic acid sequence encoding the amino acid sequence shown in SEQ ID NO: 19.
[0104] In some embodiments, the transgene comprises a rhodopsin kinase promoter effectively linked to the nucleic acid sequence shown in SEQ ID NO: 35. In some embodiments, the transgene comprises a rhodopsin kinase promoter effectively linked to the nucleic acid sequence encoding amino acids 1-380 and 580-1180 of human CEP290. In some embodiments, the transgene comprises a rhodopsin kinase promoter effectively linked to the nucleic acid sequence encoding amino acids 1-380 and 580-1180 of SEQ ID NO: 1. In some embodiments, the transgene comprises a rhodopsin kinase promoter effectively linked to the nucleic acid sequence encoding the amino acid sequence shown in SEQ ID NO: 36.
[0105] Some aspects of this disclosure relate to isolated nucleic acids comprising a transgene encoding one or more CEP290 fragments and a photoreceptor-specific promoter. The photoreceptor-specific promoter can target rod photoreceptor cells, cone photoreceptor cells, or both rod and cone photoreceptor cells. In some embodiments, the photoreceptor-specific promoter is a GRK promoter (e.g., a GRK promoter). In some embodiments, the transgene comprises a GRK promoter effectively linked to a nucleic acid sequence shown in any one of SEQ ID NO: 5-7, 20-29, and 34-35.
[0106] In some embodiments, the transgene further comprises one or more (e.g., 1, 2, 3, 4, 5 or more) introns. The length of the introns can vary. In some embodiments, the length of the introns ranges from about 100 nucleotides to about 1000 nucleotides (e.g., 100 to 500, 250 to 700, 500 to 1000, etc.). In some embodiments, the introns comprise chicken β-actin (CBA) introns, such as those shown in SEQ ID NO: 37. In some embodiments, the introns comprise synthetic introns, such as those comprising the sequence shown in SEQ ID NO: 38. In some embodiments, the introns comprise MBL introns, such as those shown in SEQ ID NO: 39. In some embodiments, the introns are located between a promoter (e.g., the CBA promoter, etc.) and a miniCEP290 protein-coding sequence (e.g., the sequences described in any one of SEQ ID NO: 5-7, 20-29, and 34-35).
[0107] In some aspects, this disclosure relates to an rAAV vector comprising an expression cassette containing a nucleic acid encoding the sequence shown in SEQ ID NO: 29 or 34 (e.g., a nucleic acid sequence encoding the amino acid sequence shown in SEQ ID NO: 19) effectively linked to a rhodopsin kinase (RK) promoter, wherein the expression cassette is flanked by AAV2ITRs. In some embodiments, the rAAV vector is capsidated with one or more AAV capsid proteins. In some embodiments, the one or more AAV capsid proteins are AAV8 capsid proteins or AAV5 capsid proteins.
[0108] In some embodiments, the promoter is an RNA polymerase III (pol III) promoter. Non-limiting examples of pol III promoters include the U6 and H1 promoter sequences. In some embodiments, the promoter is an RNA polymerase II (pol II) promoter. Non-limiting examples of pol II promoters include the T7, T3, SP6, RSV, and cytomegalovirus promoter sequences. In some embodiments, the pol III promoter sequence drives the expression of one or more repressive nucleic acids, and the pol II promoter sequence drives the expression of small genes.
[0109] Recombinant adeno-associated virus (rAAV)
[0110] In some respects, this disclosure provides isolated AAV. As used herein with respect to AAV, the term "isolated" refers to artificially produced or obtained AAV. Isolated AAV can be produced using recombinant methods. Such AAV is referred to herein as "recombinant AAV". Recombinant AAV (rAAV) preferably has tissue-specific targeting capability, such that the nuclease and / or transgene of rAAV will be specifically delivered to one or more predetermined tissues. The AAV capsid is an important element determining these tissue-specific targeting capabilities. Therefore, rAAVs with capsids suitable for the targeted tissues can be selected.
[0111] In some aspects, this disclosure relates to an rAAV comprising (i) a nucleic acid (e.g., an rAAV vector) containing an expression cassette encoding a sequence shown in SEQ ID NO: 29 or 34 (e.g., a nucleic acid sequence encoding the amino acid sequence shown in SEQ ID NO: 19) effectively linked to a rhodopsin kinase (RK) promoter, wherein the expression cassette is flanked by an AAV2ITR, and (ii) one or more AAV capsid proteins. In some embodiments, the one or more capsid proteins are AAV5 or AAV8 capsid proteins.
[0112] Methods for obtaining recombinant AAV with the desired capsid protein are well known in the art (see, for example, US 2003 / 0138772, the contents of which are incorporated herein by reference in their entirety). Typically, these methods involve culturing a nucleic acid sequence encoding an AAV capsid protein; a functional rep gene; a recombinant AAV vector containing an AAV inverted terminal repeat (ITR) sequence and a transgene; and a host cell sufficient to allow the packaging of the recombinant AAV vector into the AAV capsid protein for auxiliary function. In some embodiments, the capsid protein is a structural protein encoded by the AAV cap gene. AAV contains three capsid proteins: viral particle proteins 1 through 3 (named VP1, VP2, and VP3), all of which are transcribed from a single cap gene via alternative splicing. In some embodiments, VP1, VP2, and VP3 have molecular weights of approximately 87 kDa, approximately 72 kDa, and approximately 62 kDa, respectively. In some embodiments, during translation, the capsid protein forms a spherical 60-mer protein shell around the viral genome. In some implementations, the capsid protein functions to protect the viral genome, deliver the genome, and interact with the host. In some aspects, the capsid protein delivers the viral genome to the host in a tissue-specific manner.
[0113] In some embodiments, the AAV capsid protein has an AAV serotype selected from the group consisting of AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAV9, and AAV10. In some embodiments, the AAV capsid protein has a serotype derived from a non-human primate, such as the AAVrh8 serotype. In some embodiments, the AAV capsid protein has a serotype that is attracted to the subject's eye, such as AAVs that transduce the subject's ocular cells more effectively than other vectors (e.g., AAV5, AAV6, AAV6.2, AAV7, AAV8, AAV9, AAVrh.8, AAVrh.10, AAVrh.39, and AAVrh.43). In some embodiments, the AAV capsid protein has either the AAV8 serotype or the AAV5 serotype. In some embodiments, the AAV capsid protein comprises the sequence shown in SEQ ID NO: 9.
[0114] Components intended for culturing in host cells to package the rAAV vector into an AAV capsid can be trans-provided to the host cells. Alternatively, any one or more desired components (e.g., recombinant AAV vector, rep sequence, cap sequence, and / or helper function) can be provided by stable host cells engineered to contain one or more desired components using methods known to those skilled in the art. Most preferably, such stable host cells will contain the desired components under the control of an inducible promoter. However, the desired components may be under the control of a constitutive promoter. Examples of suitable inducible and constitutive promoters are provided herein when discussing regulatory elements suitable for use with transgenes. In another alternative, selected stable host cells may contain selected components under the control of a constitutive promoter and other selected components under the control of one or more inducible promoters. For example, stable host cells derived from 293 cells (containing E1 helper function under the control of a constitutive promoter) but containing rep and / or cap proteins under the control of an inducible promoter can be generated. Other stable host cells can be generated by those skilled in the art.
[0115] In some embodiments, this disclosure relates to host cells containing nucleic acids comprising a coding sequence for a protein (e.g., the CEP290 protein fragment). In some embodiments, this disclosure relates to compositions comprising the aforementioned host cells. In some embodiments, the compositions comprising the aforementioned host cells further comprise a cryopreservative.
[0116] The recombinant AAV vector, rep sequence, cap sequence, and helper function required for the production of the rAAV of this disclosure can be delivered to the packaging host cell using any suitable genetic element (vector). The selected genetic element can be delivered by any suitable method, including those described herein. Methods used to construct any embodiment of this disclosure are known to those skilled in the art of nucleic acid manipulation and include genetic engineering, recombinant engineering, and synthetic techniques. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY. Similarly, methods for producing rAAV viral particles are well known, and the choice of suitable method is not a limitation of this disclosure. See, for example, K. Fisher et al., J. Virol., 70:520-532 (1993) and U.S. Patent No. 5,478,745.
[0117] In some embodiments, recombinant AAV can be produced using a triple transfection method (described in detail in U.S. Patent No. 6,001,650). Typically, recombinant AAV is produced by transfecting host cells with a recombinant AAV vector (containing a transgene) to be packaged into AAV particles, an AAV helper function vector, and a helper function vector. The AAV helper function vector encodes “AAV helper function” sequences (i.e., rep and cap), which function in the trans configuration for productive AAV replication and capsid formation. Preferably, the AAV helper function vector supports efficient AAV vector production without producing any detectable wild-type AAV virus particles (i.e., AAV virus particles containing functional rep and cap genes). Non-limiting examples of vectors suitable for use with this disclosure include the pHLP19 vector described in U.S. Patent No. 6,001,650 and the pRep6cap6 vector described in U.S. Patent No. 6,156,303, the entire contents of which are incorporated herein by reference. Helper functions encode nucleotide sequences for non-AAV-derived viral and / or cellular functions that AAV depends on for replication (i.e., "helper functions"). Helper functions include those required for AAV replication, including but not limited to those involved in activating AAV gene transcription, stage-specific AAV mRNA splicing, AAV DNA replication, cap expression product synthesis, and AAV capsid assembly. Virus-based helper functions can be derived from any known helper virus, such as adenovirus, herpesvirus (except herpes simplex virus type 1), and vaccinia virus.
[0118] In some respects, this disclosure provides transfected host cells. The term “transfection” is used to refer to the uptake of exogenous DNA by a cell, and the cell is “transfected” when the exogenous DNA is introduced into the cell membrane. Many transfection techniques are well known in the art. See, for example, Graham et al. (1973) Virology, 52:456, Sambrook et al. (1989) Molecular Cloning, a laboratory manual, Cold Spring Harbor Laboratories, New York, Davis et al. (1986) Basic Methods in Molecular Biology, Elsevier, and Chu et al. (1981) Gene 13:197. Such techniques can be used to introduce one or more exogenous nucleic acids, such as nucleotide integrative vectors and other nucleic acid molecules, into suitable host cells.
[0119] "Host cell" refers to any cell that has or is capable of having the target substance. Typically, host cells are mammalian cells. Host cells can serve as recipients of AAV helper constructs, AAV small gene plasmids, helper functional vectors, or other transferred DNA related to recombinant AAV production. The term includes the offspring of the original transfected cell. Therefore, as used herein, "host cell" can refer to a cell that has been transfected with a foreign DNA sequence. It should be understood that the offspring of a single parent cell may not necessarily be identical to the original parent in morphology, genome, or total DNA complement due to natural, accidental, or intentional mutations.
[0120] As used herein, the term "cell line" refers to a population of cells capable of continuous or prolonged growth and division in vitro. Typically, a cell line is a clonal population derived from a single progenitor cell. It is also known in the art that spontaneous or induced changes in karyotype can occur during the storage or transfer of such clonal populations. Therefore, cells derived from the cell lines mentioned may not be identical to the ancestral cells or cultures, and the cell lines mentioned include such variants.
[0121] As used herein, the term “recombinant cell” refers to a cell in which a foreign DNA fragment has been introduced (e.g., a DNA fragment that leads to the transcription of bioactive polypeptides or the production of bioactive nucleic acids (e.g., RNA)).
[0122] As used herein, the term "vector" includes any genetic element, such as plasmids, bacteriophages, transposons, granules, chromosomes, artificial chromosomes, viruses, viral particles, etc., which is capable of replicating when bound to a suitable control element and can transfer gene sequences between cells. Therefore, the term includes cloning and expression vectors, as well as viral vectors. In some embodiments, the intended useful vectors are those in which the nucleic acid fragment to be transcribed is under the transcriptional control of a promoter. The term "expression vector or construct" refers to any type of gene construct containing nucleic acids, wherein some or all of the nucleic acid coding sequence can be transcribed. In some embodiments, expression involves the transcription of nucleic acids, for example, to produce a biologically active polypeptide product or functional RNA (e.g., guide RNA) from a transcribed gene.
[0123] The foregoing methods for packaging recombinant vectors in desired AAV capsids to produce the rAAV of this disclosure are not intended to limit, and other suitable methods will be apparent to those skilled in the art.
[0124] Delivery of CEP290 genetically modified organisms to the eyes
[0125] This document provides a method for delivering a transgene to the eye tissue of a subject (e.g., photoreceptor cells, such as rod or cone cells, retinal cells, retinal pigment epithelial cells, etc.). This method typically involves administering to the subject an effective amount of isolated nucleic acid, rAAV, or a composition containing nucleic acid for expressing the transgene in the subject (e.g., the CEP290 protein fragment). The subject can be any suitable mammalian organism. In some embodiments, the subject is a human. Other examples of subjects include mice, rats, non-human primates, pigs, dogs, cats, or horses.
[0126] The “effective dose” of rAAV is an amount sufficient to infect a sufficient number of cells in the target tissue of a subject. In some embodiments, the target tissue is eye tissue (e.g., photoreceptors, retina, retinal pigment epithelium, etc.). The effective dose can be an amount sufficient to provide a therapeutic benefit in the subject, such as improving one or more symptoms of the subject’s disease, such as symptoms of ocular cilia (e.g., ocular cilia associated with deletion or mutation of the CEP290 gene, such as LCA). In some cases, the effective dose can be an amount sufficient to produce a stable somatic transgenic animal model. The effective dose will depend on a variety of factors, such as the subject’s species, age, weight, health status, and the eye tissue to be targeted, and therefore may vary from subject to subject and tissue.
[0127] The effective amount can also depend on the rAAV used. This invention is based in part on the understanding that rAAVs containing capsid proteins of a specific serotype (e.g., AAV5, AAV6, AAV6.2, AAV7, AAV8, AAV9, AAVrh.8, AAVrh.10, AAVrh.39, and AAVrh.43) mediate transduction in ocular tissues (e.g., photoreceptors, retina, etc.) more effectively than rAAVs containing capsid proteins of different serotypes. Therefore, in some embodiments, rAAVs contain capsid proteins of AAV serotypes selected from the group consisting of: AAV5, AAV6, AAV6.2, AAV7, AAV8, AAV9, AAVrh.8, AAVrh.10, AAVrh.39, and AAVrh.43. In some embodiments, rAAVs contain the capsid protein of serotype AAV8 (SEQ ID NO: 9). In some embodiments, the capsid protein comprises at least 70%, at least 80%, at least 90%, at least 95%, or at least 99% of the same amino acid sequence as SEQ ID NO: 9. In some embodiments, the capsid protein is the AAV5 capsid protein.
[0128] In some implementations, the effective amount of rAAV is 10. 10 10 11 10 12 10 13 Or 1014 One genome copy / kg. In some implementations, the effective dose of rAAV is 10 per subject. 10 10 11 10 12 10 13 10 14 Or 10 15 One genome copy.
[0129] The effective dose can also depend on the method of administration. For example, in some cases, targeting ocular tissue (e.g., photoreceptors, retina, etc.) by intrastromal or subcutaneous injection may require a different (e.g., higher or lower) dose than targeting ocular tissue (e.g., photoreceptors, retina, etc.) by another method (e.g., systemic, local, subretinal, etc.). In some embodiments, intrastromal injection (IS) has effective transduction of rAAV-mediated ocular (e.g., corneal, photoreceptor, retina, etc.) cells by certain serotypes (e.g., AAV5, AAV6, AAV6.2, AAV7, AAV8, AAV9, AAVrh.8, AAVrh.10, AAVrh.39, and AAVrh.43). Therefore, in some embodiments, the injection is intrastromal injection (IS). In some embodiments, administration is by injection, optionally subretinal or intravitreal. In some embodiments, the injection is subretinal. In some embodiments, the injection is suprachoroidal. In some embodiments, the injection is local administration (e.g., local application to the eye). In some cases, multiple doses of rAAV are administered.
[0130] Without being bound by any particular theory, the efficient transduction of rAAV to ocular cells (e.g., photoreceptors, retina, retinal pigment epithelium, etc.) described herein can be used to treat subjects suffering from ocular diseases (e.g., ocular cilia). Therefore, methods and compositions for treating ocular diseases are also provided herein. In some aspects, this disclosure provides a method for treating ocular cilia (e.g., ocular cilia associated with deletion or mutation of the CEP290 gene), the method comprising: administering an effective amount of rAAV to a subject suffering from or suspected of having ocular cilia, wherein the rAAV comprises (i) a capsid protein having a serotype selected from AAV5, AAV6, AAV6.2, AAV7, AAV8, AAV9, AAVrh.8, AAVrh.10, AAVrh.39, and AAVrh.43, and (ii) a nucleic acid comprising a promoter efficiently linked to a transgene (e.g., a transgene encoding a CEP290 protein fragment as described herein).
[0131] In some embodiments, application of rAAV (or isolated nucleic acid) as described in this disclosure results in transduction of one or more cells comprising cilia, optionally photoreceptor-sensing cilia. Photoreceptor (PR)-sensing cilia nucleate from the basal body on the apical surface of the inner segment. As microtubules extend, they form a bitubular structure called a connecting cilia (CC). CCs resemble the transition zone of the protocilia and extend into the outer segment (OS) of the photoreceptor cell. CCs act as conduits for the unidirectional or bidirectional transport of cargo portions between the inner and outer segments. CCs also act as “gatekeepers” to regulate the entry and exit of cargo, which helps maintain their distinctive composition. In some embodiments, application of rAAV (or isolated nucleic acid) as described in this disclosure results in the growth or formation of photoreceptor-sensing cilia, connecting cilia, or a combination thereof.
[0132] In some embodiments, delivery of rAAV (or isolated nucleic acid) as described in this disclosure, such as miniCEP290-1-200 / 580-1180, results in improved structural and / or functional rescue relative to previously described miniCEP290 vectors (e.g., miniCEP290-580-1180) (e.g., as measured by ERG, immunofluorescence analysis, etc.). In some embodiments, delivery of rAAV improves structural and / or functional rescue by 2 to 100 times (e.g., 2, 3, 4, 5, 10, 20, 25, 50, 75, 100 times). In some embodiments, delivery of rAAV improves structural and / or functional rescue by more than 100 times (e.g., 100, 200, 300, 400, 500, etc.).
[0133] rAAV can be delivered to a subject in compositional form using any suitable method known in the art. rAAV, preferably suspended in a physiologically compatible carrier (i.e., in the composition), can be administered to a subject, i.e., a host animal, such as a human, mouse, rat, cat, dog, sheep, rabbit, horse, cattle, goat, pig, guinea pig, hamster, chicken, turkey, or non-human primate (e.g., rhesus monkey). In some embodiments, the host animal does not include humans.
[0134] RAAV can be delivered to mammalian subjects by, for example, intraocular injection, subretinal injection, choroidal injection, or topical application (e.g., eye drops). In some embodiments, intraocular injection is intrastromal injection, subconjunctival injection, or intravitreal injection. In some embodiments, the injection is not a topical application. Combinations of application methods (e.g., topical application and intrastromal injection) may also be used.
[0135] The compositions disclosed herein may comprise a single rAAV, or an rAAV in combination with one or more other viruses (e.g., a second rAAV encoding one or more different transgenes, such as multiple rAAVs, each encoding a different CEP290 fragment). In some embodiments, the composition comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different rAAVs, each having one or more different transgenes. Those skilled in the art will recognize that in some embodiments, multiple isolated nucleic acids (or vectors, such as plasmids, lentiviral vectors, etc.) are administered to a subject, each of which encodes a different CEP290 fragment.
[0136] In some embodiments, the composition further comprises a pharmaceutically acceptable carrier. Those skilled in the art can readily select a suitable carrier considering the rAAV or the indication the composition targets. For example, a suitable carrier includes saline, which can be formulated with a variety of buffer solutions (e.g., phosphate-buffered saline). Other exemplary carriers include sterile saline, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, and water. The choice of carrier does not constitute a limitation of the invention.
[0137] Optionally, in addition to rAAV and (one or more) carriers, the compositions disclosed herein may also contain other pharmaceutical ingredients, such as preservatives or chemical stabilizers. Suitable exemplary preservatives include chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, parabens, ethyl vanillin, glycerin, phenol, and p-chlorophenol. Suitable chemical stabilizers include gelatin and albumin.
[0138] The composition (e.g., a composition comprising one or more rAAVs) is applied in sufficient amounts to transfect cells of the desired tissue (e.g., ocular tissue, such as photoreceptors, retina, etc.) and to provide adequate gene transfer and expression levels without producing undue adverse effects. Examples of pharmaceutically acceptable routes of administration include, but are not limited to, direct delivery to the selected organ (e.g., subretinal delivery to the eye), oral, inhalation (including intranasal and intratracheal delivery), intraocular, intravenous, intramuscular, subcutaneous, intradermal, intratumoral, and other parenteral routes. Routes of administration may be combined if desired.
[0139] The dosage of rAAV viral particles required to achieve a specific "therapeutic effect," such as the dosage unit of genome copies per kilogram of body weight (GC / kg), will vary depending on a variety of factors, including but not limited to: the route of administration of the rAAV viral particles, the gene or RNA expression level required to achieve the therapeutic effect, the specific disease or condition being treated, and the stability of the gene or RNA product. Those skilled in the art can readily determine the dosage range of rAAV viral particles for treating patients with a specific disease or condition based on the above and other factors.
[0140] An effective amount of rAAV is an amount sufficient to target and infect the animal and the desired tissue. The effective amount will depend primarily on factors such as the species, age, weight, health status of the subject, and the tissue to be targeted, and therefore can vary from animal to tissue. In some embodiments, the volume of rAAV administered (e.g., a composition containing rAAV) ranges from about 10 μl to about 1000 μl per eye. In some embodiments, rAAV is administered at approximately 10 μl per eye. 11 To about 10 13 One genome copy or about 10 11 To about 10 14 A dose of one rAAV genome copy / ml is administered. In some embodiments, the effective amount is generated by multiple doses of rAAV.
[0141] In some embodiments, a single dose of rAAV is administered to the subject no more than once per calendar day (e.g., a 24-hour cycle). In some embodiments, the dose is administered to the subject only once throughout their lifetime. In some embodiments, a single dose is administered only once in each eye of the subject throughout their lifetime. In some embodiments, the administration is bilateral, and the doses may be administered at intervals of approximately 1 week, approximately 2 weeks, approximately 3 weeks, approximately 4 weeks, approximately 1 month, or approximately 2 months. In some embodiments, a single dose of rAAV is administered to the subject no more than once every 2, 3, 4, 5, 6, or 7 calendar days. In some embodiments, a single dose of rAAV is administered to the subject no more than once per calendar week (e.g., 7 calendar days). In some embodiments, a single dose of rAAV is administered to the subject no more than once every two weeks (e.g., once between two calendar weeks). In some embodiments, a single dose of rAAV is administered to the subject no more than once per calendar month (e.g., once in 30 calendar days). In some embodiments, a single dose of rAAV is administered to the subject no more than once every six calendar months. In some embodiments, a single dose of rAAV is administered to the subject no more than once per calendar year (e.g., 365 days or 366 days in a leap year). In some embodiments, a single dose of rAAV is administered after birth. In some embodiments, a single dose of rAAV is administered between day 7 and day 13 after birth. In some embodiments, a single dose of rAAV is administered on day 10 after birth.
[0142] In some embodiments, the rAAV composition is formulated to reduce the aggregation of AAV particles in the composition, particularly in the presence of high rAAV concentrations (e.g., ~10). 13 In cases where GC / ml or higher, appropriate methods to reduce aggregation can be used, including, for example, the addition of surfactants, pH adjustment, salt concentration adjustment, etc. (See, for example, Wright FR, et al., Molecular Therapy (2005) 12, 171–178, the contents of which are incorporated herein by reference.)
[0143] The formulation of pharmaceutically acceptable excipients and carrier solutions is well known to those skilled in the art, as is the development of suitable dosages and treatment regimens for the use of the specific compositions described herein in a variety of therapeutic applications. Typically, these formulations may contain at least about 0.1% or more of the active compound, although the percentage of (one or more) active ingredients can, of course, vary and can conveniently be between about 1 or 2% of the total weight or volume of the formulation and about 70% or 80% or more. Naturally, the amount of the active compound in each therapeutically useful composition can be prepared in such a way that a suitable dose will be obtained at any given unit dose of the compound. Those skilled in the art of preparing such pharmaceutical formulations will consider factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, and other pharmacological considerations, and therefore, a variety of dosages and treatment regimens may be desirable.
[0144] In some embodiments, rAAV is delivered directly to the target tissue, such as ocular tissue (e.g., photoreceptors, retina, etc.), in the form of a suitably formulated pharmaceutical composition disclosed herein. However, in some cases, it may be necessary to deliver the rAAV-based therapeutic construct, alone or additionally, via another route, such as subcutaneously, intrapancreatically, intranasally, parenterally, intravenously, intramuscularly, intrathecally, or orally, intraperitoneally, or by inhalation. In some embodiments, rAAV can be delivered using administration methods as described in U.S. Patent Nos. 5,543,158, 5,641,515, and 5,399,363 (each expressly incorporated herein by reference). In some embodiments, preferred administration methods include intravitreal injection or subretinal injection.
[0145] Suitable drug forms for injection include suspension-based formulations, sterile aqueous solutions or dispersions, and sterile powders for the ad hoc preparation of sterile injections or dispersions. Dispersions can also be prepared in glycerol, liquid polyethylene glycol, mixtures thereof, and in oils. Under normal storage and use conditions, these formulations contain preservatives to prevent microbial growth. In many cases, the form is sterile and fluid to the point of ease of injection. It must be stable under manufacturing and storage conditions and must be protected against contamination by microorganisms (e.g., bacteria and fungi). The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), suitable mixtures thereof, and / or vegetable oils. For example, appropriate fluidity can be maintained by using a coating such as lecithin, by maintaining the desired particle size in the case of a dispersant, and by using surfactants. Various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc., can prevent microbial action. In many cases, isotonic agents, such as sugars or sodium chloride, are preferred. Extended absorption of injectable compositions can be achieved by using delayed absorption agents (such as aluminum monostearate and gelatin) in the composition.
[0146] For example, for the administration of injectable aqueous solutions, the solution may be appropriately buffered if necessary, and the liquid diluent should first be made isotonic with sufficient saline or glucose. These specific aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration. Suitable sterile aqueous media may be used in this regard. For example, a dose may be dissolved in 1 ml of isotonic NaCl solution and added to 1000 ml of subcutaneous infusion or injected at the recommended infusion site (see, for example, Remington's Pharmaceutical Sciences, 15th edition, pp. 1035-1038 and 1570-1580). Dosage will inevitably vary depending on the host. In any case, the person responsible for administration will determine the appropriate dose for the individual host.
[0147] A sterile injectable solution is prepared by incorporating the desired amount of active rAAV, along with various other ingredients listed herein (if needed), into a suitable solvent, followed by filtration and sterilization. Typically, a dispersion is prepared by incorporating various sterilized active ingredients into a sterile medium containing a base dispersion medium and any other desired ingredients from those listed above. In the case of sterile powders used to prepare sterile injectable solutions, a preferred method of preparation is vacuum drying and freeze-drying techniques, which yield a powder of the active ingredient plus any additional desired ingredients from a previously sterile filtered solution.
[0148] The rAAV compositions disclosed herein can also be formulated into neutral or salt forms. Pharmaceutically acceptable salts include acid addition salts (formed with the free amino groups of proteins) and salts formed with inorganic acids such as hydrochloric acid or phosphoric acid, or organic acids such as acetic acid, oxalic acid, tartaric acid, mandelic acid, etc. Salts formed with free carboxyl groups can also be derived from inorganic bases such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, or ferric hydroxide, as well as organic bases such as isopropylamine, trimethylamine, histidine, procaine, etc. In formulation, the solution will be administered in a manner compatible with dosage forms and at a therapeutically effective amount. This formulation is readily available for administration in various dosage forms, such as injectable solutions, drug-release capsules, etc.
[0149] As used herein, "carrier" includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption-retarding agents, buffers, carrier solutions, suspensions, colloids, etc. The use of such media and substances for pharmaceutically active substances is well known in the art. Additional active ingredients may also be incorporated into the composition. The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that do not produce allergic reactions or similar adverse reactions when administered to a host.
[0150] The compositions of this disclosure can be introduced into suitable host cells using delivery media such as liposomes, nanocapsules, microparticles, microspheres, lipid particles, vesicles, etc. In particular, transgenes delivered by rAAV vectors can be formulated and encapsulated in lipid particles, liposomes, vesicles, nanospheres, or nanoparticles for delivery.
[0151] Such formulations may be preferred for use in pharmaceutically acceptable formulations that introduce the nucleic acid or rAAV constructs disclosed herein. The formation and use of liposomes are generally known to those skilled in the art. Recently, liposomes with improved serum stability and circulating half-life have been developed (US Patent No. 5,741,516). Furthermore, various methods for using liposomes and liposome-like formulations as potential drug delivery carriers have been described (US Patent Nos. 5,567,434; 5,552,157; 5,565,213; 5,738,868 and 5,795,587).
[0152] Liposomes have been successfully used in many cell types that are typically resistant to transfection by other procedures. Furthermore, liposomes do not have the DNA length limitations typical of virus-based delivery systems. Liposomes have been efficiently used to introduce genes, drugs, radiotherapeutic agents, viruses, transcription factors, and allosteric effectors into a wide variety of cultured cell lines and animals. In addition, several successful clinical trials have been completed to examine the effectiveness of liposome-mediated drug delivery.
[0153] Liposomes are formed from phospholipids dispersed in an aqueous medium and spontaneously form multilayered concentric bilayered vesicles (also known as multilayered vesicles (MLVs)). MLVs typically have a diameter of 25 nm to 4 μm. Sonication of MLVs results in the formation of vesicles with diameters ranging from 200 nm to... Small monolayer vesicles (SUVs) within the range contain an aqueous solution in their core.
[0154] Alternatively, nanocapsule formulations of rAAV can be used. Nanocapsules can typically capture substances in a stable and reproducible manner. To avoid the side effects of intracellular polymer overload, these ultrafine particles (approximately 0.1 μm in size) should be designed using polymers that are biodegradable in vivo. Consider using biodegradable alkyl cyanoacrylate nanoparticles that meet these requirements.
[0155] Kits and related compositions
[0156] In some embodiments, the pharmaceutical agents described herein may be assembled into pharmaceutical or diagnostic or research kits to facilitate their use in therapeutic, diagnostic, or research applications. A kit may include one or more containers containing the components of this disclosure and instructions for use. Specifically, such a kit may include one or more pharmaceutical agents described herein, along with instructions describing the intended use and proper use of these agents. In some embodiments, the pharmaceutical agents in the kit may be in a form of pharmaceutical formulation and dosage suitable for a particular application and for methods of administration. Kits for research purposes may contain appropriate concentrations or quantities of ingredients for running various experiments.
[0157] In some embodiments, this disclosure relates to a kit for producing rAAV, the kit comprising a container holding isolated nucleic acids containing a transgene encoding a CEP290 protein fragment having the amino acid sequence shown in any one of SEQ ID NOs: 2-4 and 10-19. In some embodiments, the kit further comprises a container holding isolated nucleic acids encoding an AAV capsid protein, such as the AAV8 capsid protein (e.g., SEQ ID NO: 9) or the AAV5 capsid protein.
[0158] The kit can be designed to facilitate use by researchers using the methods described herein and can take many forms. Where applicable, each composition of the kit may be provided in liquid form (e.g., solution) or solid form (e.g., dry powder). In some cases, some compositions may be constructible or otherwise processable (e.g., as an active form), for example, by adding a suitable solvent or other kind (e.g., water or cell culture medium), which may or may not be provided with the kit. As used herein, “instructions” may define the components of instructions and / or promotion and generally refers to written instructions on or associated with the packaging of this disclosure. Instructions may also include any oral or electronic instructions provided in any way that makes it clear to the user that the instructions are related to the kit, such as audiovisual (e.g., videotape, DVD, etc.), the Internet and / or network-based communications, etc. Written instructions may be in the form prescribed by a government agency regulating the manufacture, use or sale of pharmaceuticals or biological products, and may also reflect approval for animal administration by the manufacturing, using or selling agency.
[0159] The kit may contain any one or more of the components described herein in one or more containers. For example, in one embodiment, the kit may include instructions for mixing one or more components of the kit and / or separating and mixing samples for application to a subject. The kit may include a container holding the pharmaceutical agents described herein. The pharmaceutical agents may be in liquid, gel, or solid (powder) form. The pharmaceutical agents may be aseptically prepared, packaged in syringes, and shipped refrigerated. Alternatively, it may be packaged in vials or other containers for storage. A second container may contain other aseptically prepared pharmaceutical agents. Alternatively, the kit may include an active agent pre-mixed and shipped in syringes, vials, tubes, or other containers.
[0160] Exemplary embodiments of the present invention will be described in more detail through the following examples. These embodiments are examples of the present invention, and those skilled in the art will recognize that the invention is not limited to these exemplary embodiments. Example
[0161] Example 1
[0162] Treatment strategies for CEP290-LCA
[0163] The relative avoidance of the central retinal region in CEP290-LCA patients suggests that gene therapy may be a viable option for visual restoration. However, progress in developing mutation-independent gene replacement strategies for CEP290-LCA has been significantly delayed because the long CEP290 gene is not suitable for packaging into conventional AAV vector systems used for gene therapy. This embodiment describes the treatment of CEP290-LCA via AAV delivery of a CEP290 fragment. In some embodiments, the CEP290 fragment restores ciliary growth and photoreceptor function in a mutation-independent manner, and thus can be used to treat non-syndromic LCA and retinal degeneration in systemic cilia diseases caused by CEP290 mutations.
[0164] The full-length CEP290 cDNA is ~8kb long, typically exceeding the packaging limits of conventional AAV vectors. A schematic diagram of the full-length CEP290 gene representing the locations of different protein-protein interaction domains is shown below. Figure 1 Here, a CEP290 fragment that retains function in the photoreceptor (PR) and can be delivered using a conventional AAV vector was identified. Since CEP290 is a ciliary protein and regulates ciliary growth, an in vitro assay for ciliary growth was developed to serve as an alternative biomarker for testing the function of shorter CEP290 regions. It was observed that, compared to the control, the Cep290- mutant (Cep290...)... rd16 Mouse embryonic fibroblasts (MEFs) from mice (which reproduced the early-onset severe PR degeneration phenotype) had fewer ciliated cells and shorter cilia-forming cells. This observation is consistent with previous research that revealed fewer and shorter cilia in fibroblasts derived from CEP290-LCA patient samples.
[0165] like Figure 2A-2B As shown, compared with the control group having cilia of ~3.8 μm length, Cep290 rd16 The cilia length of MEF was ~2.7 μm. Furthermore, compared to the control, at Cep290... rd16 Fewer cilia were detected in MEF.
[0166] Next, the effects of expressing full-length human CEP290 protein on Cep290 were investigated. rd16 The effect of MEF on cilia length. Full-length human CEP290 protein was observed to be correctly located in cilia, as determined by co-staining with ARL13b, a cilia marker. Figure 3 Expression of the GFP protein did not lead to its localization to cilia. Furthermore, measurements of cilia length indicated that expression of the CEP290 protein significantly rescued Cep290 compared to GFP expression. rd16 cilia length in MEF.
[0167] Building vCEP290
[0168] The CEP290 gene encodes a protein that is primarily coiled and helical. Constructs with the repetitive domains of human CEP290 removed were produced, such as miniCEP290 encoding GFP fusion. 580-1695 miniCEP290 1751-2050 and miniCEP290 2037-2479 plasmids ( Figure 4A The variant was cloned into the pEGFP-C1 vector, which expresses the gene under the control of the CMV promoter. Immunoblotting analysis of protein extracts from transiently transfected mouse embryonic fibroblasts confirmed that the construct expressed a stable CEP290 protein fragment. Figure 4B (See arrow). To test the functional potential of the miniCEP290, the Cep290 was used. rd16 Alternative assay system for MEF (mouse embryonic fibroblasts). Figure 9 Other instances of the CEP290 variant are shown.
[0169] The effect of vCEP290 on cilia length
[0170] like Figure 5A As shown, different GFP-vCEP290 encoding plasmids in Cep290 rd16 Expression of vCEP290 in wild-type mouse embryonic fibroblasts indicates that... 580-1695 Primarily localized to the basal body (colocalizing with γ-tubulin) and proximal cilia (colocalizing with ADP-ribosylation factor-like 13B; ARL13B; and cilia markers). Expression of other variants indicated a relatively diffuse pattern of localization. The regulation of Cep290 by vCEP290 was then evaluated. rd16 The ability of fibroblasts to maintain ciliary length. For example... Figure 5B As shown, when expressing vCEP290 580-1695 At that time, the ciliary length of the mutant fibroblasts was significantly increased. Other variants and the negative control expressing only GFP did not show changes in fibroblast ciliary length. No effect on ciliary length of wild-type fibroblasts was observed.
[0171] Then, further research was conducted on shortening vCEP290. 580-1695 Will this lead to cilia length saving? vCEP290 encoding GFP fusion was produced. 580-1180 and vCEP290 1181-1695 The plasmids were tested in Cep290. rd16The potential for expression, localization, and cilia length rescue in fibroblasts. Immunoblot analysis using an anti-GFP antibody confirmed that both variants exhibited optimal expression and localization in cilia (…). Figures 6A-6B vCEP290 1181-1695 Data indicated diffuse staining primarily localized to the base and surrounding matrix of the cilia. Cilia rescue assay data showed that expression of any variant resulted in Cep290. rd16 The length of the cilia in fibroblasts increased significantly. Figure 6C and Figure 10 ).
[0172] The potential of vCEP290 in the body
[0173] The in vivo functionality of the vCEP290 construct was investigated. vCEP290... 580-1180 vCEP290 1181-1695 and vCEP290 2037-2479 (As a negative control, because it did not rescue ciliary length defects in fibroblasts) was cloned into an AAV2 vector with a CBA promoter and containing an IRES (internal ribosome entry site) between the target gene (e.g., vCEP290) and GFP. This allows both CEP290 and GFP to be translated from a single bicistronic mRNA and facilitates the recognition of transduced photoreceptors using an anti-GFP antibody. Each rAAV (e.g., AAV2 / 8-CBA-vCep290) 580-1180 -IRES-GFP,AAV2 / 8-CBA-vCep290 1181-1695 -IRES-GFP,AAV2 / 8-CBA-vCep290 2037-2472 -IRES-GFP and negative control AAV2 / 8-CBA-GFP) at 8x10 9 vg / eye was injected at a volume of 1 μl into Cep290 at the P0 stage. rd1 Subretinal space of pups. PR function and retinal morphology of mice were assessed up to 5 weeks post-injection.
[0174] Electroretinography (ERG) analysis 3 weeks post-injection revealed the effects of miniCEP290 injection on PR function. 580-1180 Cuspopia (rod-mediated PR) and photopicopia (cone-mediated PR) in mice Figures 7A-7B and Figure 11-12 The response of both was improved (25-30%). Using miniCEP290 2037-2479 Or no improvement was detected in GFP. Further analysis revealed that the improvement in ERG remained stable for up to 4 weeks after injection.
[0175] The number of ONL layers associated with PR survival was also counted in retinal frozen sections: after injection of miniCep290 580-1180 Cep290 rd16 ~6-7 layers were observed in the retina; after injection of miniCep290 1181-1695 Cep290 rd16 Four to five layers were observed in the retina; after injection of miniCep290 2037-2472 Or GFP (equivalent to uninjected Cep290 at 3 weeks of age) rd16 Two to three layers were observed in the retina, such as Figure 8A As shown. Injection of miniCEP290 was also observed. 580-1180 CEP290 rd16 Ultrathin sections of the retina showed significant preservation of the outer nuclear layer (ONL). Figure 8B ).
[0176] The injection of miniCEP290 was examined by staining with peripheral protein-RDS (slow retinal degeneration, PR outer segment marker 45). 580-1180 The structure of the outer segment of the photoreceptor (PR) was preserved in mice injected with miniCEP290. RDS is a structural protein that specifically localizes to the outer segment (OS) of the optic disc and maintains the OS structure. RDS expression was undetectable in mice injected with GFP, compared to mice injected with miniCEP290. 580-1180 Cep290rd16 mice showed improved RDS localization in the outer segment ( Figure 8C The expression of two key light-transferring proteins, rhodopsin and cone opsin, was also examined. This was done after injection of miniCEP290. 2037-2479 Undetectable opsin expression was detected in the retina. However, injection of miniCEP290... 580-1180 The retina revealed the expression of rhodopsin and cone opsin in the outer segment. Figure 8D Furthermore, some staining of cone opsins was observed in the inner segment and outer nuclear layer. Overall, the data indicate that miniCEP290... 580-1180 The expression can improve CEP290 rd16 Functions, morphology, and opsin transport.
[0177] Materials and methods
[0178] Cell culture, transient transfection and immunostaining
[0179] Sources from WT and Cep290 rd16Mouse MEFs were maintained in DMEM containing 10% FBS. Transient transfection with GFP-CEP290-FL or GFP-miniCEP290 was performed using Lipofectamine 2000 (Thermo Fisher). Transfected cells were harvested for Western blotting or serum starvation to induce ciliary growth. Ciliated cells were then immunostained and imaged under a Leica microscope (DM5500). Images were then processed using ImageJ for ciliary length evaluation.
[0180] Component and AAV production
[0181] For in vitro experiments, cDNA expressing full-length or miniCEP290 was cloned into the pEGFP-C1 plasmid expressing a GFP-tagged protein controlled by the CMV promoter. For AAV production, cDNA encoding miniCEP290 was cloned into the pAAV2 vector plasmid located upstream of the IRES (internal ribosome entry site) GFP, between the CMV enhancer / CBA (chicken β-actin) promoter and the β-globin intron. This expression cassette is flanked by AAV2 inverted terminal repeats (ITRs). The recombinant AAV2 genome was packaged with an AAV8 capsid via HEK293 triple transfection and purified by CsCl gradient centrifugation.
[0182] Subretinal injection
[0183] Wild-type C57BL6 / J mice were obtained from commercial sources. Cep290 was also obtained. rd16 Mice. Cep290 rd16 Mouse pups (P0 / P1) were injected subretinally on one side with 8x10 9 The virus is present in vg / μl (total volume 1μl).
[0184] ERG and immunofluorescence microscopy of the retina
[0185] ERGs for both dark-vision and photo-vision responses were performed. For dark-vision responses, mice underwent overnight dark adaptation, and all procedures were performed under dim red light. Photo-adaptation (photo-vision) ERGs were recorded after light adaptation, with a background illumination of 30 cd / m². 2 (White light 6500K) 8 minutes.
[0186] Immunofluorescence microscopy was performed on frozen retinal sections stained with primary antibodies to examine rhodopsin, M-opsin, peripheral proteins-RDS, ARL13B, GFP (Abcam), and γ-tubulin. After washing with PBS (phosphate-buffered saline), sections were incubated with Alexa-488 or Alexa-546-conjugated secondary antibodies for 1 hour. Following washing, cell nuclei were stained with DAPI, and cells were imaged using a Leica microscope (DM5500).
[0187] Example 2
[0188] This embodiment describes an in vivo experiment investigating the expression of the CEP290 small gene. In short, a CEP290 small gene construct was injected subretinically into 10-day-old rd16 mice. The expression of the CEP290 small gene is driven by the GRK promoter. Following injection, the responses of rod (scotopic) and cone (photopic) photoreceptors were evaluated. Figure 13 The scotopic a-wave and b-wave amplitudes are shown in 10-day-old mice that received a subretinal injection of the specified miniCEP290 construct (GRK-580-1180). ERG was recorded at specified days post-injection. Figure 14 The amplitudes of photopic a and b waves are shown in 10-day-old mice injected subretinally with the designated miniCEP290 construct (GRK-580-1180). ERG was recorded at specified days post-injection. The data indicate a sustained response in rod cells for up to 67 days relative to the miniCEP290 construct driven by the CB6 promoter, and increased cone cell activity.
[0189] In vitro experiments were also conducted. Figure 15 Photomicrographs of rd16 mouse embryonic fibroblasts transiently transfected with a small gene encoding a specified protein and GFP cDNA are shown. Expression of the small gene is driven by the CB6 promoter. Figure 16 Data on ciliary length measurements in rd16 mouse embryonic fibroblasts transiently transfected with a small gene encoding a specified protein and GFP cDNA are presented. The data indicate that ciliary length was increased in cells transfected with miniCEP290 compared to control (GFP) transfected cells.
[0190] Figures 17A-17D The scotopic and photopic amplitudes of the CB6-promoter driving the specified small gene were shown, which was injected subretinally into 10-day-old rd16 mice. Figure 17A The amplitude of the dark-view alpha wave is shown. Figure 17B The amplitude of the photopic b-wave is shown. Figure 17C The amplitude of the dark-view b-wave is shown. Figure 17DThe ERG of rd16 mice injected with CB6-1-200-580-1180 miniCEP290 is shown. ERG was recorded at specified days post-injection and compared with others.
[0191] Example 3
[0192] Figure 18 This is a schematic diagram depicting other embodiments of the CEP290 small gene. In some embodiments, the expression of the small gene is driven by the CB6 promoter. In some embodiments, the expression of the small gene is driven by an eye-specific promoter, such as a rhodopsin kinase (RK) promoter, for example, the GRK promoter.
[0193] AAV vector encoding a small gene construct was injected subretinically into P10 stage mice. The small gene was encapsulated in the AAV8 capsid protein. ERG was performed at a specified age after injection, as shown in the attached figure.
[0194] Figure 19 Representative data from an ERG analysis of rhodopsin kinase (RK) promoter-driven miniCEP290-580-1180 expression in subretinal mice are presented. The rescue effect persisted for more than 10 weeks post-injection.
[0195] Figure 20 Representative data from an ERG analysis of rhodopsin kinase (RK) promoter-driven miniCEP290-1181-2479 expression in subretinal injected mice are presented. The rescue effect persisted for up to 8.5 weeks post-injection.
[0196] Figure 21 Representative data from an ERG analysis of rhodopsin kinase (RK) promoter-driven miniCEP290-580-1180 / 1800-2479 expression in subretinal mice are presented. The rescue effect persisted for up to 5.5 weeks post-injection.
[0197] Figure 22 Representative data from an ERG analysis of rhodopsin kinase (RK) promoter-driven expression of miniCEP290-1181-1695 / 1966-2479 in mice injected under the retina are shown.
[0198] Figure 23 Representative data from an ERG analysis of rhodopsin kinase (RK) promoter-driven miniCEP290-1-200 / 580-1180 expression in subretinal mice are presented. The rescue effect persisted for more than 14 weeks post-injection.
[0199] Example 4
[0200] Leber congenital amaurosis (LCA) is a debilitating eye disease and is considered one of the most severe forms of retinal degeneration. Mutations in CEP290 (LCA10) account for >26% of all LCA cases and are the most common cause of LCA. Adeno-associated virus (AAV) vectors are currently the most effective vectors for delivering genes to the retina. However, the development of LCA10 gene therapy has been challenging because the CEP290 gene is too large to be packaged into conventional AAV vectors. Mutation-specific antisense oligonucleotides and gene editing therapies have been previously reported.
[0201] This embodiment describes a mutation-independent gene therapy delivered using an AAV vector to treat LCA10, which causes severe vision loss in infancy. A functional CEP290 small gene construct (miniCEP290) was produced and can be delivered into the subretinal space using an AAV vector.
[0202] It was observed that the CEP290 small gene under the control of the pervasive promoter [e.g., the CEP290 amino acid 580-1180 domain] improved neonatal Cep290 mutant mice (Cep290 rd16 The function and survival of photoreceptors are affected. However, this effect is transient, with degeneration occurring after 5 weeks of age. Data show that expression of CEP290-580-1180 under the control of the photoreceptor-specific rhodopsin kinase promoter increases the electroretinographic (ERG) response of rod and cone photoreceptors by approximately 1.5-fold. This example describes a miniCEP290 gene construct encoding amino acids 1-200 and 580-1180 (miniCEP290-1-200 / 580-1180), which is used in Cep290... rd16 Delivery on day 10 after birth resulted in ~500% improvement in the structure and function of photoreceptors. Data also showed that expression of the novel miniCEP290 prolonged the survival of photoreceptors in Cep290rd16 mice and improved protein transport defects therein.
[0203] Figures 24A-24C Morphological analysis of the rhodopsin kinase (RK) promoter driving miniCEP290-1-200 / 580-1180 is shown: the small gene is delivered subretinally along with AAV8 at the P10 stage. The analysis was performed at 9 weeks of age. Figure 24A The miniCEP290-1-200 / 580-1180 immunofluorescence assay shows the injected retinal region (GFP; the longer arrow). Figure 24B The results show an improvement in rhodopsin (the longer arrows). The shorter arrows do not show GFP expression (non-transduction) and therefore exhibit undetectable rhodopsin expression. Figure 24C Nuclear staining was observed, and the transduced region (longer arrows and longer vertical lines) showed a greater nuclear layer in the outer nuclear layer (ONL) region compared to the untransduced region (shorter arrows and shorter vertical lines). The rescue effect persisted for more than 14 weeks post-injection.
[0204] Example 5
[0205] The codon-optimized MiniCEP290 construct was produced using the AAV5 capsid protein and packaged into rAAV. These sequences were codon-optimized to increase protein yield, reduce tandem rare codons (which can decrease translation efficiency or even derail translation), prolong mRNA half-life, and disrupt stem-loop structures. Figures 25A-25C The codon-optimized miniCEP290 construct is shown. Figure 25A The miniCEP290 1-200 / 580-1180 construct with codon optimizations for promoters (e.g., chicken β-actin promoter) and different introns (chicken β-actin intron, synthetic intron, MBL intron, etc.) is shown. Figure 25B The miniCEP290 1-380 / 580-1180 construct with codon optimizations for different promoters and introns is shown. Figure 25C Representative data for the codon-optimized miniCEP290 1-200 / 580-1180 construct, packaged in an AAV5 capsid and injected subretinally into mice at the P10 stage, are presented. Mice were then analyzed at specified ages using ERG (both scotopic and photopic).
[0206] Equivalent scheme
[0207] While several embodiments of the invention have been described and illustrated herein, those skilled in the art will readily conceive of various other means and / or structures for performing the functions described herein and / or obtaining the results and / or one or more advantages described herein, and each of these variations and / or modifications is considered to be within the scope of the invention. More generally, those skilled in the art will readily understand that all parameters, dimensions, materials, and configurations described herein are exemplary, and actual parameters, dimensions, materials, and / or configurations will depend on one or more specific applications in which the teachings of this invention are used. Those skilled in the art will recognize or be able to determine many equivalent embodiments of the specific implementations of the invention described herein using experiments not exceeding conventional methods. Therefore, it should be understood that the foregoing embodiments are presented by way of example only, and that the invention may be practiced in ways other than those specifically described and claimed within the scope of the appended claims and their equivalents. The invention relates to each individual feature, system, article, material, and / or method described herein. Furthermore, any combination of two or more such features, systems, articles, materials, and / or methods is included within the scope of the invention if such features, systems, articles, materials, and / or methods do not contradict each other.
[0208] Unless explicitly stated otherwise, the indefinite article “a (type)” used herein in the specification and claims shall be understood to mean “at least one (type)”.
[0209] The phrase “and / or” as used herein in the specification and claims should be understood to mean “one or both” of the elements so combined, i.e., the elements coexist in some cases and exist separately in others. Other elements may optionally exist in addition to those specifically identified by the “and / or” clause, whether related to or unrelated to those specifically identified, unless explicitly stated otherwise. Thus, as a non-limiting example, when used in conjunction with open-ended language such as “comprising,” a reference to “A and / or B” may in one embodiment refer to A without B (optionally including elements other than B); in another embodiment, refer to B without A (optionally including elements other than A); in yet another embodiment, refer to both A and B (optionally including other elements); and so on.
[0210] As used herein in the specification and claims, “or” should be understood to have the same meaning as “and / or” as defined above. For example, when separating items in a list, “or” or “and / or” should be interpreted as inclusive, i.e., including at least one of many elements or a list of elements, but also including more than one, as well as optional other unlisted items. Only terms explicitly indicating the opposite, such as “only one” or “solely one,” or when used in a claim, “consisting of…” will refer to including a single element or a list of elements. In general, before exclusive terms such as “any,” “one of,” “only one,” or “solely one,” the term “or” as used herein should only be interpreted as an alternative to exclusivity (i.e., “one or the other, not two”). “Substantially consisting of…” when used in a claim should have its ordinary meaning as used in the field of patent law.
[0211] As used herein in the specification and claims, the phrase “at least one” in relation to a list of one or more elements should be understood to mean at least one element selected from any one or more elements in the list of elements, but does not necessarily include at least one element from every element specifically listed in the list of elements, and does not exclude any combination of elements in the list of elements. This definition also allows for the optional presence of elements other than those specifically identified in the list of elements referred to by the phrase “at least one,” whether related to or unrelated to those specifically identified elements. Thus, as a non-limiting example, “at least one of A and B” (or equivalently “at least one of A or B”; or equivalently “at least one of A and / or B”) in one embodiment may mean at least one, optionally including more than one A but without B (and optionally including elements other than B); in another embodiment, it means at least one, optionally including more than one B but without A (and optionally including elements other than A); in yet another embodiment, it means at least one, optionally including more than one A, and at least one, optionally including more than one B (and optionally including other elements); and so on.
[0212] In the claims and in the foregoing description, all transitional phrases such as “comprising,” “including,” “carrying,” “having,” “containing,” “involving,” “holding,” etc., shall be understood as open-ended, meaning including but not limited to. Only the transitional phrases “consisting of” and “consisting substantially of” shall be closed or semi-closed transitional phrases, respectively, as described in Section 2111.03 of the U.S. Patent Examination Procedure Manual.
[0213] The use of sequential terms such as “first,” “second,” and “third” in a claim to modify a claim element does not imply any priority, order, or temporal sequence of actions of one claim element relative to another claim element, but is merely used as a label to distinguish one claim element with a specific name from another element with the same name (but used in sequential terms) to differentiate claim elements. sequence list <110> University of Massachusetts <120> Small gene therapy <130> U0120.70124WO00 <140> Not yet formulated <141> Same as above <150> US 62 / 967,521 <151> 2020-01-29 <150> US 62 / 899,601 <151> 2019-09-12 <150> US 62 / 850,405 <151> 2019-05-20 <160> 39 <170> PatentIn version 3.5 <210> 1 <211> 2479 <212> PRT <213> Homo sapiens <400> 1 Met Pro Pro Asn Ile Asn Trp Lys Glu Ile Met Lys Val Asp Pro Asp 1 5 10 15 Asp Leu Pro Arg Gln Glu Glu Leu Ala Asp Asn Leu Leu Ile Ser Leu 20 25 30 Ser Lys Val Glu Val Asn Glu Leu Lys Ser Glu Lys Gln Glu Asn Val 35 40 45 Ile His Leu Phe Arg Ile Thr Gln Ser Leu Met Lys Met Lys Ala Gln 50 55 60 Glu Val Glu Leu Ala Leu Glu Glu Val Glu Lys Ala Gly Glu Glu Gln 65 70 75 80 Ala Lys Phe Glu Asn Gln Leu Lys Thr Lys Val Met Lys Leu Glu Asn 85 90 95 Glu Leu Glu Met Ala Gln Gln Ser Ala Gly Gly Arg Asp Thr Arg Phe 100 105 110 Leu Arg Asn Glu Ile Cys Gln Leu Glu Lys Gln Leu Glu Gln Lys Asp 115 120 125 Arg Glu Leu Glu Asp Met Glu Lys Glu Leu Glu Lys Glu Lys Lys Val 130 135 140 Asn Glu Gln Leu Ala Leu Arg Asn Glu Glu Ala Glu Asn Glu Asn Ser 145 150 155 160 Lys Leu Arg Arg Glu Asn Lys Arg Leu Lys Lys Lys Asn Glu Gln Leu 165 170 175 Cys Gln Asp Ile Ile Asp Tyr Gln Lys Gln Ile Asp Ser Gln Lys Glu 180 185 190 Thr Leu Leu Ser Arg Arg Gly Glu Asp Ser Asp Tyr Arg Ser Gln Leu 195 200 205 Ser Lys Lys Asn Tyr Glu Leu Ile Gln Tyr Leu Asp Glu Ile Gln Thr 210 215 220 Leu Thr Glu Ala Asn Glu Lys Ile Glu Val Gln Asn Gln Glu Met Arg 225 230 235 240 Lys Asn Leu Glu Glu Ser Val Gln Glu Met Glu Lys Met Thr Asp Glu 245 250 255 Tyr Asn Arg Met Lys Ala Ile Val His Gln Thr Asp Asn Val Ile Asp 260 265 270 Gln Leu Lys Lys Glu Asn Asp His Tyr Gln Leu Gln Val Gln Glu Leu 275 280 285 Thr Asp Leu Leu Lys Ser Lys Asn Glu Glu Asp Asp Pro Ile Met Val 290 295 300 Ala Val Asn Ala Lys Val Glu Glu Trp Lys Leu Ile Leu Ser Ser Lys 305 310 315 320 Asp Asp Glu Ile Ile Glu Tyr Gln Gln Met Leu His Asn Leu Arg Glu 325 330 335 Lys Leu Lys Asn Ala Gln Leu Asp Ala Asp Lys Ser Asn Val Met Ala 340 345 350 Leu Gln Gln Gly Ile Gln Glu Arg Asp Ser Gln Ile Lys Met Leu Thr 355 360 365 Glu Gln Val Glu Gln Tyr Thr Lys Glu Met Glu Lys Asn Thr Cys Ile 370 375 380 Ile Glu Asp Leu Lys Asn Glu Leu Gln Arg Asn Lys Gly Ala Ser Thr 385 390 395 400 Leu Ser Gln Gln Thr His Met Lys Ile Gln Ser Thr Leu Asp Ile Leu 405 410 415 Lys Glu Lys Thr Lys Glu Ala Glu Arg Thr Ala Glu Leu Ala Glu Ala 420 425 430 Asp Ala Arg Glu Lys Asp Lys Glu Leu Val Glu Ala Leu Lys Arg Leu 435 440 445 Lys Asp Tyr Glu Ser Gly Val Tyr Gly Leu Glu Asp Ala Val Val Glu 450 455 460 Ile Lys Asn Cys Lys Asn Gln Ile Lys Ile Arg Asp Arg Glu Ile Glu 465 470 475 480 Ile Leu Thr Lys Glu Ile Asn Lys Leu Glu Leu Lys Ile Ser Asp Phe 485 490 495 Leu Asp Glu Asn Glu Ala Leu Arg Glu Arg Val Gly Leu Glu Pro Lys 500 505 510 Thr Met Ile Asp Leu Thr Glu Phe Arg Asn Ser Lys His Leu Lys Gln 515 520 525 Gln Gln Tyr Arg Ala Glu Asn Gln Ile Leu Leu Lys Glu Ile Glu Ser 530 535 540 Leu Glu Glu Glu Arg Leu Asp Leu Lys Lys Lys Ile Arg Gln Met Ala 545 550 555 560 Gln Glu Arg Gly Lys Arg Ser Ala Thr Ser Gly Leu Thr Thr Glu Asp 565 570 575 Leu Asn Leu Thr Glu Asn Ile Ser Gln Gly Asp Arg Ile Ser Glu Arg 580 585 590 Lys Leu Asp Leu Leu Ser Leu Lys Asn Met Ser Glu Ala Gln Ser Lys 595 600 605 Asn Glu Phe Leu Ser Arg Glu Leu Ile Glu Lys Glu Arg Asp Leu Glu 610 615 620 Arg Ser Arg Thr Val Ile Ala Lys Phe Gln Asn Lys Leu Lys Glu Leu 625 630 635 640 Val Glu Glu Asn Lys Gln Leu Glu Glu Gly Met Lys Glu Ile Leu Gln 645 650 655 Ala Ile Lys Glu Met Gln Lys Asp Pro Asp Val Lys Gly Gly Glu Thr 660 665 670 Ser Leu Ile Ile Pro Ser Leu Glu Arg Leu Val Asn Ala Ile Glu Ser 675 680 685 Lys Asn Ala Glu Gly Ile Phe Asp Ala Ser Leu His Leu Lys Ala Gln 690 695 700 Val Asp Gln Leu Thr Gly Arg Asn Glu Glu Leu Arg Gln Glu Leu Arg 705 710 715 720 Glu Ser Arg Lys Glu Ala Ile Asn Tyr Ser Gln Gln Leu Ala Lys Ala 725 730 735 Asn Leu Lys Ile Asp His Leu Glu Lys Glu Thr Ser Leu Leu Arg Gln 740 745 750 Ser Glu Gly Ser Asn Val Val Phe Lys Gly Ile Asp Leu Pro Asp Gly 755 760 765 Ile Ala Pro Ser Ser Ala Ser Ile Ile Asn Ser Gln Asn Glu Tyr Leu 770 775 780 Ile His Leu Leu Gln Glu Leu Glu Asn Lys Glu Lys Lys Leu Lys Asn 785 790 795 800 Leu Glu Asp Ser Leu Glu Asp Tyr Asn Arg Lys Phe Ala Val Ile Arg 805 810 815 His Gln Gln Ser Leu Leu Tyr Lys Glu Tyr Leu Ser Glu Lys Glu Thr 820 825 830 Trp Lys Thr Glu Ser Lys Thr Ile Lys Glu Glu Lys Arg Lys Leu Glu 835 840 845 Asp Gln Val Gln Gln Asp Ala Ile Lys Val Lys Glu Tyr Asn Asn Leu 850 855 860 Leu Asn Ala Leu Gln Met Asp Ser Asp Glu Met Lys Lys Ile Leu Ala 865 870 875 880 Glu Asn Ser Arg Lys Ile Thr Val Leu Gln Val Asn Glu Lys Ser Leu 885 890 895 Ile Arg Gln Tyr Thr Thr Leu Val Glu Leu Glu Arg Gln Leu Arg Lys 900 905 910 Glu Asn Glu Lys Gln Lys Asn Glu Leu Leu Ser Met Glu Ala Glu Val 915 920 925 Cys Glu Lys Ile Gly Cys Leu Gln Arg Phe Lys Glu Met Ala Ile Phe 930 935 940 Lys Ile Ala Ala Leu Gln Lys Val Val Asp Asn Ser Val Ser Leu Ser 945 950 955 960 Glu Leu Glu Leu Ala Asn Lys Gln Tyr Asn Glu Leu Thr Ala Lys Tyr 965 970 975 Arg Asp Ile Leu Gln Lys Asp Asn Met Leu Val Gln Arg Thr Ser Asn 980 985 990 Leu Glu His Leu Glu Cys Glu Asn Ile Ser Leu Lys Glu Gln Val Glu 995 1000 1005 Ser Ile Asn Lys Glu Leu Glu Ile Thr Lys Glu Lys Leu His Thr 1010 1015 1020 Ile Glu Gln Ala Trp Glu Gln Glu Thr Lys Leu Gly Asn Glu Ser 1025 1030 1035 Ser Met Asp Lys Ala Lys Lys Ser Ile Thr Asn Ser Asp Ile Val 1040 1045 1050 Ser Ile Ser Lys Lys Ile Thr Met Leu Glu Met Lys Glu Leu Asn 1055 1060 1065 Glu Arg Gln Arg Ala Glu His Cys Gln Lys Met Tyr Glu His Leu 1070 1075 1080 Arg Thr Ser Leu Lys Gln Met Glu Glu Arg Asn Phe Glu Leu Glu 1085 1090 1095 Thr Lys Phe Ala Glu Leu Thr Lys Ile Asn Leu Asp Ala Gln Lys 1100 1105 1110 Val Glu Gln Met Leu Arg Asp Glu Leu Ala Asp Ser Val Ser Lys 1115 1120 1125 Ala Val Ser Asp Ala Asp Arg Gln Arg Ile Leu Glu Leu Glu Lys 1130 1135 1140 Asn Glu Met Glu Leu Lys Val Glu Val Ser Lys Leu Arg Glu Ile 1145 1150 1155 Ser Asp Ile Ala Arg Arg Gln Val Glu Ile Leu Asn Ala Gln Gln 1160 1165 1170 Gln Ser Arg Asp Lys Glu Val Glu Ser Leu Arg Met Gln Leu Leu 1175 1180 1185 Asp Tyr Gln Ala Gln Ser Asp Glu Lys Ser Leu Ile Ala Lys Leu 1190 1195 1200 His Gln His Asn Val Ser Leu Gln Leu Ser Glu Ala Thr Ala Leu 1205 1210 1215 Gly Lys Leu Glu Ser Ile Thr Ser Lys Leu Gln Lys Met Glu Ala 1220 1225 1230 Tyr Asn Leu Arg Leu Glu Gln Lys Leu Asp Glu Lys Glu Gln Ala 1235 1240 1245 Leu Tyr Tyr Ala Arg Leu Glu Gly Arg Asn Arg Ala Lys His Leu 1250 1255 1260 Arg Gln Thr Ile Gln Ser Leu Arg Arg Gln Phe Ser Gly Ala Leu 1265 1270 1275 Pro Leu Ala Gln Gln Glu Lys Phe Ser Lys Thr Met Ile Gln Leu 1280 1285 1290 Gln Asn Asp Lys Leu Lys Ile Met Gln Glu Met Lys Asn Ser Gln 1295 1300 1305 Gln Glu His Arg Asn Met Glu Asn Lys Thr Leu Glu Met Glu Leu 1310 1315 1320 Lys Leu Lys Gly Leu Glu Glu Leu Ile Ser Thr Leu Lys Asp Thr 1325 1330 1335 Lys Gly Ala Gln Lys Val Ile Asn Trp His Met Lys Ile Glu Glu 1340 1345 1350 Leu Arg Leu Gln Glu Leu Lys Leu Asn Arg Glu Leu Val Lys Asp 1355 1360 1365 Lys Glu Glu Ile Lys Tyr Leu Asn Asn Ile Ile Ser Glu Tyr Glu 1370 1375 1380 Arg Thr Ile Ser Ser Leu Glu Glu Glu Ile Val Gln Gln Asn Lys 1385 1390 1395 Phe His Glu Glu Arg Gln Met Ala Trp Asp Gln Arg Glu Val Asp 1400 1405 1410 Leu Glu Arg Gln Leu Asp Ile Phe Asp Arg Gln Gln Asn Glu Ile 1415 1420 1425 Leu Asn Ala Ala Gln Lys Phe Glu Glu Ala Thr Gly Ser Ile Pro 1430 1435 1440 Asp Pro Ser Leu Pro Leu Pro Asn Gln Leu Glu Ile Ala Leu Arg 1445 1450 1455 Lys Ile Lys Glu Asn Ile Arg Ile Ile Leu Glu Thr Arg Ala Thr 1460 1465 1470 Cys Lys Ser Leu Glu Glu Lys Leu Lys Glu Lys Glu Ser Ala Leu 1475 1480 1485 Arg Leu Ala Glu Gln Asn Ile Leu Ser Arg Asp Lys Val Ile Asn 1490 1495 1500 Glu Leu Arg Leu Arg Leu Pro Ala Thr Ala Glu Arg Glu Lys Leu 1505 1510 1515 Ile Ala Glu Leu Gly Arg Lys Glu Met Glu Pro Lys Ser His His 1520 1525 1530 Thr Leu Lys Ile Ala His Gln Thr Ile Ala Asn Met Gln Ala Arg 1535 1540 1545 Leu Asn Gln Lys Glu Glu Val Leu Lys Lys Tyr Gln Arg Leu Leu 1550 1555 1560 Glu Lys Ala Arg Glu Glu Gln Arg Glu Ile Val Lys Lys His Glu 1565 1570 1575 Glu Asp Leu His Ile Leu His His Arg Leu Glu Leu Gln Ala Asp 1580 1585 1590 Ser Ser Leu Asn Lys Phe Lys Gln Thr Ala Trp Asp Leu Met Lys 1595 1600 1605 Gln Ser Pro Thr Pro Val Pro Thr Asn Lys His Phe Ile Arg Leu 1610 1615 1620 Ala Glu Met Glu Gln Thr Val Ala Glu Gln Asp Asp Ser Leu Ser 1625 1630 1635 Ser Leu Leu Val Lys Leu Lys Lys Val Ser Gln Asp Leu Glu Arg 1640 1645 1650 Gln Arg Glu Ile Thr Glu Leu Lys Val Lys Glu Phe Glu Asn Ile 1655 1660 1665 Light Leu Gln Leu Gln Glu Asn His Glu Asp Glu Val Light Light Val 1670 1675 1680 Lys Ala Glu Val Glu Asp Leu Lys Tyr Leu Leu Asp Gln Ser Gln 1685 1690 1695 Lys Glu Ser Gln Cys Leu Lys Ser Glu Leu Gln Ala Gln Lys Glu 1700 1705 1710 Ala Asn Ser Arg Ala Pro Thr Thr Thr Met Arg Asn Leu Val Glu 1715 1720 1725 Arg Leu Lys Ser Gln Leu Ala Leu Lys Glu Lys Gln Gln Lys Ala 1730 1735 1740 Leu Ser Arg Ala Leu Leu Glu Leu Arg Ala Glu Met Thr Ala Ala 1745 1750 1755 Ala Glu Glu Arg Ile Ile Ser Ala Thr Ser Gln Lys Glu Ala His 1760 1765 1770 Leu Asn Val Gln Gln Ile Val Asp Arg His Thr Arg Glu Leu Lys 1775 1780 1785 Thr Gln Val Glu Asp Leu Asn Glu Asn Leu Leu Lys Leu Lys Glu 1790 1795 1800 Ala Leu Lys Thr Ser Lys Asn Arg Glu Asn Ser Leu Thr Asp Asn 1805 1810 1815 Leu Asn Asp Leu Asn Asn Glu Leu Gln Lys Lys Gln Lys Ala Tyr 1820 1825 1830 Asn Lys Ile Leu Arg Glu Lys Glu Glu Ile Asp Gln Glu Asn Asp 1835 1840 1845 Glu Leu Lys Arg Gln Ile Lys Arg Leu Thr Ser Gly Leu Gln Gly 1850 1855 1860 Lys Pro Leu Thr Asp Asn Lys Gln Ser Leu Ile Glu Glu Leu Gln 1865 1870 1875 Arg Lys Val Lys Lys Leu Glu Asn Gln Leu Glu Gly Lys Val Glu 1880 1885 1890 Glu Val Asp Leu Lys Pro Met Lys Glu Lys Asn Ala Lys Glu Glu 1895 1900 1905 Leu Ile Arg Trp Glu Glu Gly Lys Lys Trp Gln Ala Lys Ile Glu 1910 1915 1920 Gly Ile Arg Asn Lys Leu Lys Glu Lys Glu Gly Glu Val Phe Thr 1925 1930 1935 Leu Thr Lys Gln Leu Asn Thr Leu Lys Asp Leu Phe Ala Lys Ala 1940 1945 1950 Asp Lys Glu Lys Leu Thr Leu Gln Arg Lys Leu Lys Thr Thr Gly 1955 1960 1965 Met Thr Val Asp Gln Val Leu Gly Ile Arg Ala Leu Glu Ser Glu 1970 1975 1980 Lys Glu Leu Glu Glu Leu Lys Lys Arg Asn Leu Asp Leu Glu Asn 1985 1990 1995 Asp Ile Leu Tyr Met Arg Ala His Gln Ala Leu Pro Arg Asp Ser 2000 2005 2010 Val Val Glu Asp Leu His Leu Gln Asn Arg Tyr Leu Gln Glu Lys 2015 2020 2025 Leu His Ala Leu Glu Lys Gln Phe Ser Lys Asp Thr Tyr Ser Lys 2030 2035 2040 Pro Ser Ile Ser Gly Ile Glu Ser Asp Asp His Cys Gln Arg Glu 2045 2050 2055 Gln Glu Leu Gln Lys Glu Asn Leu Lys Leu Ser Ser Glu Asn Ile 2060 2065 2070 Glu Leu Lys Phe Gln Leu Glu Gln Ala Asn Lys Asp Leu Pro Arg 2075 2080 2085 Leu Lys Asn Gln Val Arg Asp Leu Lys Glu Met Cys Glu Phe Leu 2090 2095 2100 Lys Lys Glu Lys Ala Glu Val Gln Arg Lys Leu Gly His Val Arg 2105 2110 2115 Gly Ser Gly Arg Ser Gly Lys Thr Ile Pro Glu Leu Glu Lys Thr 2120 2125 2130 Ile Gly Leu Met Lys Lys Val Val Glu Lys Val Gln Arg Glu Asn 2135 2140 2145 Glu Gln Leu Lys Lys Ala Ser Gly Ile Leu Thr Ser Glu Lys Met 2150 2155 2160 Ala Asn Ile Glu Gln Glu Asn Glu Lys Leu Lys Ala Glu Leu Glu 2165 2170 2175 Lys Leu Lys Ala His Leu Gly His Gln Leu Ser Met His Tyr Glu 2180 2185 2190 Ser Lys Thr Lys Gly Thr Glu Lys Ile Ile Ala Glu Asn Glu Arg 2195 2200 2205 Leu Arg Lys Glu Leu Lys Lys Glu Thr Asp Ala Ala Glu Lys Leu 2210 2215 2220 Arg Ile Ala Lys Asn Asn Leu Glu Ile Leu Asn Glu Lys Met Thr 2225 2230 2235 Val Gln Leu Glu Glu Thr Gly Lys Arg Leu Gln Phe Ala Glu Ser 2240 2245 2250 Arg Gly Pro Gln Leu Glu Gly Ala Asp Ser Lys Ser Trp Lys Ser 2255 2260 2265 Ile Val Val Thr Arg Met Tyr Glu Thr Lys Leu Lys Glu Leu Glu 2270 2275 2280 Thr Asp Ile Ala Lys Lys Asn Gln Ser Ile Thr Asp Leu Lys Gln 2285 2290 2295 Leu Val Lys Glu Ala Thr Glu Arg Glu Gln Lys Val Asn Lys Tyr 2300 2305 2310 Asn Glu Asp Leu Glu Gln Gln Ile Lys Ile Leu Lys His Val Pro 2315 2320 2325 Glu Gly Ala Glu Thr Glu Gln Gly Leu Lys Arg Glu Leu Gln Val 2330 2335 2340 Leu Arg Leu Ala Asn His Gln Leu Asp Lys Glu Lys Ala Glu Leu 2345 2350 2355 Ile His Gln Ile Glu Ala Asn Lys Asp Gln Ser Gly Ala Glu Ser 2360 2365 2370 Thr Ile Pro Asp Ala Asp Gln Leu Lys Glu Lys Ile Lys Asp Leu 2375 2380 2385 Glu Thr Gln Leu Lys Met Ser Asp Leu Glu Lys Gln His Leu Lys 2390 2395 2400 Glu Glu Ile Lys Lys Leu Lys Lys Glu Leu Glu Asn Phe Asp Pro 2405 2410 2415 Ser Phe Phe Glu Glu Ile Glu Asp Leu Lys Tyr Asn Tyr Lys Glu 2420 2425 2430 Glu Val Lys Lys Asn Ile Leu Leu Glu Glu Lys Val Lys Lys Leu 2435 2440 2445 Ser Glu Gln Leu Gly Val Glu Leu Thr Ser Pro Val Ala Ala Ser 2450 2455 2460 Glu Glu Phe Glu Asp Glu Glu Glu Ser Pro Val Asn Phe Pro Ile 2465 2470 2475 Tyr <210> 2 <211> 1116 <212> PRT <213> Homo sapiens <400> 2 Thr Glu Asn Ile Ser Gln Gly Asp Arg Ile Ser Glu Arg Lys Leu Asp 1 5 10 15 Leu Leu Ser Leu Lys Asn Met Ser Glu Ala Gln Ser Lys Asn Glu Phe 20 25 30 Leu Ser Arg Glu Leu Ile Glu Lys Glu Arg Asp Leu Glu Arg Ser Arg 35 40 45 Thr Val Ile Ala Lys Phe Gln Asn Lys Leu Lys Glu Leu Val Glu Glu 50 55 60 Asn Lys Gln Leu Glu Glu Gly Met Lys Glu Ile Leu Gln Ala Ile Lys 65 70 75 80 Glu Met Gln Lys Asp Pro Asp Val Lys Gly Gly Glu Thr Ser Leu Ile 85 90 95 Ile Pro Ser Leu Glu Arg Leu Val Asn Ala Ile Glu Ser Lys Asn Ala 100 105 110 Glu Gly Ile Phe Asp Ala Ser Leu His Leu Lys Ala Gln Val Asp Gln 115 120 125 Leu Thr Gly Arg Asn Glu Glu Leu Arg Gln Glu Leu Arg Glu Ser Arg 130 135 140 Lys Glu Ala Ile Asn Tyr Ser Gln Gln Leu Ala Lys Ala Asn Leu Lys 145 150 155 160 Ile Asp His Leu Glu Lys Glu Thr Ser Leu Leu Arg Gln Ser Glu Gly 165 170 175 Ser Asn Val Val Phe Lys Gly Ile Asp Leu Pro Asp Gly Ile Ala Pro 180 185 190 Ser Ser Ala Ser Ile Ile Asn Ser Gln Asn Glu Tyr Leu Ile His Leu 195 200 205 Leu Gln Glu Leu Glu Asn Lys Glu Lys Lys Leu Lys Asn Leu Glu Asp 210 215 220 Ser Leu Glu Asp Tyr Asn Arg Lys Phe Ala Val Ile Arg His Gln Gln 225 230 235 240 Ser Leu Leu Tyr Lys Glu Tyr Leu Ser Glu Lys Glu Thr Trp Lys Thr 245 250 255 Glu Ser Lys Thr Ile Lys Glu Glu Lys Arg Lys Leu Glu Asp Gln Val 260 265 270 Gln Gln Asp Ala Ile Lys Val Lys Glu Tyr Asn Asn Leu Leu Asn Ala 275 280 285 Leu Gln Met Asp Ser Asp Glu Met Lys Lys Ile Leu Ala Glu Asn Ser 290 295 300 Arg Lys Ile Thr Val Leu Gln Val Asn Glu Lys Ser Leu Ile Arg Gln 305 310 315 320 Tyr Thr Thr Leu Val Glu Leu Glu Arg Gln Leu Arg Lys Glu Asn Glu 325 330 335 Lys Gln Lys Asn Glu Leu Leu Ser Met Glu Ala Glu Val Cys Glu Lys 340 345 350 Ile Gly Cys Leu Gln Arg Phe Lys Glu Met Ala Ile Phe Lys Ile Ala 355 360 365 Ala Leu Gln Lys Val Val Asp Asn Ser Val Ser Leu Ser Glu Leu Glu 370 375 380 Leu Ala Asn Lys Gln Tyr Asn Glu Leu Thr Ala Lys Tyr Arg Asp Ile 385 390 395 400 Leu Gln Lys Asp Asn Met Leu Val Gln Arg Thr Ser Asn Leu Glu His 405 410 415 Leu Glu Cys Glu Asn Ile Ser Leu Lys Glu Gln Val Glu Ser Ile Asn 420 425 430 Lys Glu Leu Glu Ile Thr Lys Glu Lys Leu His Thr Ile Glu Gln Ala 435 440 445 Trp Glu Gln Glu Thr Lys Leu Gly Asn Glu Ser Ser Met Asp Lys Ala 450 455 460 Light Light Ser Ile Thr Asn Ser Asp Ile Val Ser Ile Ser Light Light Ile 465 470 475 480 Thr Met Leu Glu Met Lys Glu Leu Asn Glu Arg Gln Arg Ala Glu His 485 490 495 Cys Gln Lys Met Tyr Glu His Leu Arg Thr Ser Leu Lys Gln Met Glu 500 505 510 Glu Arg Asn Phe Glu Leu Glu Thr Lys Phe Ala Glu Leu Thr Lys Ile 515 520 525 Asn Leu Asp Ala Gln Lys Val Glu Gln Met Leu Arg Asp Glu Leu Ala 530 535 540 Asp Ser Val Ser Lys Ala Val Ser Asp Ala Asp Arg Gln Arg Ile Leu 545 550 555 560 Glu Leu Glu Lys Asn Glu Met Glu Leu Lys Val Glu Val Ser Lys Leu 565 570 575 Arg Glu Ile Ser Asp Ile Ala Arg Arg Gln Val Glu Ile Leu Asn Ala 580 585 590 Gln Gln Gln Ser Arg Asp Lys Glu Val Glu Ser Leu Arg Met Gln Leu 595 600 605 Leu Asp Tyr Gln Ala Gln Ser Asp Glu Lys Ser Leu Ile Ala Lys Leu 610 615 620 His Gln His Asn Val Ser Leu Gln Leu Ser Glu Ala Thr Ala Leu Gly 625 630 635 640 Lys Leu Glu Ser Ile Thr Ser Lys Leu Gln Lys Met Glu Ala Tyr Asn 645 650 655 Leu Arg Leu Glu Gln Lys Leu Asp Glu Lys Glu Gln Ala Leu Tyr Tyr 660 665 670 Ala Arg Leu Glu Gly Arg Asn Arg Ala Lys His Leu Arg Gln Thr Ile 675 680 685 Gln Ser Leu Arg Arg Gln Phe Ser Gly Ala Leu Pro Leu Ala Gln Gln 690 695 700 Glu Lys Phe Ser Lys Thr Met Ile Gln Leu Gln Asn Asp Lys Leu Lys 705 710 715 720 Ile Met Gln Glu Met Lys Asn Ser Gln Gln Glu His Arg Asn Met Glu 725 730 735 Asn Lys Thr Leu Glu Met Glu Leu Lys Leu Lys Gly Leu Glu Glu Leu 740 745 750 Ile Ser Thr Leu Lys Asp Thr Lys Gly Ala Gln Lys Val Ile Asn Trp 755 760 765 His Met Lys Ile Glu Glu Leu Arg Leu Gln Glu Leu Lys Leu Asn Arg 770 775 780 Glu Leu Val Lys Asp Lys Glu Glu Ile Lys Tyr Leu Asn Asn Ile Ile 785 790 795 800 Ser Glu Tyr Glu Arg Thr Ile Ser Ser Leu Glu Glu Glu Ile Val Gln 805 810 815 Gln Asn Lys Phe His Glu Glu Arg Gln Met Ala Trp Asp Gln Arg Glu 820 825 830 Val Asp Leu Glu Arg Gln Leu Asp Ile Phe Asp Arg Gln Gln Asn Glu 835 840 845 Ile Leu Asn Ala Ala Gln Lys Phe Glu Glu Ala Thr Gly Ser Ile Pro 850 855 860 Asp Pro Ser Leu Pro Leu Pro Asn Gln Leu Glu Ile Ala Leu Arg Lys 865 870 875 880 Ile Lys Glu Asn Ile Arg Ile Ile Leu Glu Thr Arg Ala Thr Cys Lys 885 890 895 Ser Leu Glu Glu Lys Leu Lys Glu Lys Glu Ser Ala Leu Arg Leu Ala 900 905 910 Glu Gln Asn Ile Leu Ser Arg Asp Lys Val Ile Asn Glu Leu Arg Leu 915 920 925 Arg Leu Pro Ala Thr Ala Glu Arg Glu Lys Leu Ile Ala Glu Leu Gly 930 935 940 Arg Lys Glu Met Glu Pro Lys Ser His His Thr Leu Lys Ile Ala His 945 950 955 960 Gln Thr Ile Ala Asn Met Gln Ala Arg Leu Asn Gln Lys Glu Glu Val 965 970 975 Leu Lys Lys Tyr Gln Arg Leu Leu Glu Lys Ala Arg Glu Glu Gln Arg 980 985 990 Glu Ile Val Lys Lys His Glu Glu Asp Leu His Ile Leu His His Arg 995 1000 1005 Leu Glu Leu Gln Ala Asp Ser Ser Leu Asn Lys Phe Lys Gln Thr 1010 1015 1020 Ala Trp Asp Leu Met Lys Gln Ser Pro Thr Pro Val Pro Thr Asn 1025 1030 1035 Lys His Phe Ile Arg Leu Ala Glu Met Glu Gln Thr Val Ala Glu 1040 1045 1050 Gln Asp Asp Ser Leu Ser Ser Leu Leu Val Lys Leu Lys Lys Val 1055 1060 1065 Ser Gln Asp Leu Glu Arg Gln Arg Glu Ile Thr Glu Leu Lys Val 1070 1075 1080 Lys Glu Phe Glu Asn Ile Lys Leu Gln Leu Gln Glu Asn His Glu 1085 1090 1095 Asp Glu Val Lys Lys Val Lys Ala Glu Val Glu Asp Leu Lys Tyr 1100 1105 1110 Leu Leu Asp 1115 <210> 3 <211> 601 <212> PRT <213> Homo sapiens <400> 3 Thr Glu Asn Ile Ser Gln Gly Asp Arg Ile Ser Glu Arg Lys Leu Asp 1 5 10 15[[ID= / ID=24]] Leu Leu Ser Leu Lys Asn Met Ser Glu Ala Gln Ser Lys Asn Glu Phe 20 25 30 Leu Ser Arg Glu Leu Ile Glu Lys Glu Arg Asp Leu Glu Arg Ser Arg 35 40 45 Thr Val Ile Ala Lys Phe Gln Asn Lys Leu Lys Glu Leu Val Glu Glu 50 55 60 Asn Lys Gln Leu Glu Glu Gly Met Lys Glu Ile Leu Gln Ala Ile Lys 65 70 75 80 Glu Met Gln Lys Asp Pro Asp Val Lys Gly Gly Glu Thr Ser Leu Ile 85 90 95 Ile Pro Ser Leu Glu Arg Leu Val Asn Ala Ile Glu Ser Lys Asn Ala[[ID=]] 100 105 110 Glu Gly Ile Phe Asp Ala Ser Leu His Leu Lys Ala Gln Val Asp Gln 115 120 125 Leu Thr Gly Arg Asn Glu Glu Leu Arg Gln Glu Leu Arg Glu Ser Arg 130 135 140 Lys Glu Ala Ile Asn Tyr Ser Gln Gln Leu Ala Lys Ala Asn Leu Lys 145 150 155 160 Ile Asp His Leu Glu Lys Glu Thr Ser Leu Leu Arg Gln Ser Glu Gly 165 170 175 Ser Asn Val Val Phe Lys Gly Ile Asp Leu Pro Asp Gly Ile Ala Pro 180 185 190 Ser Ser Ala Ser Ile Ile Asn Ser Gln Asn Glu Tyr Leu Ile His Leu 195 200 205 Leu Gln Glu Leu Glu Asn Lys Glu Lys Lys Leu Lys Asn Leu Glu Asp 210 215 220 Ser Leu Glu Asp Tyr Asn Arg Lys Phe Ala Val Ile Arg His Gln Gln 225 230 235 240 Ser Leu Leu Tyr Lys Glu Tyr Leu Ser Glu Lys Glu Thr Trp Lys Thr 245 250 255 Glu Ser Lys Thr Ile Lys Glu Glu Lys Arg Lys Leu Glu Asp Gln Val 260 265 270 Gln Gln Asp Ala Ile Lys Val Lys Glu Tyr Asn Asn Leu Leu Asn Ala 275 280 285 Leu Gln Met Asp Ser Asp Glu Met Lys Lys Ile Leu Ala Glu Asn Ser 290 295 300 Arg Lys Ile Thr Val Leu Gln Val Asn Glu Lys Ser Leu Ile Arg Gln 305 310 315 320 Tyr Thr Thr Leu Val Glu Leu Glu Arg Gln Leu Arg Lys Glu Asn Glu 325 330 335 Lys Gln Lys Asn Glu Leu Leu Ser Met Glu Ala Glu Val Cys Glu Lys 340 345 350 Ile Gly Cys Leu Gln Arg Phe Lys Glu Met Ala Ile Phe Lys Ile Ala 355 360 365 Ala Leu Gln Lys Val Val Asp Asn Ser Val Ser Leu Ser Glu Leu Glu 370 375 380 Leu Ala Asn Lys Gln Tyr Asn Glu Leu Thr Ala Lys Tyr Arg Asp Ile 385 390 395 400 Leu Gln Lys Asp Asn Met Leu Val Gln Arg Thr Ser Asn Leu Glu His 405 410 415 Leu Glu Cys Glu Asn Ile Ser Leu Lys Glu Gln Val Glu Ser Ile Asn 420 425 430 Lys Glu Leu Glu Ile Thr Lys Glu Lys Leu His Thr Ile Glu Gln Ala 435 440 445 Trp Glu Gln Glu Thr Lys Leu Gly Asn Glu Ser Ser Met Asp Lys Ala 450 455 460 Lys Lys Ser Ile Thr Asn Ser Asp Ile Val Ser Ile Ser Lys Lys Ile 465 470 475 480 Thr Met Leu Glu Met Lys Glu Leu Asn Glu Arg Gln Arg Ala Glu His 485 490 495 Cys Gln Lys Met Tyr Glu His Leu Arg Thr Ser Leu Lys Gln Met Glu 500 505 510 Glu Arg Asn Phe Glu Leu Glu Thr Lys Phe Ala Glu Leu Thr Lys Ile 515 520 525 Asn Leu Asp Ala Gln Lys Val Glu Gln Met Leu Arg Asp Glu Leu Ala 530 535 540 Asp Ser Val Ser Lys Ala Val Ser Asp Ala Asp Arg Gln Arg Ile Leu 545 550 555 560 Glu Leu Glu Lys Asn Glu Met Glu Leu Lys Val Glu Val Ser Lys Leu 565 570 575 Arg Glu Ile Ser Asp Ile Ala Arg Arg Gln Val Glu Ile Leu Asn Ala 580 585 590 Gln Gln Gln Ser Arg Asp Lys Glu Val 595 600 <210> 4 <211> 515 <212> PRT <213> Homo sapiens <400> 4 Glu Ser Leu Arg Met Gln Leu Leu Asp Tyr Gln Ala Gln Ser Asp Glu 1 5 10 15 Lys Ser Leu Ile Ala Lys Leu His Gln His Asn Val Ser Leu Gln Leu 20 25 30 Ser Glu Ala Thr Ala Leu Gly Lys Leu Glu Ser Ile Thr Ser Lys Leu 35 40 45 Gln Lys Met Glu Ala Tyr Asn Leu Arg Leu Glu Gln Lys Leu Asp Glu 50 55 60 Lys Glu Gln Ala Leu Tyr Tyr Ala Arg Leu Glu Gly Arg Asn Arg Ala 65 70 75 80 Lys His Leu Arg Gln Thr Ile Gln Ser Leu Arg Arg Gln Phe Ser Gly 85 90 95 Ala Leu Pro Leu Ala Gln Gln Glu Lys Phe Ser Lys Thr Met Ile Gln 100 105 110 Leu Gln Asn Asp Lys Leu Lys Ile Met Gln Glu Met Lys Asn Ser Gln 115 120 125 Gln Glu His Arg Asn Met Glu Asn Lys Thr Leu Glu Met Glu Leu Lys 130 135 140 Leu Lys Gly Leu Glu Glu Leu Ile Ser Thr Leu Lys Asp Thr Lys Gly 145 150 155 160 Ala Gln Lys Val Ile Asn Trp His Met Lys Ile Glu Glu Leu Arg Leu 165 170 175 Gln Glu Leu Lys Leu Asn Arg Glu Leu Val Lys Asp Lys Glu Glu Ile 180 185 190 Lys Tyr Leu Asn Asn Ile Ile Ser Glu Tyr Glu Arg Thr Ile Ser Ser 195 200 205 Leu Glu Glu Glu Ile Val Gln Gln Asn Lys Phe His Glu Glu Arg Gln 210 215 220 Met Ala Trp Asp Gln Arg Glu Val Asp Leu Glu Arg Gln Leu Asp Ile 225 230 235 240 Phe Asp Arg Gln Gln Asn Glu Ile Leu Asn Ala Ala Gln Lys Phe Glu 245 250 255 Glu Ala Thr Gly Ser Ile Pro Asp Pro Ser Leu Pro Leu Pro Asn Gln 260 265 270 Leu Glu Ile Ala Leu Arg Lys Ile Lys Glu Asn Ile Arg Ile Ile Leu 275 280 285 Glu Thr Arg Ala Thr Cys Lys Ser Leu Glu Glu Lys Leu Lys Glu Lys 290 295 300 Glu Ser Ala Leu Arg Leu Ala Glu Gln Asn Ile Leu Ser Arg Asp Lys 305 310 315 320 Val Ile Asn Glu Leu Arg Leu Arg Leu Pro Ala Thr Ala Glu Arg Glu 325 330 335 Lys Leu Ile Ala Glu Leu Gly Arg Lys Glu Met Glu Pro Lys Ser His 340 345 350 His Thr Leu Lys Ile Ala His Gln Thr Ile Ala Asn Met Gln Ala Arg 355 360 365 Leu Asn Gln Lys Glu Glu Val Leu Lys Lys Tyr Gln Arg Leu Leu Glu 370 375 380 Lys Ala Arg Glu Glu Gln Arg Glu Ile Val Lys Lys His Glu Glu Asp 385 390 395 400 Leu His Ile Leu His His Arg Leu Glu Leu Gln Ala Asp Ser Ser Leu 405 410 415 Asn Lys Phe Lys Gln Thr Ala Trp Asp Leu Met Lys Gln Ser Pro Thr 420 425 430 Pro Val Pro Thr Asn Lys His Phe Ile Arg Leu Ala Glu Met Glu Gln 435 440 445 Thr Val Ala Glu Gln Asp Asp Ser Leu Ser Leu Val Val Lys Leu 450 455 460 Lys Lys Will Be Gln Asp Leu Glue Arg Gln Arg Glue Ile Thr Leu Glue 465 470 475 480 Lys Val Lys Glu Phe Glu Asn And Lys Leu Gln Leu Gln Glu Asn His 485,490,495 Glu Asp Glu Val Lys Val Lys Ala Glu Val Glu Asp Leu Lys Tyr 500 505 510 Leopard Leopard Asp 515 <210> 5 <211> 3606 <212> DNA <213> Humans (Homo sapiens) <400> 5 actgaaaaca tttctcagg agatagata agtgaaagaa aattggattt attgagccctc 60 aaaatatga gtgagcaca atcaagaat gatttctttt cavagaact attgaaaaa 120 gaagagatt tagaaggag taggacagtg atagccaat ttcagaata atttaaagaa 180 ttagttgag aaataagca acttgaagaa ggtagaag aaatattgca agcaattaag 240 gaatgcaga aagatcctga tgttaaagga ggagaaacat ctctattat ccctagcctt 300 gaaagactag ttaatgctat agaatcaaag aatgcagaag gaatctttga tgcgagtctg 360 catttgaaag cccaagttga tcagcttacc ggagaaatg aagaattaag acaggagctc 420 agggaatctc ggaaagaggc tataaattat tcacagcagt tggcaaaagc taatttaaag 480 atagaccatc ttgaaaaaga aactagtctt ttacgacaat cagaaggatc gaatgttgtt 540 tttaaaggaa ttgacttacc tgatgggata gcaccatcta gtgccagtat cattaattct 600 cagaatgaat atttaataca tttgttacag gaactagaaa ataaagaaaa aaagttaaag 660 aatttagaag attctcttga agattacaac agaaaatttg ctgtaattcg tcatcaacaa 720 agtttgttgt ataaagaata cctaagtgaa aggagacct ggaaaacaga atctaaaaca 780 ataaagagg aaaagagaaa acttgaggat caagtccaac aagatgctat aaaagtaaaa 840 gaatataata atttgctcaa tgctcttcag atggattcgg atgaaatgaa aaaaatactt 900 gcagaaaata gtaggaaaat tactgttttg caagtgaatg aaaaatcact tataaggcaa 960 tatacaacct tagtagaatt ggagcgaacaa cttagaaaag aaaatgagaa gcaaaagaat 1020 gaattgttgt caatggaggc tgaagttttgt gaaaaaattg ggtgtttgca aagatttaag 1080 gaaatggcca ttttcaagat tgcagctctc caaaaagttg tagataatag tgtttctttg 1140 tctgaactag aactggctaa taaacagtac aatgaactga ctgctaagta cagggacatc 1200 ttgcaaaaag ataatatgct tgttcaaaga acaagtaact tggaacacct ggagtgtgaa 1260 aacatctcct taaaagaaca agtggagtct aataataaag aactggagat taccaaggaa 1320 aaacttcaca ctattgaaca agcctgggaa caggaaacta aattaggtaa tgaatctagc 1380 atggataagg caaagaaatc aataaccaac agtgacattg tttccatttc aaaaaaata 1440 actatgctgg aaatgaagga attaaatgaa aggcagcggg ctgaacattg tcaaaaaatg 1500 tatgaacact tacggacttc gttaaagcaa atggaggaac gtaatttga attggaaacc 1560 aaatttgctg agcttaccaa aatcaatttg gatgcacaga aggtggaaca gatgttaaga 1620 gatgaattag ctgatagtgt gagcaaggca gtaagtgatg ctgataggca acggattcta 1680 gaattagaga agaatgaaat ggaactaaaa gttgaagtgt caaaactgag agagatttct 1740 gatattgcca gaagacaagt tgaaattttg aatgcacaac aacaatctag ggacaaggaa 1800 gtaactgaaa acatttctca aggagataga ataagtgaaa gaaaattgga tttattgagc 1860 ctcaaaaata tgagtgaagc acaatcaaag aatgaatttc tttcaagaga actaattgaa 1920 aaagaaagag atttagaaag gagtaggaca gtgatagcca aatttcagaa taaattaaaa 1980 gaattagttg aagaaaataa gcaacttgaa gaaggtatga aagaaatatt gcaagcaatt 2040 aaggaaatgc agaaagatcc tgatgttaaa ggaggagaaa catctctaat tatccctagc 2100 cttgaaagac tagttaatgc tatagaatca aagaatgcag aaagaatctt tgatgcgagt 2160 ctgcatttga aagcccaagt tgatcagctt accggaagaa atgaagaatt aagacaggag 2220 ctcagggaat ctcggaaaga ggctataaat tattcacagc agttggcaaa agctaattta 2280 aagatagacc atcttgaaaa agaaactagt cttttacgac aatcagaagg atcgaatgtt 2340 gtttttaaag gaattgactt acctgatggg atagcaccat ctagtgccag tatcattaat 2400 tctcagaatg aatatttaat acatttgtta caggaactag aaaataaga aaaaaagtta 2460 aagaatttag aagattctct tgaagattac aacagaaaat ttgctgtaat tcgtcatcaa 2520 caaagtttgt tgtataaaga atacctaagt gaaaaggaga cctggaaaac agaatctaaa 2580 acaataaaag aggaaaagag aaaacttgag gatcaagtcc aacaagatgc tataaaagta 2640 aaagaatata ataatttgct caatgctctt cagatggatt cggatgaaat gaaaaaaaata 2700 cttgcagaaa atagtaggaa aattactgtt ttgcaagtga atgaaaaatc acttataagg 2760 caatatacaa ccttagtaga attggagcga caacttagaa aagaaaatga gaagcaaaag 2820 aatgaattgt tgtcaatgga ggctgaagtt tgtgaaaaaa ttgggtgttt gcaaagattt 2880 aaggaaatgg ccattttcaa gattgcagct ctccaaaaag ttgtagaataa tagtgtttct 2940 ttgtctgaac tagaactggc taataaacag tacaatgaac tgactgctaa gtacagggac 3000 atcttgcaaa aagataatat gcttgttcaa agaacaagta acttggaaca cctggagtgt 3060 gaaaacatct ccttaaaaaga acaagtggag tctataaata aagaactgga gattaccaag 3120 gaaaaaacttc acactattga acaagcctgg gaacaggaaa ctaaattagg taatgaatct 3180 agcatggata aggcaaagaa atcaataacc aacagtgaca ttgttccat ttcaaaaaa 3240 ataactatgc tggaaatgaa ggaatttaat gaaggcagc gggctgaaca ttgtcaaaaa 3300 atgtatgaac acttacggac ttcgttaaag caatggagg aacgtaattt tgaattggaa 3360 accaaatttg ctgagcttac caaatcaat ttggatgcac agaagtgga acagatgtta 3420 agagatgaat tagctgatag tgtgagcaag gcagtaagtg atgctgaat gcaacggatt 3480 ctagaattag agagaatga aatgaacta aaagttgaag tgtcaaact gagagagatt 3540 tctgatattg ccagagaca agttgaattt ttgaatgcac aacaacaatc tagggacaag 3600 Gagta 3606 <210> 6 <211> 1803 <212> DNA <213> Humans (Homo sapiens) <400> 6 actgaaaaca tttctcagg agatagata agtgaaagaa aattggattt attgagccctc 60 aaaatatga gtgagcaca atcaagaat gatttctttt cavagaact attgaaaaa 120 gaagagatt tagaaggag taggacagtg atagccaat ttcagaata atttaaagaa 180 ttagttgaag aaaataagca acttgaagaa ggtatgaaag aaatattgca agcaattaag 240 gaaatgcaga aagatcctga tgttaaaagga ggagaaacat ctctaattat ccctagcctt 300 gaaagactag ttaatgctat agaatcaaag aatgcagaag gaatctttga tgcgagtctg 360 catttgaaag cccaagttga tcagcttacc ggagaaatg aagaattaag acaggagctc 420 agggaatctc ggaaagaggc tataaattat tcacagcagt tggcaaaagc taatttaaag 480 atagaccatc ttgaaaaaga aactagtctt ttacgacaat cagaaggatc gaatgttgtt 540 tttaaaggaa ttgacttacc tgatgggata gcaccatcta gtgccagtat cattaattct 600 cagaatgaat atttaataca tttgttacag gaactagaaa ataaagaaaa aaagttaaag 660 aatttagaag attctcttga agattacaac agaaaatttg ctgtaattcg tcatcaacaa 720 agtttgttgt ataaagaata cctaagtgaa aggagacct ggaaaacaga atctaaaaca 780 ataaagagg aaaagagaaa acttgaggat caagtccaac aagatgctat aaaagtaaaa 840 gaatataata atttgctcaa tgctcttcag atggattcgg atgaaatgaa aaaaatactt 900 gcagaaaata gtaggaaaat tactgttttg caagtgaatg aaaaatcact tataaggcaa 960 tatacaact taggaatt ggagggaaaaaatgaaa gxaaagaat 1020 gattgttgt caatggaggc tgaagttttgt gaaaaattg gttgtttgca aagatttaag 1080 gaaatggcca ttttcagat tgcagctctc caaaagttg tagatatag tgtttctttg 1140 tctgaactag aactggctaa taacagtac atgactga ctgctaagta cagggacatc 1200 ttgcaaaag atatatgct tgttcaaga acagtact tggacacct ggagtgtgaa 1260 aacatctcct taaaagaca agtggagtct aataaag aactggagat taccaggaa 1320 aaacttcaca ctattgaca agcctgggaa caggaacta aattaggtaa tgaatctagc 1380 atggatagg aaagaatc aaaccac agtgacattg tttccattc aaaaaaata 1440 actatgctgg aaatgaagga atttaatgaa agcagcggg ctgaacattg tcaaaaatg 1500 tatgacact tacggactc gttaaagcaa taggaggac gtattttga attggaacc 1560 aaatttgctg agcttaccaa atcaatttg gatgcacaga aggtggaca gatgttaaga 1620 gatgaattag ctgatagtgt gagcaaggca gtaagtgatg ctgataggca acggattcta 1680 gaattagaga agaatgaaat ggaactaaaa gttgaagtgt caaaactgag agagatttct 1740 gatattgcca gaagacaagt tgaaattttg aatgcacaac aacaatctag ggacaaggaa 1800 gta 1803 <210> 7 <211> 1545 <212> DNA <213> Homo sapiens <400> 7 gagtccctca gaatgcaact gctagactat caggcacagt ctgatgaaaa gtcgctcatt 60 gccaagttgc accaacataa tgtctctctt caactgagtg aggctactgc tcttggtaag 120 ttggagtcaa ttacatctaa actgcagaag atggaggcct acaacttgcg cttagagcag 180 aaacttgatg aaaaagaaca ggctctctat tatgctcgtt tggagggaag aaacagagca 240 aaacatctgc gccaaacaat tcagtctcta cgacgacagt ttagtggagc tttacccttg 300 gcacaacagg aaaagttctc caaaacaatg attcaactac aaaatgacaa acttaagata 360 atgcaagaaa tgaaaaattc tcaacaagaa catagaaata tggagaacaa aacattggag 420 atggaattta atttaaaggg cctggaagg ttaatagca ctttaagga taccaagga 480 gcccaaaagg taatcaactg gcatatgaaa atagagaac ttcgtcttca agaacttaaa 540 ctaaatcgggg atttagtcaa gaataagaa gaataaaat atttgataa cataatttct 600 gaatgaac gtacaatcag cagtcttgaa gagaaatttg tgcaacaga caagtttcat 660 gagaaagac aaatggcctg ggatcaaga gaagttgacc tggaacgcca actagacatt 720 tttgaccgtc agcaaatga atactaat gcggcacaa agtttgaaga agctacagga 780 tcaatccctg accctagttt gccccttcca aatcaacttg agatcgctct aaggaaatt 840 aaggagaaca ttcgaataat tcagaaaca cgggcaactt gcaatcact agagagaaa 900 ctaaaagaga aagaatctgc tttaggtta gcagaacaa atactgtc aagagacaa 960 gtaatcaatg aactgaggct tcgattgcct gccactgcag aagagaaaa gctcatagct 1020 gagctaggca gaaaagagat ggaaccaaaa tctcaccaca cattgaaat tgctcatcaa 1080 accattgcaa acatgcaagc aaggttaat caaaagaag aagtattaa gaagtatca 1140 cgtctctctag aaaaagccag agagagca agagaattg tgagaaca tgaggac 1200 cttcatattc ttcacacag attagaacta caggctgata gttcactaaa taattcaa 1260 caaacggctt gggatttaat gaacagtct cccactccag ttcctaccaa caagcatttt 1320 attcgtctgg ctgagatgga acagacagta gcagaacaag atgactct ttcctcactc 1380 ttggtcaaac taaagaagt atcacagat ttggagac aagagaat cactgaatta 1440 aaagtaaag aatttgaaa tatcaatta cagctcaag aaaaccatga agatgaagtg 1500 aaaaagtaa aagcggagt agaggatttta aagtatctctc tggac 1545 <210> 8 <211> 7972 <212> DNA <213> Humans (Homo sapiens) <400> 8 atttgaagtc ctcgttccac gccttctcat catcctgac accgagctct gggactccgg 60 cggagaatct aaacgtaag catcaccac gtcgtgaac tgtaggctct cctggcatcc 120 gggatcttat tctggccttg gcggagttgg ggatggtgtc gcctagcagc cgctgccgct 180 ttggcttgct cgggaccatt tggctggacc cagagtccgc gtggaccgc gatagggatc 240 tgtcagggcc cgcggccggg tccagcttgg tggttgcggt agtgagaggc ctccgctggt 300 tgccaggctt ggtctagagg tggagcacag tgaaagaatt caatgcca cctaatataa 360 actggaaaga aaatgaaa gttgaccag atgacctgcc ccgtcaagaa gaacggcag 420 ataatttatt gatttcctta tccaggtgg aagtaaatga gctaaaagt gaaagcaag 480 aaaatgtgat acaccttttc agaattactc agtcactaat gaagaatgaa gctcaagaag 540 tggagctggc tttggaagaa gtagaaaag ctggagaaga acagcaaa tttgaaaatc 600 aattaaaaac taaagtaatg aaactgaaa atgaactgga gatggctcag cagtctgcag 660 gtggacgaga tactcggttt ttacgtaatg aaatttgcca acttgaaaaa cattagaac 720 aaaagatag agaattgag gattgaa aggagttgg gaagagag aagtg 780 agcaatggc tctcgaat gaggaggcag aaatgaaaa cagcaatta agagagaga 840 aaacgtct aaagaaaaag atgaacac ttgtcagga tattattgac taccagaac 900 aaatagattc acagaagaa acactttt aagaagggg gggacagt gactaccgat 960 cacagttgtc taaaaaaaac tatgagctta tccaatatct tgatgaaatt cagactttaa 1020 cagaagctaa tgagaaaatt gaagttcaga atcaagaaat gagaaaaaat ttagaagagt 1080 ctgtacagga aatggagaag atgactgatg aataataat aatgaaagct attgtgcatc 1140 agacagataa tgtaatagat cagttaaaaa aagaaaacga tcattatcaa cttcaagtgc 1200 aggagcttac agatcttctg aaatcaaaaa atgaagaaga tgatccaatt atggtagctg 1260 tcaatgcaaa agtagaagaa tggaagctaa ttttgtcttc taaagatgat gaaattattg 1320 agtatcagca aatgttacat aacctaaggg agaaacttaa gaatgctcag cttgatgctg 1380 ataaagtaa tgttatggct ctacagcagg gtatacagga acgagacagt caaattaaga 1440 tgctcaccga acaagtagaa caatatacaa aagaaatgga aaagaatact tgtattattg 1500 aagatttgaa aaatgagctc caaagaaaca aaggtgcttc aaccctttct caacagactc 1560 atatgaaaat tcagtcaacg ttagacattt taaaagagaa aactaaagag gctgagagaa 1620 cagctgaact ggctgaggct gatgctaggg aaaaggataa agaattagtt gaggctctga 1680 agaggttaaa agattatgaa tcgggagtat atggtttaga agatgctgtc gttgaaataa 1740 agaattgtaa aaaccaaatt aaaataagag atcgagagat tgaaatatta acaaaggaaa 1800 tcaataaact tgaattgaag atcagtgatt tccttgatga aaatgaggca cttagagagc 1860 gtgtgggcct tgaaccaaag acaatgattg atttaactga atttagaaat agcaaacact 1920 taaaacagca gcagtacaga gctgaaaacc agattcttttt gaaagagatt gaaagtctag 1980 aggaagaacg acttgatctg aaaaaaaaa ttcgtcaaat ggctcaagaa agaggaaaaa 2040 gaagtgcaac ttcaggatta accactgagg acctgaacct aactgaaaac atttctcaag 2100 gagatagaat aagtgaaaga aaattggatt tattgagcct caaaaatatg agtgaagcac 2160 aatcaaagaa tgaatttctt tcaagagaac taattgaaaa agaaagagat ttagaaagga 2220 gtaggacagt gatagccaaa tttcagaata attaaaaga attagttgaa gaaaataagc 2280 aacttgaaga aggtatgaaa gaaatattgc aagcaattaa ggaaatgcag aaagatcctg 2340 atgttaaagg aggagaaaca tctctaatta tccctagcct tgaaagacta gttaatgcta 2400 tagaatcaa gatgcagaa ggaatctttg atgcgagtct gcatttgaaa gcccaagttg 2460 atcagcttac cggagaat gagaatta gaggagct cagggaatct cggaaggg 2520 ctataaatta ttcacag ttggcaaag ctaatttaaa gatagaccac cttgaaaaag 2580 aaactagtct tttacgacaa tcagaaggat cgaatgttgt ttttaagga attgacttac 2640 ctgatgggat agcaccatct agtgccagta tcattaattc tcagaatgaa tattatac 2700 atttgttaca gaactagaaaaagaaaaagttaaa gatttaga gattctcttg 2760 aagattaca cagaaattt gctgtaattc gtcatcaaca aagtttgttg tataaagaat 2820 acctaagtga aaggagacc tggaaacag atctaaaac aaaaagag gaaagagaa 2880 aacttgagga tcaagtccaa acatgcta taaaagtaaa agatataat aatttgctca 2940 atgctcttca gatgattcg gatgaatga aaaaaatact tgcagaaaat agtaggaaaa 3000 ttactgtttt gcaagtgaat gaaaaatcac ttataggca atacaacc ttagtagaat 3060 tggagcgaca acttagaaaa gaaatgaga agcaaagaa tgaattgttg tcaatggagg 3120 ctgaagtttg tgaaaaaatt gggtgtttgc aagatttaa ggaatggcc attttcaaga 3180 ttgcagctct ccaaaagtt gtagataata gtgttcttt gtctgaacta gaactggcta 3240 aaacagta caatgaactg actgctaagt acaggcat cttgcaaaa gataatgc 3300 ttgttcaaag aacaagtaac ttggacacc tggagtgtga aacacatctcc ttaaaagaac 3360 aagtggagtc tataaataa gaacggaga ttaccaagga aaacttcac actattgac 3420 aagcctggga acaggaact aattaggta atgaatctag catggatag gcaagaat 3480 caataaccaa cagtgacatt gttccattt caaaaaaat actagctg gaatgaagg 3540 aattaatga aaggcagcgg gctgacatt gtcaaaaat gtatgacac tacggactt 3600 cgttaaagca aatggaggaa cgtaattttg aattggaaac caattgct gagcttacca 3660 aaatcaattt ggatgcacag aaggtggaac agatgttaag agatgatta gctgatagtg 3720 tgagcaaggc agtaagtgat gctgataggc aacggattct agattagag agaatgaa 3780 tggaactaa agttgaagtg tcaaactga gagagatttc tgatattgcc agagacaag 3840 ttgaaatttt gatgcacaacaatcta gggaagga agtagagtcc ctcagaatgc 3900 aactgctaga ctatcaggca cagtctgatg aaagtcgct cattgccaag ttgcaccac 3960 ataatgtctc tctcactg agtgaggcta ctgctcttgg taagttggag tcattacat 4020 ctaaactgca gagatggag gcctacaact tgcgcttaga gcagaaactt gatgaaaag 4080 aacaggctct ctattatgct cgttggagg gagaaacag agcaaacat ctgcgccaaa 4140 caattcagtc tctacgacga cagtttagtg gagctttacc cttggcaca caggaaagt 4200 tctccaaaac atgattca ctacaaatg acaacttaa gatatgca gaatgaaa 4260 attctcaca agaacataga atatggaga acaaacatt gagatggaa ttaaattta 4320 agggcctgga agagttaata agcactttaa aggataccaa agggccca aaggtaatca 4380 actggcatat gaaatagaa gaacttcgtc ttcagaact taaactaat cgggaattag 4440 tcaggaata agagaata aaatattttga atacataat ttctgaata gaacgtaca 4500 tcagcagtct tgagagaa attgtgcaac agaacaagtt tcatgagaa agacaatgg 4560 cctgggatca aagagaagtt gacctggaac gccaactaga cattttgac cgtcagcaaa 4620 atgaaatact aaatgcggca caaagttttg aagaagctac aggatcaatc cctgacccta 4680 gtttgcccct tccaatcaa ctgagatcg ctctaggaaattaggag aacattcgaa 4740 taattctga aacacggggca acttgcaat cactagaga gaactaaaa gagaagaat 4800 ctgctttaag gttagcagaaaaatac tgtcagaga caagtaatc atgaactga 4860 ggcttcgatt gcctgccact gcagaaagag aaagctcat agctgagcta ggcagaaaag 4920 agatggaacc aaaatctcac cacacattga aaattgctca tcaaccatt gcaaaccc 4980 aaagcaaggtt aaatcaaaaa gagaagtt tcaacgtctt ctagaaaag 5040 ccagagagga gcaagagaa attgtgaga aacatgagga agaccttcat attcttcatc 5100 acagattaga actacaggct gatagttcac taaataatt siaaaacg gcttgggatt 5160 taatgaaaca gtctcccact ccagttccta ccaacaagca ttttattcgt ctggctgaga 5220 tggaacagac agtagcagaa caatgact ctctttccctc actcttggtc aaactaaga 5280 aagtatcaca agatttggag agacaagag aaatcactga attaaagta aagaatttg 5340 aaataatcaattacagctt siagaaaacc atgagatga agtgaaaaaa gtaaaagcgg 5400 aagtagagga ttagtat cttctggacc agtcacaaaa ggagtcacag tgtttaaaat 5460 ctgaacttca gggctcaaaaa gaagcaatt cagagctcc aacaactaca atgagaatc 5520 tagtagaacg gctaagagc cattagcct tgaggagaaaacagaaa gcacttagtc 5580 gggcactttt agaactccgg gcagaaatga cagcagctgc tgagaacgt attatttctg 5640 caacttctca aaagaggcc catctcaatg ttcacaaat cgttgatcga catactagag 5700 agctaagac acagttga gatttaatg aaatctttt aaattgaa gaagcactta 5760 aaacagtaaaacagagaaactcacta ctgataattt gatgactta aatgaac 5820 tgcaaaaaaaaaagcc tataaaa tacttagaga gaagaggaa attgatcaag 5880 agaatgatga actgaaaagg cavaaaaa gactaaccag tggattacag ggcaacccc 5940 tgacagataaaactagaagt ctaattgaag aactcaaag gaagttaaaaactagaga 6000 accaattaga gggaaggtg gaggagtag acctaaacc tatgaagaa aagaatgcta 6060 aagagaatt attaggtgg gagaaggta aaagtgca agccaaata gaggattc 6120 gaaacaagtt aaagagaaa gagggggag tctttactt aaaaagcag ttgatactt 6180 tgaaggatct tttgccaaa gccgataaag agaacttac tttgcagagg aaactaaaaa 6240 caactggcat gactgttgat caggttttgg gatacgagc tttggagtca gaaaaagaat 6300 tggaagattt aaaaagaga atcttgact tggaaatga tattgtat atgaggcccc 6360 accaagctct tcctcgagat tctgttgtag aagatttaca tttacaaat agatacctcc 6420 aagaaaaact tcatgcttta gaaaaacagt ttcaagga tacatattct aagccttca 6480 ttcaggaat agatcagat gatcattgtc aggagaaca ggaggctcag aaggaaaact 6540 tgaagttgtc atctgaaaat attgaactga aatttcagct tgaacaagca aaaagatt 6600 tgccagatt aaagaatcaa gtcagagatt tgaggaat gtgtgaattt cttagaaag 6660 aaaaagcaga agttcagcgg aaacttggcc atgttagagg gtctggtaga agtggaaga 6720 caatcccaga actggaaaaa accattggtt taatgaaaaa agtagttgaa aaagtccaga 6780 gagaaaatga acagttgaa aaagcatcag gatatttgac tagtgaaaa atggctaata 6840 ttgagcagga aaatgaaaaa ttgaggctg aattagaaaa acttaaagct catcttgggc 6900 atcagttgag catgcactat gatccaaga ccaaggcac agaaaaaatt attgctgaaa 6960 atgaaaggct tcgtaagaa cttaaaaaag aactgatgc tgcagagaaa ttacggatag 7020 chaagaa tttagata tttaagaga nationalgacagt tcactaga gagactggta 7080 agagattgca gtttgcagaa agcagaggtc cacagcttga agtgctgac agtaagagct 7140 ggaaatccat tgtggttaca agaatgtag aaaccaagtt aaagaattg gaactgata 7200 ttgccaaaaa aaatcaaagc attackgacc ttaacagct tgtaaaagaa gcaacagaga 7260 gagaaaaaaaaaaaaa tacaatgaag accttgaaca acagattaag attcttaac 7320 atgttcctga aggtgctgag acgagcaag gccttaaacg ggagcttca gttcttagat 7380 tagctaatca tcagctggat aagagaaag cagattaat ccatcagata gaagctaca 7440 aggaccaaag tggactgaa agcaccatac ctgatgctga tcaactaag gaaaaaataa 7500 aagatctaga ccacagctc aaatgtcag atctgaaaa gcagcattg aaggaggaaa 7560 taaagaagct gaaaaaagaa ctggaaattt ttgatccttc attttttgaa gaaattgaag 7620 atcttagta tattacag gagagtga agagat tctcttaga gagaggta 7680 aaaaactttc agacaattg ggagttgaat taactagccc tgttgctgct tctgaagagt 7740 ttgaagatga agaagaagt cctgttaatt tcccattta ctaaaggtca cctataaact 7800 ttgtttcatt taactattta ttactttat aagttaaata tacttggaaa taagcagttc 7860 tccgaactgt agtatttcct tccactacc tgtaccttt atacttagat tggaatttctt 7920 aaaaaa attattatgaa attttcaact tattaaaaaaaaaaaaa aaaaaaaaaaaa7972 <210> 9 <211> 738 <212> PRT <213> Unknown <220> <223> AAV8 connectivity <400> 9 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 5 10 15 Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Lys Pro 20 25 30 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro 35 40 45 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 70 75 80 Gln Gln Leu Gln Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala 85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly 100 105 110 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro 115 120 125 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg 130 135 140 Pro Val Glu Pro Ser Pro Gln Arg Ser Pro Asp Ser Ser Thr Gly Ile 145 150 155 160 Gly Lys Lys Gly Gln Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly Gln 165 170 175 Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro 180 185 190 Pro Ala Ala Pro Ser Gly Val Gly Pro Asn Thr Met Ala Ala Gly Gly 195 200 205 Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser 210 215 220 Ser Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val 225 230 235 240 Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His 245 250 255 Leu Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ala Thr Asn Asp 260 265 270 Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn 275 280 285 Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn 290 295 300 Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Ser Phe Lys Leu Phe Asn 305 310 315 320 Ile Gln Val Lys Glu Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala 325 330 335 Asn Asn Leu Thr Ser Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln 340 345 350 Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe 355 360 365 Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn 370 375 380 Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr 385 390 395 400 Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Thr Tyr 405 410 415 Thr Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser 420 425 430 Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu 435 440 445 Ser Arg Thr Gln Thr Thr Gly Gly Thr Ala Asn Thr Gln Thr Leu Gly 450 455 460 Phe Ser Gln Gly Gly Pro Asn Thr Met Ala Asn Gln Ala Lys Asn Trp 465 470 475 480 Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Thr Gly 485 490 495 Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Ala Gly Thr Lys Tyr His 500 505 510 Leu Asn Gly Arg Asn Ser Leu Ala Asn Pro Gly Ile Ala Met Ala Thr 515 520 525 His Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser Asn Gly Ile Leu Ile 530 535 540 Phe Gly Lys Gln Asn Ala Ala Arg Asp Asn Ala Asp Tyr Ser Asp Val 545 550 555 560 Met Leu Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr 565 570 575 Glu Glu Tyr Gly Ile Val Ala Asp Asn Leu Gln Gln Gln Asn Thr Ala 580 585 590 Pro Gln Ile Gly Thr Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val 595 600 605 Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile 610 615 620 Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe 625 630 635 640 Gly Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val 645 650 655 Pro Ala Asp Pro Pro Thr Thr Phe Asn Gln Ser Lys Leu Asn Ser Phe 660 665 670 Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu 675 680 685 Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr 690 695 700 Ser Asn Tyr Tyr Lys Ser Thr Ser Val Asp Phe Ala Val Asn Thr Glu 705 710 715 720 Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg 725 730 735 Asn Leu <210> 10 <211> 1299 <212> PRT <213> Homo sapiens <400> 10 Glu Ser Leu Arg Met Gln Leu Leu Asp Tyr Gln Ala Gln Ser Asp Glu 1 5 10 15 Lys Ser Leu Ile Ala Lys Leu His Gln His Asn Val Ser Leu Gln Leu 20 25 30 Ser Glu Ala Thr Ala Leu Gly Lys Leu Glu Ser Ile Thr Ser Lys Leu 35 40 45 Gln Lys Met Glu Ala Tyr Asn Leu Arg Leu Glu Gln Lys Leu Asp Glu 50 55 60 Lys Glu Gln Ala Leu Tyr Tyr Ala Arg Leu Glu Gly Arg Asn Arg Ala 65 70 75 80 Lys His Leu Arg Gln Thr Ile Gln Ser Leu Arg Arg Gln Phe Ser Gly 85 90 95 Ala Leu Pro Leu Ala Gln Gln Glu Lys Phe Ser Lys Thr Met Ile Gln 100 105 110 Leu Gln Asn Asp Lys Leu Lys Ile Met Gln Glu Met Lys Asn Ser Gln 115 120 125 Gln Glu His Arg Asn Met Glu Asn Lys Thr Leu Glu Met Glu Leu Lys 130 135 140 Leu Lys Gly Leu Glu Glu Leu Ile Ser Thr Leu Lys Asp Thr Lys Gly 145 150 155 160 Ala Gln Lys Val Ile Asn Trp His Met Lys Ile Glu Glu Leu Arg Leu 165 170 175 Gln Glu Leu Lys Leu Asn Arg Glu Leu Val Lys Asp Lys Glu Glu Ile 180 185 190 Lys Tyr Leu Asn Asn Ile Ile Ser Glu Tyr Glu Arg Thr Ile Ser Ser 195 200 205 Leu Glu Glu Glu Ile Val Gln Gln Asn Lys Phe His Glu Glu Arg Gln 210 215 220 Met Ala Trp Asp Gln Arg Glu Val Asp Leu Glu Arg Gln Leu Asp Ile 225 230 235 240 Phe Asp Arg Gln Gln Asn Glu Ile Leu Asn Ala Ala Gln Lys Phe Glu 245 250 255 Glu Ala Thr Gly Ser Ile Pro Asp Pro Ser Leu Pro Leu Pro Asn Gln 260 265 270 Leu Glu Ile Ala Leu Arg Lys Ile Lys Glu Asn Ile Arg Ile Ile Leu 275 280 285 Glu Thr Arg Ala Thr Cys Lys Ser Leu Glu Glu Lys Leu Lys Glu Lys 290 295 300 Glu Ser Ala Leu Arg Leu Ala Glu Gln Asn Ile Leu Ser Arg Asp Lys 305 310 315 320 Val Ile Asn Glu Leu Arg Leu Arg Leu Pro Ala Thr Ala Glu Arg Glu 325 330 335 Lys Leu Ile Ala Glu Leu Gly Arg Lys Glu Met Glu Pro Lys Ser His 340 345 350 His Thr Leu Lys Ile Ala His Gln Thr Ile Ala Asn Met Gln Ala Arg 355 360 365 Leu Asn Gln Lys Glu Glu Val Leu Lys Lys Tyr Gln Arg Leu Leu Glu 370 375 380 Lys Ala Arg Glu Glu Gln Arg Glu Ile Val Lys Lys His Glu Glu Asp 385 390 395 400 Leu His Ile Leu His His Arg Leu Glu Leu Gln Ala Asp Ser Ser Leu 405 410 415 Asn Lys Phe Lys Gln Thr Ala Trp Asp Leu Met Lys Gln Ser Pro Thr 420 425 430 Pro Val Pro Thr Asn Lys His Phe Ile Arg Leu Ala Glu Met Glu Gln 435 440 445 Thr Val Ala Glu Gln Asp Asp Ser Leu Ser Ser Leu Leu Val Lys Leu 450 455 460 Lys Lys Val Ser Gln Asp Leu Glu Arg Gln Arg Glu Ile Thr Glu Leu 465 470 475 480 Lys Val Lys Glu Phe Glu Asn Ile Lys Leu Gln Leu Gln Glu Asn His 485 490 495 Glu Asp Glu Val Lys Lys Val Lys Ala Glu Val Glu Asp Leu Lys Tyr 500 505 510 Leu Leu Asp Gln Ser Gln Lys Glu Ser Gln Cys Leu Lys Ser Glu Leu 515 520 525 Gln Ala Gln Lys Glu Ala Asn Ser Arg Ala Pro Thr Thr Thr Met Arg 530 535 540 Asn Leu Val Glu Arg Leu Lys Ser Gln Leu Ala Leu Lys Glu Lys Gln 545 550 555 560 Gln Lys Ala Leu Ser Arg Ala Leu Leu Glu Leu Arg Ala Glu Met Thr 565 570 575 Ala Ala Ala Glu Glu Arg Ile Ile Ser Ala Thr Ser Gln Lys Glu Ala 580 585 590 His Leu Asn Val Gln Gln Ile Val Asp Arg His Thr Arg Glu Leu Lys 595 600 605 Thr Gln Val Glu Asp Leu Asn Glu Asn Leu Leu Lys Leu Lys Glu Ala 610 615 620 Leu Lys Thr Ser Lys Asn Arg Glu Asn Ser Leu Thr Asp Asn Leu Asn 625 630 635 640 Asp Leu Asn Asn Glu Leu Gln Lys Lys Gln Lys Ala Tyr Asn Lys Ile 645 650 655 Leu Arg Glu Lys Glu Glu Ile Asp Gln Glu Asn Asp Glu Leu Lys Arg 660 665 670 Gln Ile Lys Arg Leu Thr Ser Gly Leu Gln Gly Lys Pro Leu Thr Asp 675 680 685 Asn Lys Gln Ser Leu Ile Glu Glu Leu Gln Arg Lys Val Lys Lys Leu 690 695 700 Glu Asn Gln Leu Glu Gly Lys Val Glu Glu Val Asp Leu Lys Pro Met 705 710 715 720 Lys Glu Lys Asn Ala Lys Glu Glu Leu Ile Arg Trp Glu Glu Gly Lys 725 730 735 Lys Trp Gln Ala Lys Ile Glu Gly Ile Arg Asn Lys Leu Lys Glu Lys 740 745 750 Glu Gly Glu Val Phe Thr Leu Thr Lys Gln Leu Asn Thr Leu Lys Asp 755 760 765 Leu Phe Ala Lys Ala Asp Lys Glu Lys Leu Thr Leu Gln Arg Lys Leu 770 775 780 Lys Thr Thr Gly Met Thr Val Asp Gln Val Leu Gly Ile Arg Ala Leu 785 790 795 800 Glu Ser Glu Lys Glu Leu Glu Glu Leu Lys Lys Arg Asn Leu Asp Leu 805 810 815 Glu Asn Asp Ile Leu Tyr Met Arg Ala His Gln Ala Leu Pro Arg Asp 820 825 830 Ser Val Val Glu Asp Leu His Leu Gln Asn Arg Tyr Leu Gln Glu Lys 835 840 845 Leu His Ala Leu Glu Lys Gln Phe Ser Lys Asp Thr Tyr Ser Lys Pro 850 855 860 Ser Ile Ser Gly Ile Glu Ser Asp Asp His Cys Gln Arg Glu Gln Glu 865 870 875 880 Leu Gln Lys Glu Asn Leu Lys Leu Ser Ser Glu Asn Ile Glu Leu Lys 885 890 895 Phe Gln Leu Glu Gln Ala Asn Lys Asp Leu Pro Arg Leu Lys Asn Gln 900 905 910 Val Arg Asp Leu Lys Glu Met Cys Glu Phe Leu Lys Lys Glu Lys Ala 915 920 925 Glu Val Gln Arg Lys Leu Gly His Val Arg Gly Ser Gly Arg Ser Gly 930 935 940 Lys Thr Ile Pro Glu Leu Glu Lys Thr Ile Gly Leu Met Lys Lys Val 945 950 955 960 Val Glu Lys Val Gln Arg Glu Asn Glu Gln Leu Lys Lys Ala Ser Gly 965 970 975 Ile Leu Thr Ser Glu Lys Met Ala Asn Ile Glu Gln Glu Asn Glu Lys 980 985 990 Leu Lys Ala Glu Leu Glu Lys Leu Lys Ala His Leu Gly His Gln Leu 995 1000 1005 Ser Met His Tyr Glu Ser Lys Thr Lys Gly Thr Glu Lys Ile Ile 1010 1015 1020 Ala Glu Asn Glu Arg Leu Arg Lys Glu Leu Lys Lys Glu Thr Asp 1025 1030 1035 Ala Ala Glu Lys Leu Arg Ile Ala Lys Asn Asn Leu Glu Ile Leu 1040 1045 1050 Asn Glu Lys Met Thr Val Gln Leu Glu Glu Thr Gly Lys Arg Leu 1055 1060 1065 Gln Phe Ala Glu Ser Arg Gly Pro Gln Leu Glu Gly Ala Asp Ser 1070 1075 1080 Lys Ser Trp Lys Ser Ile Val Val Thr Arg Met Tyr Glu Thr Lys 1085 1090 1095 Leu Lys Glu Leu Glu Thr Asp Ile Ala Lys Lys Asn Gln Ser Ile 1100 1105 1110 Thr Asp Leu Lys Gln Leu Val Lys Glu Ala Thr Glu Arg Glu Gln 1115 1120 1125 Lys Val Asn Lys Tyr Asn Glu Asp Leu Glu Gln Gln Ile Lys Ile 1130 1135 1140 Leu Lys His Val Pro Glu Gly Ala Glu Thr Glu Gln Gly Leu Lys 1145 1150 1155 Arg Glu Leu Gln Val Leu Arg Leu Ala Asn His Gln Leu Asp Lys 1160 1165 1170 Glu Lys Ala Glu Leu Ile His Gln Ile Glu Ala Asn Lys Asp Gln 1175 1180 1185 Ser Gly Ala Glu Ser Thr Ile Pro Asp Ala Asp Gln Leu Lys Glu 1190 1195 1200 Lys Ile Lys Asp Leu Glu Thr Gln Leu Lys Met Ser Asp Leu Glu 1205 1210 1215 Lys Gln His Leu Lys Glu Glu Ile Lys Lys Leu Lys Lys Glu Leu 1220 1225 1230 Glu Asn Phe Asp Pro Ser Phe Phe Glu Glu Ile Glu Asp Leu Lys 1235 1240 1245 Tyr Asn Tyr Lys Glu Glu Val Lys Lys Asn Ile Leu Leu Glu Glu 1250 1255 1260 Lys Val Lys Lys Leu Ser Glu Gln Leu Gly Val Glu Leu Thr Ser 1265 1270 1275 Pro Val Ala Ala Ser Glu Glu Phe Glu Asp Glu Glu Glu Ser Pro 1280 1285 1290 Val Asn Phe Pro Ile Tyr 1295 <210> 11 <211> 400 <212> PRT <213> Homo sapiens <400> 11 Ile Leu Thr Lys Glu Ile Asn Lys Leu Glu Leu Lys Ile Ser Asp Phe 1 5 10 15 Leu Asp Glu Asn Glu Ala Leu Arg Glu Arg Val Gly Leu Glu Pro Lys 20 25 30 Thr Met Ile Asp Leu Thr Glu Phe Arg Asn Ser Lys His Leu Lys Gln 35 40 45 Gln Gln Tyr Arg Ala Glu Asn Gln Ile Leu Leu Lys Glu Ile Glu Ser[[ID=2c]] 50 55 60 Leu Glu Glu Glu Arg Leu Asp Leu Lys Lys Lys Ile Arg Gln Met Ala 65 70 75 80 Gln Glu Arg Gly Lys Arg Ser Ala Thr Ser Gly Leu Thr Thr Glu Asp 85 90 95 Leu Asn Leu Thr Glu Asn Ile Ser Gln Gly Asp Arg Ile Ser Glu Arg 100 105 110 Lys Leu Asp Leu Leu Ser Leu Lys Asn Met Ser Glu Ala Gln Ser Lys 115 120 125 It should be noted that there seems to be a minor error in the original text where line 27's tag was misspelled as " c>" in the original but should be "<000I802>" as per the normal sequence. I've corrected it in the translation for consistency. If this is not an error on your part, please double-check the original text.Asn Glu Phe Leu Ser Arg Glu Leu Ile Glu Lys Glu Arg Asp Leu Glu 130 135 140 Arg Ser Arg Thr Val Ile Ala Lys Phe Gln Asn Lys Leu Lys Glu Leu 145 150 155 160 Val Glu Glu Asn Lys Gln Leu Glu Glu Gly Met Lys Glu Ile Leu Gln 165 170 175 Ala Ile Lys Glu Met Gln Lys Asp Pro Asp Val Lys Gly Gly Glu Thr 180 185 190 Ser Leu Ile Ile Pro Ser Leu Glu Arg Leu Val Asn Ala Ile Glu Ser 195 200 205 Lys Asn Ala Glu Gly Ile Phe Asp Ala Ser Leu His Leu Lys Ala Gln 210 215 220 Val Asp Gln Leu Thr Gly Arg Asn Glu Glu Leu Arg Gln Glu Leu Arg 225 230 235 240 Glu Ser Arg Lys Glu Ala Ile Asn Tyr Ser Gln Gln Leu Ala Lys Ala 245 250 255 Asn Leu Lys Ile Asp His Leu Glu Lys Glu Thr Ser Leu Leu Arg Gln 260 265 270 Ser Glu Gly Ser Asn Val Val Phe Lys Gly Ile Asp Leu Pro Asp Gly 275 280 285 Ile Ala Pro Ser Ser Ala Ser Ile Ile Asn Ser Gln Asn Glu Tyr Leu 290 295 300 Ile His Leu Leu Gln Glu Leu Glu Asn Lys Glu Lys Lys Leu Lys Asn 305 310 315 320 Leu Glu Asp Ser Leu Glu Asp Tyr Asn Arg Lys Phe Ala Val Ile Arg 325 330 335 His Gln Gln Ser Leu Leu Tyr Lys Glu Tyr Leu Ser Glu Lys Glu Thr 340 345 350 Trp Lys Thr Glu Ser Lys Thr Ile Lys Glu Glu Lys Arg Lys Leu Glu 355 360 365 Asp Gln Val Gln Gln Asp Ala Ile Lys Val Lys Glu Tyr Asn Asn Leu 370 375 380 Leu Asn Ala Leu Gln Met Asp Ser Asp Glu Met Lys Lys Ile Leu Ala 385 390 395 400 <210> 12 <211> 1029 <212> PRT <213> Homo sapiens <400> 12 Glu Ser Leu Arg Met Gln Leu Leu Asp Tyr Gln Ala Gln Ser Asp Glu 1 5 10 15 Lys Ser Leu Ile Ala Lys Leu His Gln His Asn Val Ser Leu Gln Leu 20 25 30 Ser Glu Ala Thr Ala Leu Gly Lys Leu Glu Ser Ile Thr Ser Lys Leu 35 40 45 Gln Lys Met Glu Ala Tyr Asn Leu Arg Leu Glu Gln Lys Leu Asp Glu 50 55 60 Lys Glu Gln Ala Leu Tyr Tyr Ala Arg Leu Glu Gly Arg Asn Arg Ala 65 70 75 80 Lys His Leu Arg Gln Thr Ile Gln Ser Leu Arg Arg Gln Phe Ser Gly 85 90 95 Ala Leu Pro Leu Ala Gln Gln Glu Lys Phe Ser Lys Thr Met Ile Gln 100 105 110 Leu Gln Asn Asp Lys Leu Lys Ile Met Gln Glu Met Lys Asn Ser Gln 115 120 125 Gln Glu His Arg Asn Met Glu Asn Lys Thr Leu Glu Met Glu Leu Lys 130 135 140 Leu Lys Gly Leu Glu Glu Leu Ile Ser Thr Leu Lys Asp Thr Lys Gly 145 150 155 160 Ala Gln Lys Val Ile Asn Trp His Met Lys Ile Glu Glu Leu Arg Leu 165 170 175 Gln Glu Leu Lys Leu Asn Arg Glu Leu Val Lys Asp Lys Glu Glu Ile 180 185 190 Lys Tyr Leu Asn Asn Ile Ile Ser Glu Tyr Glu Arg Thr Ile Ser Ser 195 200 205 Leu Glu Glu Glu Ile Val Gln Gln Asn Lys Phe His Glu Glu Arg Gln 210 215 220 Met Ala Trp Asp Gln Arg Glu Val Asp Leu Glu Arg Gln Leu Asp Ile 225 230 235 240 Phe Asp Arg Gln Gln Asn Glu Ile Leu Asn Ala Ala Gln Lys Phe Glu 245 250 255 Glu Ala Thr Gly Ser Ile Pro Asp Pro Ser Leu Pro Leu Pro Asn Gln 260 265 270 Leu Glu Ile Ala Leu Arg Lys Ile Lys Glu Asn Ile Arg Ile Ile Leu 275 280 285 Glu Thr Arg Ala Thr Cys Lys Ser Leu Glu Glu Lys Leu Lys Glu Lys 290 295 300 Glu Ser Ala Leu Arg Leu Ala Glu Gln Asn Ile Leu Ser Arg Asp Lys 305 310 315 320 Val Ile Asn Glu Leu Arg Leu Arg Leu Pro Ala Thr Ala Glu Arg Glu 325 330 335 Lys Leu Ile Ala Glu Leu Gly Arg Lys Glu Met Glu Pro Lys Ser His 340 345 350 His Thr Leu Lys Ile Ala His Gln Thr Ile Ala Asn Met Gln Ala Arg 355 360 365 Leu Asn Gln Lys Glu Glu Val Leu Lys Lys Tyr Gln Arg Leu Leu Glu 370 375 380 Lys Ala Arg Glu Glu Gln Arg Glu Ile Val Lys Lys His Glu Glu Asp 385 390 395 400 Leu His Ile Leu His His Arg Leu Glu Leu Gln Ala Asp Ser Ser Leu 405 410 415 Asn Lys Phe Lys Gln Thr Ala Trp Asp Leu Met Lys Gln Ser Pro Thr 420 425 430 Pro Val Pro Thr Asn Lys His Phe Ile Arg Leu Ala Glu Met Glu Gln 435 440 445 Thr Val Ala Glu Gln Asp Asp Ser Leu Ser Ser Leu Leu Val Lys Leu 450 455 460 Lys Lys Val Ser Gln Asp Leu Glu Arg Gln Arg Glu Ile Thr Glu Leu 465 470 475 480 Lys Val Lys Glu Phe Glu Asn Ile Lys Leu Gln Leu Gln Glu Asn His 485 490 495 Glu Asp Glu Val Lys Lys Val Lys Ala Glu Val Glu Asp Leu Lys Tyr 500 505 510 Leu Leu Asp Thr Thr Gly Met Thr Val Asp Gln Val Leu Gly Ile Arg 515 520 525 Ala Leu Glu Ser Glu Lys Glu Leu Glu Glu Leu Lys Lys Arg Asn Leu 530 535 540 Asp Leu Glu Asn Asp Ile Leu Tyr Met Arg Ala His Gln Ala Leu Pro 545 550 555 560 Arg Asp Ser Val Val Glu Asp Leu His Leu Gln Asn Arg Tyr Leu Gln 565 570 575 Glu Lys Leu His Ala Leu Glu Lys Gln Phe Ser Lys Asp Thr Tyr Ser 580 585 590 Lys Pro Ser Ile Ser Gly Ile Glu Ser Asp Asp His Cys Gln Arg Glu 595 600 605 Gln Glu Leu Gln Lys Glu Asn Leu Lys Leu Ser Ser Glu Asn Ile Glu 610 615 620 Leu Lys Phe Gln Leu Glu Gln Ala Asn Lys Asp Leu Pro Arg Leu Lys 625 630 635 640 Asn Gln Val Arg Asp Leu Lys Glu Met Cys Glu Phe Leu Lys Lys Glu 645 650 655 Lys Ala Glu Val Gln Arg Lys Leu Gly His Val Arg Gly Ser Gly Arg 660 665 670 Ser Gly Lys Thr Ile Pro Glu Leu Glu Lys Thr Ile Gly Leu Met Lys 675 680 685 Lys Val Val Glu Lys Val Gln Arg Glu Asn Glu Gln Leu Lys Lys Ala 690 695 700 Ser Gly Ile Leu Thr Ser Glu Lys Met Ala Asn Ile Glu Gln Glu Asn 705 710 715 720 Glu Lys Leu Lys Ala Glu Leu Glu Lys Leu Lys Ala His Leu Gly His 725 730 735 Gln Leu Ser Met His Tyr Glu Ser Lys Thr Lys Gly Thr Glu Lys Ile 740 745 750 Ile Ala Glu Asn Glu Arg Leu Arg Lys Glu Leu Lys Lys Glu Thr Asp 755 760 765 Ala Ala Glu Lys Leu Arg Ile Ala Lys Asn Asn Leu Glu Ile Leu Asn 770 775 780 Glu Lys Met Thr Val Gln Leu Glu Glu Thr Gly Lys Arg Leu Gln Phe 785 790 795 800 Ala Glu Ser Arg Gly Pro Gln Leu Glu Gly Ala Asp Ser Lys Ser Trp 805 810 815 Lys Ser Ile Val Val Thr Arg Met Tyr Glu Thr Lys Leu Lys Glu Leu 820 825 830 Glu Thr Asp Ile Ala Lys Lys Asn Gln Ser Ile Thr Asp Leu Lys Gln 835 840 845 Leu Val Lys Glu Ala Thr Glu Arg Glu Gln Lys Val Asn Lys Tyr Asn 850 855 860 Glu Asp Leu Glu Gln Gln Ile Lys Ile Leu Lys His Val Pro Glu Gly 865 870 875 880 Ala Glu Thr Glu Gln Gly Leu Lys Arg Glu Leu Gln Val Leu Arg Leu 885 890 895 Ala Asn His Gln Leu Asp Lys Glu Lys Ala Glu Leu Ile His Gln Ile 900 905 910 Glu Ala Asn Lys Asp Gln Ser Gly Ala Glu Ser Thr Ile Pro Asp Ala 915 920 925 Asp Gln Leu Lys Glu Lys Ile Lys Asp Leu Glu Thr Gln Leu Lys Met 930 935 940 Ser Asp Leu Glu Lys Gln His Leu Lys Glu Glu Ile Lys Lys Leu Lys 945 950 955 960 Lys Glu Leu Glu Asn Phe Asp Pro Ser Phe Phe Glu Glu Ile Glu Asp 965 970 975 Leu Lys Tyr Asn Tyr Lys Glu Glu Val Lys Lys Asn Ile Leu Leu Glu 980 985 990 Glu Lys Val Lys Lys Leu Ser Glu Gln Leu Gly Val Glu Leu Thr Ser 995 1000 1005 Pro Val Ala Ala Ser Glu Glu Phe Glu Asp Glu Glu Glu Ser Pro 1010 1015 1020 Val Asn Phe Pro Ile Tyr [[ID=Asn Lys Gln Leu Glu Glu Gly Met Lys Glu Ile Leu Gln Ala Ile Lys 65 70 75 80 Glu Met Gln Lys Asp Pro Asp Val Lys Gly Gly Glu Thr Ser Leu Ile 85 90 95 Ile Pro Ser Leu Glu Arg Leu Val Asn Ala Ile Glu Ser Lys Asn Ala 100 105 110 Glu Gly Ile Phe Asp Ala Ser Leu His Leu Lys Ala Gln Val Asp Gln 115 120 125 Leu Thr Gly Arg Asn Glu Glu Leu Arg Gln Glu Leu Arg Glu Ser Arg 130 135 140 Lys Glu Ala Ile Asn Tyr Ser Gln Gln Leu Ala Lys Ala Asn Leu Lys 145 150 155 160 Ile Asp His Leu Glu Lys Glu Thr Ser Leu Leu Arg Gln Ser Glu Gly 165 170 175 Ser Asn Val Val Phe Lys Gly Ile Asp Leu Pro Asp Gly Ile Ala Pro 180 185 190 Ser Ser Ala Ser Ile Ile Asn Ser Gln Asn Glu Tyr Leu Ile His Leu 195 200 205 Leu Gln Glu Leu Glu Asn Lys Glu Lys Lys Leu Lys Asn Leu Glu Asp 210 215 220 Ser Leu Glu Asp Tyr Asn Arg Lys Phe Ala Val Ile Arg His Gln Gln 225 230 235 240 Ser Leu Leu Tyr Lys Glu Tyr Leu Ser Glu Lys Glu Thr Trp Lys Thr 245 250 255 Glu Ser Lys Thr Ile Lys Glu Glu Lys Arg Lys Leu Glu Asp Gln Val 260 265 270 Gln Gln Asp Ala Ile Lys Val Lys Glu Tyr Asn Asn Leu Leu Asn Ala 275 280 285 Leu Gln Met Asp Ser Asp Glu Met Lys Lys Ile Leu Ala Glu Asn Ser 290 295 300 Arg Lys Ile Thr Val Leu Gln Val Asn Glu Lys Ser Leu Ile Arg Gln 305 310 315 320 Tyr Thr Thr Leu Val Glu Leu Glu Arg Gln Leu Arg Lys Glu Asn Glu 325 330 335 Lys Gln Lys Asn Glu Leu Leu Ser Met Glu Ala Glu Val Cys Glu Lys 340 345 350 Ile Gly Cys Leu Gln Arg Phe Lys Glu Met Ala Ile Phe Lys Ile Ala 355 360 365 Ala Leu Gln Lys Val Val Asp Asn Ser Val Ser Leu Ser Glu Leu Glu 370 375 380 Leu Ala Asn Lys Gln Tyr Asn Glu Leu Thr Ala Lys Tyr Arg Asp Ile 385 390 395 400 Leu Gln Lys Asp Asn Met Leu Val Gln Arg Thr Ser Asn Leu Glu His 405 410 415 Leu Glu Cys Glu Asn Ile Ser Leu Lys Glu Gln Val Glu Ser Ile Asn 420 425 430 Lys Glu Leu Glu Ile Thr Lys Glu Lys Leu His Thr Ile Glu Gln Ala 435 440 445 Trp Glu Gln Glu Thr Lys Leu Gly Asn Glu Ser Ser Met Asp Lys Ala 450 455 460 Lys Lys Ser Ile Thr Asn Ser Asp Ile Val Ser Ile Ser Lys Lys Ile 465 470 475 480 Thr Met Leu Glu Met Lys Glu Leu Asn Glu Arg Gln Arg Ala Glu His 485 490 495 Cys Gln Lys Met Tyr Glu His Leu Arg Thr Ser Leu Lys Gln Met Glu 500 505 510 Glu Arg Asn Phe Glu Leu Glu Thr Lys Phe Ala Glu Leu Thr Lys Ile 515 520 525 Asn Leu Asp Ala Gln Lys Val Glu Gln Met Leu Arg Asp Glu Leu Ala 530 535 540 Asp Ser Val Ser Lys Ala Val Ser Asp Ala Asp Arg Gln Arg Ile Leu 545 550 555 560 Glu Leu Glu Lys Asn Glu Met Glu Leu Lys Val Glu Val Ser Lys Leu 565 570 575 Arg Glu Ile Ser Asp Ile Ala Arg Arg Gln Val Glu Ile Leu Asn Ala 580 585 590 Gln Gln Gln Ser Arg Asp Lys Glu Val Lys Leu Lys Glu Ala Leu Lys 595 600 605 Thr Ser Lys Asn Arg Glu Asn Ser Leu Thr Asp Asn Leu Asn Asp Leu 610 615 620 Asn Asn Glu Leu Gln Lys Lys Gln Lys Ala Tyr Asn Lys Ile Leu Arg 625 630 635 640 Glu Lys Glu Glu Ile Asp Gln Glu Asn Asp Glu Leu Lys Arg Gln Ile 645 650 655 Lys Arg Leu Thr Ser Gly Leu Gln Gly Lys Pro Leu Thr Asp Asn Lys 660 665 670 Gln Ser Leu Ile Glu Glu Leu Gln Arg Lys Val Lys Lys Leu Glu Asn 675 680 685 Gln Leu Glu Gly Lys Val Glu Glu Val Asp Leu Lys Pro Met Lys Glu 690 695 700 Lys Asn Ala Lys Glu Glu Leu Ile Arg Trp Glu Glu Gly Lys Lys Trp 705 710 715 720 Gln Ala Lys Ile Glu Gly Ile Arg Asn Lys Leu Lys Glu Lys Glu Gly 725 730 735 Glu Val Phe Thr Leu Thr Lys Gln Leu Asn Thr Leu Lys Asp Leu Phe 740 745 750 Ala Lys Ala Asp Lys Glu Lys Leu Thr Leu Gln Arg Lys Leu Lys Thr 755 760 765 Thr Gly Met Thr Val Asp Gln Val Leu Gly Ile Arg Ala Leu Glu Ser 770 775 780 Glu Lys Glu Leu Glu Glu Leu Lys Lys Arg Asn Leu Asp Leu Glu Asn 785 790 795 800 Asp Ile Leu Tyr Met Arg Ala His Gln Ala Leu Pro Arg Asp Ser Val 805 810 815 Val Glu Asp Leu His Leu Gln Asn Arg Tyr Leu Gln Glu Lys Leu His 820 825 830 Ala Leu Glu Lys Gln Phe Ser Lys Asp Thr Tyr Ser Lys Pro Ser Ile 835 840 845 Ser Gly Ile Glu Ser Asp Asp His Cys Gln Arg Glu Gln Glu Leu Gln 850 855 860 Lys Glu Asn Leu Lys Leu Ser Ser Glu Asn Ile Glu Leu Lys Phe Gln 865 870 875 880 Leu Glu Gln Ala Asn Lys Asp Leu Pro Arg Leu Lys Asn Gln Val Arg 885 890 895 Asp Leu Lys Glu Met Cys Glu Phe Leu Lys Lys Glu Lys Ala Glu Val 900 905 910 Gln Arg Lys Leu Gly His Val Arg Gly Ser Gly Arg Ser Gly Lys Thr 915 920 925 Ile Pro Glu Leu Glu Lys Thr Ile Gly Leu Met Lys Lys Val Val Glu 930 935 940 Lys Val Gln Arg Glu Asn Glu Gln Leu Lys Lys Ala Ser Gly Ile Leu 945 950 955 960 Thr Ser Glu Lys Met Ala Asn Ile Glu Gln Glu Asn Glu Lys Leu Lys 965 970 975 Ala Glu Leu Glu Lys Leu Lys Ala His Leu Gly His Gln Leu Ser Met 980 985 990 His Tyr Glu Ser Lys Thr Lys Gly Thr Glu Lys Ile Ile Ala Glu Asn 995 1000 1005 Glu Arg Leu Arg Lys Glu Leu Lys Lys Glu Thr Asp Ala Ala Glu 1010 1015 1020 Lys Leu Arg Ile Ala Lys Asn Asn Leu Glu Ile Leu Asn Glu Lys 1025 1030 1035 Met Thr Val Gln Leu Glu Glu Thr Gly Lys Arg Leu Gln Phe Ala 1040 1045 1050 Glu Ser Arg Gly Pro Gln Leu Glu Gly Ala Asp Ser Lys Ser Trp 1055 1060 1065 Lys Ser Ile Val Val Thr Arg Met Tyr Glu Thr Lys Leu Lys Glu 1070 1075 1080 Leu Glu Thr Asp Ile Ala Lys Lys Asn Gln Ser Ile Thr Asp Leu 1085 1090 1095 Lys Gln Leu Val Lys Glu Ala Thr Glu Arg Glu Gln Lys Val Asn 1100 1105 1110 Lys Tyr Asn Glu Asp Leu Glu Gln Gln Ile Lys Ile Leu Lys His 1115 1120 1125 Val Pro Glu Gly Ala Glu Thr Glu Gln Gly Leu Lys Arg Glu Leu 1130 1135 1140 Gln Val Leu Arg Leu Ala Asn His Gln Leu Asp Lys Glu Lys Ala 1145 1150 1155 Glu Leu Ile His Gln Ile Glu Ala Asn Lys Asp Gln Ser Gly Ala 1160 1165 1170 Glu Ser Thr Ile Pro Asp Ala Asp Gln Leu Lys Glu Lys Ile Lys 1175 1180 1185 Asp Leu Glu Thr Gln Leu Lys Met Ser Asp Leu Glu Lys Gln His 1190 1195 1200 Leu Lys Glu Glu Ile Lys Lys Leu Lys Lys Glu Leu Glu Asn Phe 1205 1210 1215 Asp Pro Ser Phe Phe Glu Glu Ile Glu Asp Leu Lys Tyr Asn Tyr 1220 1225 1230 Lys Glu Glu Val Lys Lys Asn Ile Leu Leu Glu Glu Lys Val Lys 1235 1240 1245 Lys Leu Ser Glu Gln Leu Gly Val Glu Leu Thr Ser Pro Val Ala[[ID=?]] [[ID=?]]1250 1255 1260[[ID=?]] Ala Ser Glu Glu Phe Glu Asp Glu Glu Glu Ser Pro Val Asn Phe 1265 1270 1275 Pro Ile Tyr 1280 <210> 14 <211> 786 <212> PRT <213> Homo sapiens <400> 14 It should be noted that there seems to be an issue with the "?" tags in the original text where the line numbers are not in a proper sequential format as expected. This might cause some confusion in the context of a proper translation and understanding of the text structure. The translation is done as accurately as possible based on the provided text.Glu Ser Leu Arg Met Gln Leu Leu Asp Tyr Gln Ala Gln Ser Asp Glu 1 5 10 15 Lys Ser Leu Ile Ala Lys Leu His Gln His Asn Val Ser Leu Gln Leu 20 25 30 Ser Glu Ala Thr Ala Leu Gly Lys Leu Glu Ser Ile Thr Ser Lys Leu 35 40 45 Gln Lys Met Glu Ala Tyr Asn Leu Arg Leu Glu Gln Lys Leu Asp Glu 50 55 60 Lys Glu Gln Ala Leu Tyr Tyr Ala Arg Leu Glu Gly Arg Asn Arg Ala 65 70 75 80 Lys His Leu Arg Gln Thr Ile Gln Ser Leu Arg Arg Gln Phe Ser Gly 85 90 95 Ala Leu Pro Leu Ala Gln Gln Glu Lys Phe Ser Lys Thr Met Ile Gln 100 105 110 Leu Gln Asn Asp Lys Leu Lys Ile Met Gln Glu Met Lys Asn Ser Gln 115 120 125 Gln Glu His Arg Asn Met Glu Asn Lys Thr Leu Glu Met Glu Leu Lys 130 135 140 Leu Lys Gly Leu Glu Glu Leu Ile Ser Thr Leu Lys Asp Thr Lys Gly 145 150 155 160 Ala Gln Lys Val Ile Asn Trp His Met Lys Ile Glu Glu Leu Arg Leu 165 170 175 Gln Glu Leu Lys Leu Asn Arg Glu Leu Val Lys Asp Lys Glu Glu Ile 180 185 190 Lys Tyr Leu Asn Asn Ile Ile Ser Glu Tyr Glu Arg Thr Ile Ser Ser 195 200 205 Leu Glu Glu Glu Ile Val Gln Gln Asn Lys Phe His Glu Glu Arg Gln 210 215 220 Met Ala Trp Asp Gln Arg Glu Val Asp Leu Glu Arg Gln Leu Asp Ile 225 230 235 240 Phe Asp Arg Gln Gln Asn Glu Ile Leu Asn Ala Ala Gln Lys Phe Glu 245 250 255 Glu Ala Thr Gly Ser Ile Pro Asp Pro Ser Leu Pro Leu Pro Asn Gln 260 265 270 Leu Glu Ile Ala Leu Arg Lys Ile Lys Glu Asn Ile Arg Ile Ile Leu 275 280 285 Glu Thr Arg Ala Thr Cys Lys Ser Leu Glu Glu Lys Leu Lys Glu Lys 290 295 300 Glu Ser Ala Leu Arg Leu Ala Glu Gln Asn Ile Leu Ser Arg Asp Lys 305 310 315 320 Val Ile Asn Glu Leu Arg Leu Arg Leu Pro Ala Thr Ala Glu Arg Glu 325 330 335 Lys Leu Ile Ala Glu Leu Gly Arg Lys Glu Met Glu Pro Lys Ser His 340 345 350 His Thr Leu Lys Ile Ala His Gln Thr Ile Ala Asn Met Gln Ala Arg 355 360 365 Leu Asn Gln Lys Glu Glu Val Leu Lys Lys Tyr Gln Arg Leu Leu Glu 370 375 380 Lys Ala Arg Glu Glu Gln Arg Glu Ile Val Lys Lys His Glu Glu Asp 385 390 395 400 Leu His Ile Leu His His Arg Leu Glu Leu Gln Ala Asp Ser Ser Leu 405 410 415 Asn Lys Phe Lys Gln Thr Ala Trp Asp Leu Met Lys Gln Ser Pro Thr 420 425 430 Pro Val Pro Thr Asn Lys His Phe Ile Arg Leu Ala Glu Met Glu Gln 435 440 445 Thr Val Ala Glu Gln Asp Asp Ser Leu Ser Ser Leu Leu Val Lys Leu 450 455 460 Lys Lys Val Ser Gln Asp Leu Glu Arg Gln Arg Glu Ile Thr Glu Leu 465 470 475 480 Lys Val Lys Glu Phe Glu Asn Ile Lys Leu Gln Leu Gln Glu Asn His 485 490 495 Glu Asp Glu Val Lys Lys Val Lys Ala Glu Val Glu Asp Leu Lys Tyr 500 505 510 Leu Leu Asp Gln Ser Gln Lys Glu Ser Gln Cys Leu Lys Ser Glu Leu 515 520 525 Gln Ala Gln Lys Glu Ala Asn Ser Arg Ala Pro Thr Thr Thr Met Arg 530 535 540 Asn Leu Val Glu Arg Leu Lys Ser Gln Leu Ala Leu Lys Glu Lys Gln 545 550 555 560 Gln Lys Ala Leu Ser Arg Ala Leu Leu Glu Leu Arg Ala Glu Met Thr 565 570 575 Ala Ala Ala Glu Glu Arg Ile Ile Ser Ala Thr Ser Gln Lys Glu Ala 580 585 590 His Leu Asn Val Gln Gln Ile Val Asp Arg His Thr Arg Glu Leu Lys 595 600 605 Thr Gln Val Glu Asp Leu Asn Glu Asn Leu Leu Lys Leu Lys Glu Ala 610 615 620 Leu Lys Thr Ser Lys Asn Arg Glu Asn Ser Leu Thr Asp Asn Leu Asn 625 630 635 640 Asp Leu Asn Asn Glu Leu Gln Lys Lys Gln Lys Ala Tyr Asn Lys Ile 645 650 655 Leu Arg Glu Lys Glu Glu Ile Asp Gln Glu Asn Asp Glu Leu Lys Arg 660 665 670 Gln Ile Lys Arg Leu Thr Ser Gly Leu Gln Gly Lys Pro Leu Thr Asp 675 680 685 Asn Lys Gln Ser Leu Ile Glu Glu Leu Gln Arg Lys Val Lys Lys Leu 690 695 700 Glu Asn Gln Leu Glu Gly Lys Val Glu Glu Val Asp Leu Lys Pro Met 705 710 715 720 Lys Glu Lys Asn Ala Lys Glu Glu Leu Ile Arg Trp Glu Glu Gly Lys 725 730 735 Lys Trp Gln Ala Lys Ile Glu Gly Ile Arg Asn Lys Leu Lys Glu Lys 740 745 750 Glu Gly Glu Val Phe Thr Leu Thr Lys Gln Leu Asn Thr Leu Lys Asp 755 760 765 Leu Phe Ala Lys Ala Asp Lys Glu Lys Leu Thr Leu Gln Arg Lys Leu 770 775 780 Lys Thr 785 <210> 15 <211> 914 <212> PRT <213> Homo sapiens <400> 15 Ile Leu Thr Lys Glu Ile Asn Lys Leu Glu Leu Lys Ile Ser Asp Phe 1 5 10 15 Leu Asp Glu Asn Glu Ala Leu Arg Glu Arg Val Gly Leu Glu Pro Lys 20 25 30 Thr Met Ile Asp Leu Thr Glu Phe Arg Asn Ser Lys His Leu Lys Gln 35 40 45 Gln Gln Tyr Arg Ala Glu Asn Gln Ile Leu Leu Lys Glu Ile Glu Ser 50 55 60 Leu Glu Glu Glu Arg Leu Asp Leu Lys Lys Lys Ile Arg Gln Met Ala 65 70 75 80 Gln Glu Arg Gly Lys Arg Ser Ala Thr Ser Gly Leu Thr Thr Glu Asp 85 90 95 Leu Asn Leu Thr Glu Asn Ile Ser Gln Gly Asp Arg Ile Ser Glu Arg 100 105 110 Lys Leu Asp Leu Leu Ser Leu Lys Asn Met Ser Glu Ala Gln Ser Lys 115 120 125 Asn Glu Phe Leu Ser Arg Glu Leu Ile Glu Lys Glu Arg Asp Leu Glu 130 135 140 Arg Ser Arg Thr Val Ile Ala Lys Phe Gln Asn Lys Leu Lys Glu Leu 145 150 155 160 Val Glu Glu Asn Lys Gln Leu Glu Glu Gly Met Lys Glu Ile Leu Gln 165 170 175 Ala Ile Lys Glu Met Gln Lys Asp Pro Asp Val Lys Gly Gly Glu Thr 180 185 190 Ser Leu Ile Ile Pro Ser Leu Glu Arg Leu Val Asn Ala Ile Glu Ser 195 200 205 Lys Asn Ala Glu Gly Ile Phe Asp Ala Ser Leu His Leu Lys Ala Gln 210 215 220 Val Asp Gln Leu Thr Gly Arg Asn Glu Glu Leu Arg Gln Glu Leu Arg 225 230 235 240 Glu Ser Arg Lys Glu Ala Ile Asn Tyr Ser Gln Gln Leu Ala Lys Ala 245 250 255 Asn Leu Lys Ile Asp His Leu Glu Lys Glu Thr Ser Leu Leu Arg Gln 260 265 270 Ser Glu Gly Ser Asn Val Val Phe Lys Gly Ile Asp Leu Pro Asp Gly 275 280 285 Ile Ala Pro Ser Ser Ala Ser Ile Ile Asn Ser Gln Asn Glu Tyr Leu 290 295 300 Ile His Leu Leu Gln Glu Leu Glu Asn Lys Glu Lys Lys Leu Lys Asn 305 310 315 320 Leu Glu Asp Ser Leu Glu Asp Tyr Asn Arg Lys Phe Ala Val Ile Arg 325 330 335 His Gln Gln Ser Leu Leu Tyr Lys Glu Tyr Leu Ser Glu Lys Glu Thr 340 345 350 Trp Lys Thr Glu Ser Lys Thr Ile Lys Glu Glu Lys Arg Lys Leu Glu 355 360 365 Asp Gln Val Gln Gln Asp Ala Ile Lys Val Lys Glu Tyr Asn Asn Leu 370 375 380 Leu Asn Ala Leu Gln Met Asp Ser Asp Glu Met Lys Lys Ile Leu Ala 385 390 395 400 Thr Thr Gly Met Thr Val Asp Gln Val Leu Gly Ile Arg Ala Leu Glu 405 410 415 Ser Glu Lys Glu Leu Glu Glu Leu Lys Lys Arg Asn Leu Asp Leu Glu 420 425 430 Asn Asp Ile Leu Tyr Met Arg Ala His Gln Ala Leu Pro Arg Asp Ser 435 440 445 Val Val Glu Asp Leu His Leu Gln Asn Arg Tyr Leu Gln Glu Lys Leu 450 455 460 His Ala Leu Glu Lys Gln Phe Ser Lys Asp Thr Tyr Ser Lys Pro Ser 465 470 475 480 Ile Ser Gly Ile Glu Ser Asp Asp His Cys Gln Arg Glu Gln Glu Leu 485 490 495 Gln Lys Glu Asn Leu Lys Leu Ser Ser Glu Asn Ile Glu Leu Lys Phe 500 505 510 Gln Leu Glu Gln Ala Asn Lys Asp Leu Pro Arg Leu Lys Asn Gln Val 515 520 525 Arg Asp Leu Lys Glu Met Cys Glu Phe Leu Lys Lys Glu Lys Ala Glu 530 535 540 Val Gln Arg Lys Leu Gly His Val Arg Gly Ser Gly Arg Ser Gly Lys 545 550 555 560 Thr Ile Pro Glu Leu Glu Lys Thr Ile Gly Leu Met Lys Lys Val Val 565 570 575 Glu Lys Val Gln Arg Glu Asn Glu Gln Leu Lys Lys Ala Ser Gly Ile 580 585 590 Leu Thr Ser Glu Lys Met Ala Asn Ile Glu Gln Glu Asn Glu Lys Leu 595 600 605 Lys Ala Glu Leu Glu Lys Leu Lys Ala His Leu Gly His Gln Leu Ser 610 615 620 Met His Tyr Glu Ser Lys Thr Lys Gly Thr Glu Lys Ile Ile Ala Glu 625 630 635 640 Asn Glu Arg Leu Arg Lys Glu Leu Lys Lys Glu Thr Asp Ala Ala Glu 645 650 655 Lys Leu Arg Ile Ala Lys Asn Asn Leu Glu Ile Leu Asn Glu Lys Met 660 665 670 Thr Val Gln Leu Glu Glu Thr Gly Lys Arg Leu Gln Phe Ala Glu Ser 675 680 685 Arg Gly Pro Gln Leu Glu Gly Ala Asp Ser Lys Ser Trp Lys Ser Ile 690 695 700 Val Val Thr Arg Met Tyr Glu Thr Lys Leu Lys Glu Leu Glu Thr Asp 705 710 715 720 Ile Ala Lys Lys Asn Gln Ser Ile Thr Asp Leu Lys Gln Leu Val Lys 725 730 735 Glu Ala Thr Glu Arg Glu Gln Lys Val Asn Lys Tyr Asn Glu Asp Leu 740 745 750 Glu Gln Gln Ile Lys Ile Leu Lys His Val Pro Glu Gly Ala Glu Thr 755 760 765 Glu Gln Gly Leu Lys Arg Glu Leu Gln Val Leu Arg Leu Ala Asn His 770 775 780 Gln Leu Asp Lys Glu Lys Ala Glu Leu Ile His Gln Ile Glu Ala Asn 785 790 795 800 Lys Asp Gln Ser Gly Ala Glu Ser Thr Ile Pro Asp Ala Asp Gln Leu 805 810 815 Lys Glu Lys Ile Lys Asp Leu Glu Thr Gln Leu Lys Met Ser Asp Leu 820 825 830 Glu Lys Gln His Leu Lys Glu Glu Ile Lys Lys Leu Lys Lys Glu Leu 835 840 845 Glu Asn Phe Asp Pro Ser Phe Phe Glu Glu Ile Glu Asp Leu Lys Tyr 850 855 860 Asn Tyr Lys Glu Glu Val Lys Lys Asn Ile Leu Leu Glu Glu Lys Val 865 870 875 880 Lys Lys Leu Ser Glu Gln Leu Gly Val Glu Leu Thr Ser Pro Val Ala 885 890 895 Ala Ser Glu Glu Phe Glu Asp Glu Glu Glu Ser Pro Val Asn Phe Pro 900 905 910 Ile Tyr <210> 16 <211> 885 <212> PRT <213> Homo sapiens <400> 16 Ile Leu Thr Lys Glu Ile Asn Lys Leu Glu Leu Lys Ile Ser Asp Phe 1 5 10 15 Leu Asp Glu Asn Glu Ala Leu Arg Glu Arg Val Gly Leu Glu Pro Lys 20 25 30 Thr Met Ile Asp Leu Thr Glu Phe Arg Asn Ser Lys His Leu Lys Gln 35 40 45 Gln Gln Tyr Arg Ala Glu Asn Gln Ile Leu Leu Lys Glu Ile Glu Ser 50 55 60 Leu Glu Glu Glu Arg Leu Asp Leu Lys Lys Lys Ile Arg Gln Met Ala 65 70 75 80 Gln Glu Arg Gly Lys Arg Ser Ala Thr Ser Gly Leu Thr Thr Glu Asp 85 90 95 Leu Asn Leu Glu Ser Leu Arg Met Gln Leu Leu Asp Tyr Gln Ala Gln 100 105 110 Ser Asp Glu Lys Ser Leu Ile Ala Lys Leu His Gln His Asn Val Ser 115 120 125 Leu Gln Leu Ser Glu Ala Thr Ala Leu Gly Lys Leu Glu Ser Ile Thr 130 135 140 Ser Lys Leu Gln Lys Met Glu Ala Tyr Asn Leu Arg Leu Glu Gln Lys 145 150 155 160 Leu Asp Glu Lys Glu Gln Ala Leu Tyr Tyr Ala Arg Leu Glu Gly Arg 165 170 175 Asn Arg Ala Lys His Leu Arg Gln Thr Ile Gln Ser Leu Arg Arg Gln 180 185 190 Phe Ser Gly Ala Leu Pro Leu Ala Gln Gln Glu Lys Phe Ser Lys Thr 195 200 205 Met Ile Gln Leu Gln Asn Asp Lys Leu Lys Ile Met Gln Glu Met Lys 210 215 220 Asn Ser Gln Gln Glu His Arg Asn Met Glu Asn Lys Thr Leu Glu Met 225 230 235 240 Glu Leu Lys Leu Lys Gly Leu Glu Glu Leu Ile Ser Thr Leu Lys Asp 245 250 255 Thr Lys Gly Ala Gln Lys Val Ile Asn Trp His Met Lys Ile Glu Glu 260 265 270 Leu Arg Leu Gln Glu Leu Lys Leu Asn Arg Glu Leu Val Lys Asp Lys 275 280 285 Glu Glu Ile Lys Tyr Leu Asn Asn Ile Ile Ser Glu Tyr Glu Arg Thr 290 295 300 Ile Ser Ser Leu Glu Glu Glu Ile Val Gln Gln Asn Lys Phe His Glu 305 310 315 320 Glu Arg Gln Met Ala Trp Asp Gln Arg Glu Val Asp Leu Glu Arg Gln 325 330 335 Leu Asp Ile Phe Asp Arg Gln Gln Asn Glu Ile Leu Asn Ala Ala Gln 340 345 350 Lys Phe Glu Glu Ala Thr Gly Ser Ile Pro Asp Pro Ser Leu Pro Leu 355 360 365 Pro Asn Gln Leu Glu Ile Ala Leu Arg Lys Ile Lys Glu Asn Ile Arg 370 375 380 Ile Ile Leu Glu Thr Arg Ala Thr Cys Lys Ser Leu Glu Glu Lys Leu 385 390 395 400 Lys Glu Lys Glu Ser Ala Leu Arg Leu Ala Glu Gln Asn Ile Leu Ser 405 410 415 Arg Asp Lys Val Ile Asn Glu Leu Arg Leu Arg Leu Pro Ala Thr Ala 420 425 430 Glu Arg Glu Lys Leu Ile Ala Glu Leu Gly Arg Lys Glu Met Glu Pro 435 440 445 Lys Ser His His Thr Leu Lys Ile Ala His Gln Thr Ile Ala Asn Met 450 455 460 Gln Ala Arg Leu Asn Gln Lys Glu Glu Val Leu Lys Lys Tyr Gln Arg 465 470 475 480 Leu Leu Glu Lys Ala Arg Glu Glu Gln Arg Glu Ile Val Lys Lys His 485 490 495 Glu Glu Asp Leu His Ile Leu His His Arg Leu Glu Leu Gln Ala Asp 500 505 510 Ser Ser Leu Asn Lys Phe Lys Gln Thr Ala Trp Asp Leu Met Lys Gln 515 520 525 Ser Pro Thr Pro Val Pro Thr Asn Lys His Phe Ile Arg Leu Ala Glu 530 535 540 Met Glu Gln Thr Val Ala Glu Gln Asp Asp Ser Leu Ser Ser Leu Leu 545 550 555 560 Val Lys Leu Lys Lys Val Ser Gln Asp Leu Glu Arg Gln Arg Glu Ile 565 570 575 Thr Glu Leu Lys Val Lys Glu Phe Glu Asn Ile Lys Leu Gln Leu Gln 580 585 590 Glu Asn His Glu Asp Glu Val Lys Lys Val Lys Ala Glu Val Glu Asp 595 600 605 Leu Lys Tyr Leu Leu Asp Gln Ser Gln Lys Glu Ser Gln Cys Leu Lys 610 615 620 Ser Glu Leu Gln Ala Gln Lys Glu Ala Asn Ser Arg Ala Pro Thr Thr 625 630 635 640 Thr Met Arg Asn Leu Val Glu Arg Leu Lys Ser Gln Leu Ala Leu Lys 645 650 655 Glu Lys Gln Gln Lys Ala Leu Ser Arg Ala Leu Leu Glu Leu Arg Ala 660 665 670 Glu Met Thr Ala Ala Ala Glu Glu Arg Ile Ile Ser Ala Thr Ser Gln 675 680 685 Lys Glu Ala His Leu Asn Val Gln Gln Ile Val Asp Arg His Thr Arg 690 695 700 Glu Leu Lys Thr Gln Val Glu Asp Leu Asn Glu Asn Leu Leu Lys Leu 705 710 715 720 Lys Glu Ala Leu Lys Thr Ser Lys Asn Arg Glu Asn Ser Leu Thr Asp 725 730 735 Asn Leu Asn Asp Leu Asn Asn Glu Leu Gln Lys Lys Gln Lys Ala Tyr 740 745 750 Asn Lys Ile Leu Arg Glu Lys Glu Glu Ile Asp Gln Glu Asn Asp Glu 755 760 765 Leu Lys Arg Gln Ile Lys Arg Leu Thr Ser Gly Leu Gln Gly Lys Pro 770 775 780 Leu Thr Asp Asn Lys Gln Ser Leu Ile Glu Glu Leu Gln Arg Lys Val 785 790 795 800 Lys Lys Leu Glu Asn Gln Leu Glu Gly Lys Val Glu Glu Val Asp Leu 805 810 815 Lys Pro Met Lys Glu Lys Asn Ala Lys Glu Glu Leu Ile Arg Trp Glu 820 825 830 Glu Gly Lys Lys Trp Gln Ala Lys Ile Glu Gly Ile Arg Asn Lys Leu 835 840 845 Lys Glu Lys Glu Gly Glu Val Phe Thr Leu Thr Lys Gln Leu Asn Thr 850 855 860 Leu Lys Asp Leu Phe Ala Lys Ala Asp Lys Glu Lys Leu Thr Leu Gln 865 870 875 880 Arg Lys Leu Lys Thr 885 <210> 17 <211> 671 <212> PRT <213> Homo sapiens <400> 17 Ile Leu Thr Lys Glu Ile Asn Lys Leu Glu Leu Lys Ile Ser Asp Phe 1 5 10 15 Leu Asp Glu Asn Glu Ala Leu Arg Glu Arg Val Gly Leu Glu Pro Lys 20 25 30 Thr Met Ile Asp Leu Thr Glu Phe Arg Asn Ser Lys His Leu Lys Gln 35 40 45 Gln Gln Tyr Arg Ala Glu Asn Gln Ile Leu Leu Lys Glu Ile Glu Ser 50 55 60 Leu Glu Glu Glu Arg Leu Asp Leu Lys Lys Lys Ile Arg Gln Met Ala 65 70 75 80 Gln Glu Arg Gly Lys Arg Ser Ala Thr Ser Gly Leu Thr Thr Glu Asp 85 90 95 Leu Asn Leu Thr Glu Asn Ile Ser Gln Gly Asp Arg Ile Ser Glu Arg 100 105 110 Lys Leu Asp Leu Leu Ser Leu Lys Asn Met Ser Glu Ala Gln Ser Lys 115 120 125 Asn Glu Phe Leu Ser Arg Glu Leu Ile Glu Lys Glu Arg Asp Leu Glu 130 135 140 Arg Ser Arg Thr Val Ile Ala Lys Phe Gln Asn Lys Leu Lys Glu Leu 145 150 155 160 Val Glu Glu Asn Lys Gln Leu Glu Glu Gly Met Lys Glu Ile Leu Gln 165 170 175 Ala Ile Lys Glu Met Gln Lys Asp Pro Asp Val Lys Gly Gly Glu Thr 180 185 190 Ser Leu Ile Ile Pro Ser Leu Glu Arg Leu Val Asn Ala Ile Glu Ser 195 200 205 Lys Asn Ala Glu Gly Ile Phe Asp Ala Ser Leu His Leu Lys Ala Gln 210 215 220 Val Asp Gln Leu Thr Gly Arg Asn Glu Glu Leu Arg Gln Glu Leu Arg 225 230 235 240 Glu Ser Arg Lys Glu Ala Ile Asn Tyr Ser Gln Gln Leu Ala Lys Ala 245 250 255 Asn Leu Lys Ile Asp His Leu Glu Lys Glu Thr Ser Leu Leu Arg Gln 260 265 270 Ser Glu Gly Ser Asn Val Val Phe Lys Gly Ile Asp Leu Pro Asp Gly 275 280 285 Ile Ala Pro Ser Ser Ala Ser Ile Ile Asn Ser Gln Asn Glu Tyr Leu 290 295 300 Ile His Leu Leu Gln Glu Leu Glu Asn Lys Glu Lys Lys Leu Lys Asn 305 310 315 320 Leu Glu Asp Ser Leu Glu Asp Tyr Asn Arg Lys Phe Ala Val Ile Arg 325 330 335 His Gln Gln Ser Leu Leu Tyr Lys Glu Tyr Leu Ser Glu Lys Glu Thr 340 345 350 Trp Lys Thr Glu Ser Lys Thr Ile Lys Glu Glu Lys Arg Lys Leu Glu 355 360 365 Asp Gln Val Gln Gln Asp Ala Ile Lys Val Lys Glu Tyr Asn Asn Leu 370 375 380 Leu Asn Ala Leu Gln Met Asp Ser Asp Glu Met Lys Lys Ile Leu Ala 385 390 395 400 Gln Ser Gln Lys Glu Ser Gln Cys Leu Lys Ser Glu Leu Gln Ala Gln 405 410 415 Lys Glu Ala Asn Ser Arg Ala Pro Thr Thr Thr Met Arg Asn Leu Val 420 425 430 Glu Arg Leu Lys Ser Gln Leu Ala Leu Lys Glu Lys Gln Gln Lys Ala 435 440 445 Leu Ser Arg Ala Leu Leu Glu Leu Arg Ala Glu Met Thr Ala Ala Ala 450 455 460 Glu Glu Arg Ile Ile Ser Ala Thr Ser Gln Lys Glu Ala His Leu Asn 465 470 475 480 Val Gln Gln Ile Val Asp Arg His Thr Arg Glu Leu Lys Thr Gln Val 485 490 495 Glu Asp Leu Asn Glu Asn Leu Leu Lys Leu Lys Glu Ala Leu Lys Thr 500 505 510 Ser Lys Asn Arg Glu Asn Ser Leu Thr Asp Asn Leu Asn Asp Leu Asn 515 520 525 Asn Glu Leu Gln Lys Lys Gln Lys Ala Tyr Asn Lys Ile Leu Arg Glu 530 535 540 Lys Glu Glu Ile Asp Gln Glu Asn Asp Glu Leu Lys Arg Gln Ile Lys 545 550 555 560 Arg Leu Thr Ser Gly Leu Gln Gly Lys Pro Leu Thr Asp Asn Lys Gln 565 570 575 Ser Leu Ile Glu Glu Leu Gln Arg Lys Val Lys Lys Leu Glu Asn Gln 580 585 590 Leu Glu Gly Lys Val Glu Glu Val Asp Leu Lys Pro Met Lys Glu Lys 595 600 605 Asn Ala Lys Glu Glu Leu Ile Arg Trp Glu Glu Gly Lys Lys Trp Gln 610 615 620 Ala Lys Ile Glu Gly Ile Arg Asn Lys Leu Lys Glu Lys Glu Gly Glu 625 630 635 640 Val Phe Thr Leu Thr Lys Gln Leu Asn Thr Leu Lys Asp Leu Phe Ala 645 650 655 Lys Ala Asp Lys Glu Lys Leu Thr Leu Gln Arg Lys Leu Lys Thr 660 665 670 <210> 18 <211> 572 <212> PRT <213> Homo sapiens <400> 18 Thr Glu Asn Ile Ser Gln Gly Asp Arg Ile Ser Glu Arg Lys Leu Asp 1 5 10 15 Leu Leu Ser Leu Lys Asn Met Ser Glu Ala Gln Ser Lys Asn Glu Phe 20 25 30 Leu Ser Arg Glu Leu Ile Glu Lys Glu Arg Asp Leu Glu Arg Ser Arg 35 40 45 Thr Val Ile Ala Lys Phe Gln Asn Lys Leu Lys Glu Leu Val Glu Glu 50 55 60 Asn Lys Gln Leu Glu Glu Gly Met Lys Glu Ile Leu Gln Ala Ile Lys 65 70 75 80 Glu Met Gln Lys Asp Pro Asp Val Lys Gly Gly Glu Thr Ser Leu Ile 85 90 95 Ile Pro Ser Leu Glu Arg Leu Val Asn Ala Ile Glu Ser Lys Asn Ala 100 105 110 Glu Gly Ile Phe Asp Ala Ser Leu His Leu Lys Ala Gln Val Asp Gln 115 120 125 Leu Thr Gly Arg Asn Glu Glu Leu Arg Gln Glu Leu Arg Glu Ser Arg 130 135 140 Lys Glu Ala Ile Asn Tyr Ser Gln Gln Leu Ala Lys Ala Asn Leu Lys 145 150 155 160 Ile Asp His Leu Glu Lys Glu Thr Ser Leu Leu Arg Gln Ser Glu Gly 165 170 175 Ser Asn Val Val Phe Lys Gly Ile Asp Leu Pro Asp Gly Ile Ala Pro 180 185 190 Ser Ser Ala Ser Ile Ile Asn Ser Gln Asn Glu Tyr Leu Ile His Leu 195 200 205 Leu Gln Glu Leu Glu Asn Lys Glu Lys Lys Leu Lys Asn Leu Glu Asp 210 215 220 Ser Leu Glu Asp Tyr Asn Arg Lys Phe Ala Val Ile Arg His Gln Gln 225 230 235 240 Ser Leu Leu Tyr Lys Glu Tyr Leu Ser Glu Lys Glu Thr Trp Lys Thr 245 250 255 Glu Ser Lys Thr Ile Lys Glu Glu Lys Arg Lys Leu Glu Asp Gln Val 260 265 270 Gln Gln Asp Ala Ile Lys Val Lys Glu Tyr Asn Asn Leu Leu Asn Ala 275 280 285 Leu Gln Met Asp Ser Asp Glu Met Lys Lys Ile Leu Ala Gln Ser Gln 290 295 300 Lys Glu Ser Gln Cys Leu Lys Ser Glu Leu Gln Ala Gln Lys Glu Ala 305 310 315 320 Asn Ser Arg Ala Pro Thr Thr Thr Met Arg Asn Leu Val Glu Arg Leu 325 330 335 Lys Ser Gln Leu Ala Leu Lys Glu Lys Gln Gln Lys Ala Leu Ser Arg 340 345 350 Ala Leu Leu Glu Leu Arg Ala Glu Met Thr Ala Ala Ala Glu Glu Arg 355 360 365 Ile Ile Ser Ala Thr Ser Gln Lys Glu Ala His Leu Asn Val Gln Gln 370 375 380 Ile Val Asp Arg His Thr Arg Glu Leu Lys Thr Gln Val Glu Asp Leu 385 390 395 400 Asn Glu Asn Leu Leu Lys Leu Lys Glu Ala Leu Lys Thr Ser Lys Asn 405 410 415 Arg Glu Asn Ser Leu Thr Asp Asn Leu Asn Asp Leu Asn Asn Glu Leu 420 425 430 Gln Lys Lys Gln Lys Ala Tyr Asn Lys Ile Leu Arg Glu Lys Glu Glu 435 440 445 Ile Asp Gln Glu Asn Asp Glu Leu Lys Arg Gln Ile Lys Arg Leu Thr 450 455 460 Ser Gly Leu Gln Gly Lys Pro Leu Thr Asp Asn Lys Gln Ser Leu Ile 465 470 475 480 Glu Glu Leu Gln Arg Lys Val Lys Lys Leu Glu Asn Gln Leu Glu Gly 485 490 495 Lys Val Glu Glu Val Asp Leu Lys Pro Met Lys Glu Lys Asn Ala Lys 500 505 510 Glu Glu Leu Ile Arg Trp Glu Glu Gly Lys Lys Trp Gln Ala Lys Ile 515 520 525 Glu Gly Ile Arg Asn Lys Leu Lys Glu Lys Glu Gly Glu Val Phe Thr 530 535 540 Leu Thr Lys Gln Leu Asn Thr Leu Lys Asp Leu Phe Ala Lys Ala Asp 545 550 555 560 Lys Glu Lys Leu Thr Leu Gln Arg Lys Leu Lys Thr 565 570 <210> 19 <211> 801 <212> PRT <213> Homo sapiens <400> 19 Met Pro Pro Asn Ile Asn Trp Lys Glu Ile Met Lys Val Asp Pro Asp 1 5 10 15 Asp Leu Pro Arg Gln Glu Glu Leu Ala Asp Asn Leu Leu Ile Ser Leu 20 25 30 Ser Lys Val Glu Val Asn Glu Leu Lys Ser Glu Lys Gln Glu Asn Val 35 40 45 Ile His Leu Phe Arg Ile Thr Gln Ser Leu Met Lys Met Lys Ala Gln 50 55 60 Glu Val Glu Leu Ala Leu Glu Glu Val Glu Lys Ala Gly Glu Glu Gln 65 70 75 80 Ala Lys Phe Glu Asn Gln Leu Lys Thr Lys Val Met Lys Leu Glu Asn 85 90 95 Glu Leu Glu Met Ala Gln Gln Ser Ala Gly Gly Arg Asp Thr Arg Phe 100 105 110 Leu Arg Asn Glu Ile Cys Gln Leu Glu Lys Gln Leu Glu Gln Lys Asp 115 120 125 Arg Glu Leu Glu Asp Met Glu Lys Glu Leu Glu Lys Glu Lys Lys Val 130 135 140 Asn Glu Gln Leu Ala Leu Arg Asn Glu Glu Ala Glu Asn Glu Asn Ser 145 150 155 160 Lys Leu Arg Arg Glu Asn Lys Arg Leu Lys Lys Lys Asn Glu Gln Leu 165 170 175 Cys Gln Asp Ile Ile Asp Tyr Gln Lys Gln Ile Asp Ser Gln Lys Glu 180 185 190 Thr Leu Leu Ser Arg Arg Gly Glu Thr Glu Asn Ile Ser Gln Gly Asp 195 200 205 Arg Ile Ser Glu Arg Lys Leu Asp Leu Leu Ser Leu Lys Asn Met Ser 210 215 220 Glu Ala Gln Ser Lys Asn Glu Phe Leu Ser Arg Glu Leu Ile Glu Lys 225 230 235 240 Glu Arg Asp Leu Glu Arg Ser Arg Thr Val Ile Ala Lys Phe Gln Asn 245 250 255 Lys Leu Lys Glu Leu Val Glu Glu Asn Lys Gln Leu Glu Glu Gly Met 260 265 270 Lys Glu Ile Leu Gln Ala Ile Lys Glu Met Gln Lys Asp Pro Asp Val 275 280 285 Lys Gly Gly Glu Thr Ser Leu Ile Ile Pro Ser Leu Glu Arg Leu Val 290 295 300 Asn Ala Ile Glu Ser Lys Asn Ala Glu Gly Ile Phe Asp Ala Ser Leu 305 310 315 320 His Leu Lys Ala Gln Val Asp Gln Leu Thr Gly Arg Asn Glu Glu Leu 325 330 335 Arg Gln Glu Leu Arg Glu Ser Arg Lys Glu Ala Ile Asn Tyr Ser Gln 340 345 350 Gln Leu Ala Lys Ala Asn Leu Lys Ile Asp His Leu Glu Lys Glu Thr 355 360 365 Ser Leu Leu Arg Gln Ser Glu Gly Ser Asn Val Val Phe Lys Gly Ile 370 375 380 Asp Leu Pro Asp Gly Ile Ala Pro Ser Ser Ala Ser Ile Ile Asn Ser 385 390 395 400 Gln Asn Glu Tyr Leu Ile His Leu Leu Gln Glu Leu Glu Asn Lys Glu 405 410 415 Lys Lys Leu Lys Asn Leu Glu Asp Ser Leu Glu Asp Tyr Asn Arg Lys 420 425 430 Phe Ala Val Ile Arg His Gln Gln Ser Leu Leu Tyr Lys Glu Tyr Leu 435 440 445 Ser Glu Lys Glu Thr Trp Lys Thr Glu Ser Lys Thr Ile Lys Glu Glu 450 455 460 Lys Arg Lys Leu Glu Asp Gln Val Gln Gln Asp Ala Ile Lys Val Lys 465 470 475 480 Glu Tyr Asn Asn Leu Leu Asn Ala Leu Gln Met Asp Ser Asp Glu Met 485 490 495 Lys Lys Ile Leu Ala Glu Asn Ser Arg Lys Ile Thr Val Leu Gln Val 500 505 510 Asn Glu Lys Ser Leu Ile Arg Gln Tyr Thr Thr Leu Val Glu Leu Glu 515 520 525 Arg Gln Leu Arg Lys Glu Asn Glu Lys Gln Lys Asn Glu Leu Leu Ser 530 535 540 Met Glu Ala Glu Val Cys Glu Lys Ile Gly Cys Leu Gln Arg Phe Lys 545 550 555 560 Glu Met Ala Ile Phe Lys Ile Ala Ala Leu Gln Lys Val Val Asp Asn 565 570 575 Ser Val Ser Leu Ser Glu Leu Glu Leu Ala Asn Lys Gln Tyr Asn Glu 580 585 590 Leu Thr Ala Lys Tyr Arg Asp Ile Leu Gln Lys Asp Asn Met Leu Val 595 600 605 Gln Arg Thr Ser Asn Leu Glu His Leu Glu Cys Glu Asn Ile Ser Leu 610 615 620 Lys Glu Gln Val Glu Ser Ile Asn Lys Glu Leu Glu Ile Thr Lys Glu 625 630 635 640 Lys Leu His Thr Ile Glu Gln Ala Trp Glu Gln Glu Thr Lys Leu Gly 645 650 655 Asn Glu Ser Ser Met Asp Lys Ala Lys Lys Ser Ile Thr Asn Ser Asp 660 665 670 Ile Val Ser Ile Ser Lys Lys Ile Thr Met Leu Glu Met Lys Glu Leu 675 680 685 Asn Glu Arg Gln Arg Ala Glu His Cys Gln Lys Met Tyr Glu His Leu 690 695 700 Arg Thr Ser Leu Lys Gln Met Glu Glu Arg Asn Phe Glu Leu Glu Thr 705 710 715 720 Lys Phe Ala Glu Leu Thr Lys Ile Asn Leu Asp Ala Gln Lys Val Glu 725 730 735 Gln Met Leu Arg Asp Glu Leu Ala Asp Ser Val Ser Lys Ala Val Ser 740 745 750 Asp Ala Asp Arg Gln Arg Ile Leu Glu Leu Glu Lys Asn Glu Met Glu 755 760 765 Leu Lys Val Glu Val Ser Lys Leu Arg Glu Ile Ser Asp Ile Ala Arg 770 775 780 Arg Gln Val Glu Ile Leu Asn Ala Gln Gln Gln Ser Arg Asp Lys Glu 785 790 795 800 Val <210> 20 <211> 3900 <212> DNA <213> Homo sapiens <400> 20 gagtccctca gaatgcaact gctagactat caggcacagt ctgatgaaaa gtcgctcatt 60 gccaagttgc accaacataa tgtctctctt caactgagtg aggctactgc tcttggtaag 120 ttggagtcaa ttacatctaa actgcagaag atggaggcct acaacttgcg cttagagcag 180 aaacttgatg aaaaagaaca ggctctctat tatgctcgtt tggagggaag aaacagagca 240 aaacatctgc gccaaacaat tcagtctcta cgacgacagt ttagtggagc tttacccttg 300 gcacaacagg aaaagttctc caaaacaatg attcaactac aaaatgacaa acttaagata 360 atgcaagaaa tgaaaaattc tcaacaagaa catagaaata tggagaacaa aacattggag 420 atggaattaa aattaaaggg cctggaagag ttaataagca ctttaaagga taccaaagga 480 gcccaaaagg taatcaactg gcatatgaaa atagaagaac ttcgtcttca agaacttaaa 540 ctaaatcgggg atttagtcaa gaataagaa gaataaaat atttgataa cataatttct 600 gaatgaac gtacaatcag cagtcttgaa gagaaatttg tgcaacaga caagtttcat 660 gagaaagac aaatggcctg ggatcaaga gaagttgacc tggaacgcca actagacatt 720 tttgaccgtc agcaaatga atactaat gcggcacaa agtttgaaga agctacagga 780 tcaatccctg accctagttt gccccttcca aatcaacttg agatcgctct aaggaaatt 840 aaggagaaca ttcgaataat tcagaaaca cgggcaactt gcaatcact agagagaaa 900 ctaaaagaga aagaatctgc tttaggtta gcagaacaa atactgtc aagagacaa 960 gtaatcaatg aactgaggct tcgattgcct gccactgcag aagagaaaa gctcatagct 1020 gagctaggca gaaaagagat ggaaccaaaa tctcaccaca cattgaaat tgctcatcaa 1080 accattgcaa acatgcaagc aaggttaat caaaagaag aagtattaa gaagtatca 1140 cgtctctctag aaaaagccag agagagca agagaattg tgagaaca tgaggac 1200 cttcatattc ttcacacag attagaacta caggctgata gttcactaaa taattcaa 1260 caaacggctt gggatttaat gaacagtct cccactccag ttcctaccaa caagcatttt 1320 attcgtctgg ctgagatgga acagacagta gcagaacaag atgactct ttcctcactc 1380 ttggtcaaac taaagaagt atcacagat ttggagac aagagaat cactgaatta 1440 aaagtaaag aatttgaaa tatcaatta cagctcaag aaaaccatga agatgaagtg 1500 aaaaaagtaa aagcggagt agaggatttta aagtatctctc tggaccagtc aaaaggag 1560 tcacagtgtt taaaatctga acttcaggct caaaagaag caattcaag agctccaaca 1620 actacaatga gaatctagt agaacggcta aagagccaat tagccttgaa ggagaaaca 1680 cagaaagcac ttagtcggggc acttttagaa ctcggggcag aaatgacagc agctgctgaa 1740 gaacgtatta ttctgcaac ttctcaaaa gaggcccatc tcaatgttca acaaatcgtt 1800 gatcgacata ctagagagct aagacacaa gttgagatt taaatgaaa tctttaaaa 1860 ttgaagaag cactaaac agtaaaac aggaaact cactaactga tatttgaat 1920 gacttaata atgaactgca aaagaaaaaaagcctata ataaatact tagagagaaa 1980 gaggaaattg atcaagagaa tgatgaactg aaaaggcaaa ttaaaagact aaccagtgga 2040 ttacagggca aacccctgac agataataaa caaagtctaa ttgaagaact ccaaaggaaa 2100 gttaaaaaac tagagaacca attagaggga aaggtggagg aagtagacct aaaacctatg 2160 aaagaaaaga atgctaaaga agaattaatt aggtgggaag aaggtaaaaa gtggcaagcc 2220 aaaatagaag gaattcgaaa caagttaaaa gagaaagagg gggaagtctt tactttaaca 2280 aagcagttga atactttgaa ggatcttttt gccaaagccg ataaagagaa acttactttg 2340 cagaggaaac taaaaacaac tggcatgact gttgatcagg ttttgggaat acgagctttg 2400 gagtcagaaa aagaattgga agaattaaaa aagagaaatc ttgacttaga aaatgata 2460 ttgtatatga gggcccacca agctcttcct cgagattctg ttgtagaaga tttacattta 2520 caaaatagat acctccaaga aaaacttcat gctttagaaa aacagttttc aaaggataca 2580 tattctaagc cttcaatttc aggaatagag tcagatgatc attgtcagag agaacaggag 2640 cttcagaagg aaaacttgaa gttgtcatct gaaaatattg aactgaaatt tcagcttgaa 2700 caagcaaata aagatttgcc aagattaaag aatcaagtca gagatttgaa ggaaatgtgt 2760 gaatttctta agaaagaaaa agcagaagtt cagcggaaac ttggccatgt tagagggtct 2820 ggtagaagtg gaaagacaat cccagaactg gaaaaaaacca ttggtttaat gaaaaaagta 2880 gttgaaaaag tccagagaga aaatgaacag ttgaaaaaag catcaggaat attgactagt 2940 gaaaaaatgg ctaatattga gcaggaaaat gaaaattga aggctgaatt agaaaaaactt 3000 aaagctcatc ttgggcatca gttgagcatg cactatgaat ccaagaccaa aggcacagaa 3060 aaaattattg ctgaaaatga aaggcttcgt aaagaactta aaaaagaaac tgatgctgca 3120 gagaattac ggatagcaaa gaataattta gagatattaa atgagaagat gacagttcaa 3180 ctagaagaga ctggtaagag attgcagttt gcagaaagca gaggtccaca gcttgaaggt 3240 gctgacagta agagctggaa atccattgtg gttacaagaa tgtatgaaac caagttaaaa 3300 gaattggaaa ctgatattgc caaaaaaaat caaagcatta ctgaccttaa acagcttgta 3360 aaagaagcaa cagagagaga acaaaaagtt aacaaataca atgaagacct tgaacaacag 3420 attagatc ttaacatgt tcctgaggt gctgagacag agcaggcct taacgggg 3480 cttcaagttc ttagattagc taatcatcag ctggataag agaagcaga attack 3540 cagatagaag ctaacaagga ccaagtgga gctgaaagca ccatacctga tgctgatcaa 3600 ctaaaggaaaaaaaaga tctagagaca cagctcaaa tgtcagatct agaaaagcag 3660 cattgaagg aggaataa gaagctgaa aaagactg aaaattttga tccttcattt 3720 tttgaagaa ttgaagatct taagtataat tachaggaag aagtgaagaa gatatttctc 3780 ttagaagaga aggtaaaaa acttcagaa cattgggag ttgattaac tagccctgtt 3840 gctgctctg aagagtttga agatgaagaa gaagtccctg ttaatttccc cattactaa 3900 <210> 21 <211> 1200 <212> DNA <213> Humans (Homo sapiens) <400> 21 attack aggaatca taaacttgaa tgagatca gtgatttcct tgatgaaat 60 gaggcactta gagagcgtgt gggccttgaa ccaagacaa tgattgatt aactgaattt 120 agaatagca aacacttaaa acagcagcag tacagagctg aaaaccagat tcttttgaaa 180 gagattgaaa gtctagagga agaacgactt gatctgaaaa aaaaaattcg tcaaatggct 240 caagaaagag gaaaaagaag tgcaacttca ggattaacca ctgaggacct gaacctaact 300 gaaaacattt ctcaaggaga tagataagt gaaagaaaat tggatttatt gagcctcaaa 360 aatatgagtg aagcacaatc aaagaatgaa tttctttcaa gagaactaat tgaaaaagaa 420 agagatttag aaaggagtag gacagtgata gccaaatttc agaataaatt aaaagaatta 480 gttgaagaaa ataagcaact tgaagaaggt atgaaagaaa tattgcaagc aattaaggaa 540 atgcagaaag atcctgatgt taaaggagga gaaacatctc taattatccc tagccttgaa 600 agactagtta atgctataga atcaaagaat gcagaaggaa tctttgatgc gagtctgcat 660 ttgaaagccc aagttgatca gcttaccgga agaaatgaag aattaagaca ggagctcagg 720 gaatctcgga aagaggctat aaattattca cagcagttgg caaaagctaa tttaaagata 780 gaccatcttg aaaaagaaac tagtctttta cgacaatcag aaggatcgaa tgttgttttt 840 aaaggaattg acttacctga tgggatagca ccatctagtg ccagtatcat taattctcag 900 aatgaatatt taatacattt gttacaggaa ctagaaaata aagaaaaaaa gttaaagaat 960 ttagaagatt ctcttgaaga ttacaacaga aaatttgctg taattcgtca tcaacaaagt 1020 ttgttgtata aagaatacct aagtgaaaag gagacctgga aaacagaatc taaaacaata 1080 aaagaggaaa agagaaaact tgaggatcaa gtccaacaag atgctataaa agtaaaagaa 1140 tataataatt tgctcaatgc tcttcagatg gattcggatg aaatgaaaaa aatacttgca 1200 <210> 22 <211> 3090 <212> DNA <213> Homo sapiens <400> 22 gagtccctca gaatgcaact gctagactat caggcacagt ctgatgaaaa gtcgctcatt 60 gccaagttgc accaacataa tgtctctctt caactgagtg aggctactgc tcttggtaag 120 ttggagtcaa ttacatctaa actgcagaag atggaggcct acaacttgcg cttagagcag 180 aaacttgatg aaaaagaaca ggctctctat tatgctcgtt tggagggaag aaacagagca 240 aaacatctgc gccaaacaat tcagtctcta cgacgacagt ttagtggag tttacccttg 300 gcacaacagg aaagttctc siaaacaatg attcaacac aaaatgacaa acttagata 360 atgcaagaaa tgaaaaatttc tcaacaaa catagaata tggacaaaacattggag 420 atggaattta atttaaaggg cctggaagg ttaatagca ctttaagga taccaagga 480 gcccaaaagg taatcaactg gcatatgaaa atagagaac ttcgtcttca agaacttaaa 540 ctaaatcgggg atttagtcaa gaataagaa gaataaaat atttgataa cataatttct 600 gaatgaac gtacaatcag cagtcttgaa gagaaatttg tgcaacaga caagtttcat 660 gagaaagac aaatggcctg ggatcaaga gaagttgacc tggaacgcca actagacatt 720 tttgaccgtc agcaaatga atactaat gcggcacaa agtttgaaga agctacagga 780 tcaatccctg accctagttt gccccttcca aatcaacttg agatcgctct aaggaaatt 840 aaggagaaca ttcgaataat tcagaaaca cgggcaactt gcaatcact agagagaaa 900 ctaaaagaga aagaatctgc tttaggtta gcagaacaa atactgtc aagagacaa 960 gtaatcaatg aactgaggct tcgattgcct gccactgcag aagagaaaa gctcatagct 1020 gagctaggca gaaaagagat ggaaccaaaa tctcaccaca cattgaaat tgctcatcaa 1080 accattgcaa acatgcaagc aaggttaat caaaagaag aagtattaa gaagtatca 1140 cgtctctctag aaaaagccag agagagca agagaattg tgagaaca tgaggac 1200 cttcatattc ttcacacag attagaacta caggctgata gttcactaaa taattcaa 1260 caaacggctt gggatttaat gaacagtct cccactccag ttcctaccaa caagcatttt 1320 attcgtctgg ctgagatgga acagacagta gcagaacaag atgactct ttcctcactc 1380 ttggtcaaac taaagaagt atcacagat ttggagac aagagaat cactgaatta 1440 aaagtaaag aatttgaaa tatcaatta cagctcaag aaaaccatga agatgaagtg 1500 aaaaagtaa aagcggagt agaggatttta aagtatctctc tggacacac tggcatgact 1560 gttgatcagg ttttgggaat acgagctttg gagtcagaaa aagaattgga agaattaaaa 1620 aagagaaatc ttgacttaga aaatgatata ttgtatatga gggcccacca agctctttcct 1680 cgagattctg ttgtagaga tttacattta caaaatagat acctccaaga aaaacttcat 1740 gctttagaaa aacagttttc aaaggataca tattctaagc cttcaatttc aggaatagag 1800 tcagatgatc attgtcagag agaacaggag cttcagaagg aaaacttgaa gttgtcatct 1860 gaaaatattg aactgaaatt tcagcttgaa caagcaaata aagatttgcc aagattaaag 1920 aatcaagtca gagatttgaa ggaaatgtgt gaatttctta agaaagaaaa agcagaagtt 1980 cagcggaaac ttggccatgt tagagggtct ggtagaagtg gaaagacaat cccagaactg 2040 gaaaaaaacca ttggtttaat gaaaaaagta gttgaaaaag tccagagaga aaatgaacag 2100 ttgaaaaaag catcaggaat attgactagt gaaaaaatgg ctaatattga gcaggaaaat 2160 gaaaaattga aggctgaatt agaaaaactt aaagctcatc ttgggcatca gttgagcatg 2220 cactatgaat ccaagaccaa aggcacagaa aaaattattg ctgaaaatga aaggcttcgt 2280 aaagaactta aaaaagaaac tgatgctgca gagaattac ggatagcaaa gaataattta 2340 gagatattaa atgagaagat gacagttcaa ctagaagaga ctggtaagag attgcagttt 2400 gcagaaagca gaggtccaca gcttgaaggt gctgacagta agagctggaa atccattgtg 2460 gttacaagaa tgtagaaac caagttaaa gattgaaa ctgatattgc CAAAAAAAAT 2520 aaagcatta ctgaccttaa acagcttgta aaagaagcaa cagagagaga aaaagtt 2580 aaaaataca atgagacct tgaacacag atttagattc tcaacatgt tcctgaggt 2640 gctgagacag agcaggcct taaacgggag cttcaagttc ttagattagc taatcatcag 2700 ctggataag agaaagcaga attackcat cagatagag ctaachagga ccaagtgga 2760 gctgaaagca ccatacctga tgctgatcaa ctaaaggaaaaaaaga tctagagaca 2820 cagctcaaaa tgtcagatct agaaaagcag catttgaagg aggaataa gaagctgaaa 2880 aaagaactgg aaaattttga tccttcatttttgagaaa ttgaagatct tagtataat 2940 tachaggaag agtgagaa gatatttctc taggagaga aggtaaaaa actttcagaa 3000 caatgggag ttgattaac tagccctgtt gctgctctg agagtttga agatgagaa 3060 gaagtccctg ttaatttccc cattactaa 3090 <210> 23 <211> 3846 <212> DNA <213> Homo sapiens <400> 23 actgaaaaca tttctcaagg agatagaata agtgaaagaa aattggattt attgagcctc 60 aaaaatatga gtgaagcaca atcaaagaat gaatttcttt caagagaact aattgaaaaa 120 gaaagagatt tagaaaggag taggacagtg atagccaaat ttcagaataa attaaaagaa 180 ttagttgaag aaaataagca acttgaagaa ggtatgaaag aaatattgca agcaattaag 240 gaaatgcaga aagatcctga tgttaaagga ggagaaacat ctctaattat ccctagcctt 300 gaaagactag ttaatgctat agaatcaaag aatgcagaag gaatctttga tgcgagtctg 360 catttgaaag cccaagttga tcagcttacc ggaagaaatg aagaattaag acaggagctc 420 agggaatctc ggaaagaggc tataaattat tcacagcagt tggcaaaagc taatttaaag 480 atagaccatc ttgaaaaaga aactagtctt ttacgacaat cagaaggatc gaatgttgtt 540 tttaaaggaa ttgacttacc tgatgggata gcaccatcta gtgccagtat cattaattct 600 cagaatgaat atttaataca tttgttacag gaactagaaa ataaagaaaa aaagttaaag 660 aatttagaag attctcttga agattacaac agaaatttg ctgtaattcg tcatcacaa 720 agtttgttgt aaagaata cctaagtgaa aaggacct ggaaaacaga atctaaaaca 780 aaaagagg aaagagaa acttgaggt caagtccac aagatgctat aaagtaaa 840 gatatata atttgctca tgctcttcag atggattcgg atgaatgaa aaaatactt 900 gcagaaaata gtaggaaaat tactgttttg caagtgaatg aaaaatcact tataaggcaa 960 tatacaact taggaatt ggagggaaaaaatgaaa gxaaagaat 1020 gattgttgt caatggaggc tgaagttttgt gaaaaattg gttgtttgca aagatttaag 1080 gaaatggcca ttttcagat tgcagctctc caaaagttg tagatatag tgtttctttg 1140 tctgaactag aactggctaa taacagtac atgactga ctgctaagta cagggacatc 1200 ttgcaaaag atatatgct tgttcaaga acagtact tggacacct ggagtgtgaa 1260 aacatctcct taaaagaca agtggagtct aataaag aactggagat taccaggaa 1320 aaacttcaca ctattgaca agcctgggaa caggaacta aattaggtaa tgaatctagc 1380 atggataagg aaagaaatc aataaccaac agtgacattg tttccatttc aaaaaaaata 1440 actatgctgg aaatgaagga attaatgaa aggcagcggg ctgaacattg tcaaaaaatg 1500 tatgaacact tacggacttc gttaaagcaa atggaggaac gtaattttga attggaacc 1560 1620 gatgaattag ctgatagtgt gagcaaggca gtaagtgatg ctgataggca acggattcta 1680 1740 gatattgcca gaagacaagt tgaaattttg aatgcacaac aacaatctag ggacaaggaa 1800 gtaaaattga aagaagcact taaaacaagt aaaacagag aaaactcact aactgataat 1860 1920 gagaagagg aaattgatca agagaatgat gaactgaaaa ggcaaattaa aagactaacc 1980 agtggattac agggcaaacc cctgacagat aataacaaa gtctaattga agaactccaa 2040 aggaaagtta aaaaactaga gaaccaatta gagggaaag tggaggaagt agacctaaaa 2100 cctatgaaag aaaagaatgc taaagaaaattaggt gggaaagg taaaaagtgg 2160 caagccaaaa taggaggat tcgaacaag ttaaagaga agaggggga agtctttact 2220 ttaacaaagc agttgaatac tttgaaggat ctttttgcca aagccgataa agagaaactt 2280 actttgcaga ggaactaaaaaactggc atgactgttg atcaggtttt gggaatacga 2340 gctttggagt cagaaaaga attggaaa ttaaaaaga gaatcttga cttagaaaat 2400 gatatattgt atatgaggc ccaccaagct ctcctcgag attctgttgt agaagatta 2460 catttacaaa atagatacct ccaaaaaa cttcatgctt tagaaaaca gttttcaag 2520 gatacatatt ctaagccttc aatttcagga atagagtcag atgatcattg tcagagagaa 2580 caggagcttc agaaggaaaa cttgaagttg tcatctgaaa atttgaact gaatttcag 2640 cttgaacaag caataaga tttgacaga ttaagaatc aagtcagaga tttgaaggaa 2700 atgtgtgaat ttcttaagaa agaaaaagca gaagttcagc ggaaacttgg ccatgttaga 2760 gggtctggta gaagtggaaa gataccca gaacggaaaaaccattgg tttaatgaaa 2820 aaagtagttg aaaagtcca gagagaaat gacagttga aaaagcatc aggaatattg 2880 actagtgaa aaatggctaa tattgagcag gaaatgaaa attgaggc tgattagaa 2940 aaacttaaag ctcatcttgg gcatcagttg agcatgcact atgaatccaa gaccaaaggc 3000 acagaaaaaa ttattgctga aaatgaaagg ctcgtaag acttaaaaa agaactgat 3060 gctgcagaga attacggat agxaagaat atttagaga tattaatga gagatgaca 3120 gttcaacag agagactgg taagattg cagtttgcag aaagcagagg tccacagctt 3180 gaaggtgctg acagtaagg ctggaaatcc attgtggtta caagaatgta tgaaccaag 3240 ttaaaagaat tggaactga tattgccaaaaaaatcaa gcattactga ccttaaacag 3300 cttgtaaag aagcacaga gagagaaaaagttaaca atacaatga agaccttgaa 3360 siacagatta agatcttta acatgttcct gaagtgctg agacagagca aggccttaaa 3420 cgggagcttc aagttcttag attagctaat catcagctgg ataagagaa agcagaatta 3480 atccatcaga tagagcta haaggaccaa agtggagctg aaagcaccat acctgatgct 3540 gatcaacta aggaaaaat aaagatcta gagacacagc tcaaatgtc agatctagaa 3600 aagcagcatt tgaaggagga aaaagaag ctgaaaaag aactggaaa ttttgatcct 3660 tcattttg aagaaatttga agatcttaag tataattaca aggaagt gagagaat 3720 attackcttag agagaggt aaaaaaactt tcagacaat tgggagttga attackc 3780 cctgttgctg cttctgaaga gtttgaagat gagaagaaa gtcctgttaa ttccccatt 3840 tact 3846 <210> 24 <211> 2358 <212> DNA <213> Humans (Homo sapiens) <400> 24 gagtccctca gatgcaact gctagactat caggcacagt ctgatgaaaa gtcgctcatt 60 gccaagttgc accacataa tgtctctt caacgagtg aggctactgc tcttggtaag 120 ttggagtcaa ttacatctaa actgcagaag atggaggct acaacttgcg cttagagcag 180 aaacttgatg aaaaagaaca ggctctat tatgctcgtt tggagggag aaacagagca 240 aaacatctgc gccaaacaat tcagtctcta cgacgacagt ttagtggag tttacccttg 300 gcacaacagg aaagttctc siaaacaatg attcaacac aaaatgacaa acttagata 360 atgcaagaaa tgaaaaatttc tcaacaaa catagaata tggacaaaacattggag 420 atggaattta atttaaaggg cctggaagg ttaatagca ctttaagga taccaagga 480 gcccaaaagg taatcaactg gcatatgaaa atagagaac ttcgtcttca agaacttaaa 540 ctaaatcgggg atttagtcaa gaataagaa gaataaaat atttgataa cataatttct 600 gaatgaac gtacaatcag cagtcttgaa gagaaatttg tgcaacaga caagtttcat 660 gagaaagac aaatggcctg ggatcaaga gaagttgacc tggaacgcca actagacatt 720 tttgaccgtc agcaaatga atactaat gcggcacaa agtttgaaga agctacagga 780 tcaatccctg accctagttt gccccttcca aatcaacttg agatcgctct aaggaaatt 840 aaggagaaca ttcgaataat tcagaaaca cgggcaactt gcaatcact agagagaaa 900 ctaaaagaga aagaatctgc tttaggtta gcagaacaa atactgtc aagagacaa 960 gtaatcaatg aactgaggct tcgattgcct gccactgcag aagagaaaa gctcatagct 1020 gagctaggca gaaaagagat ggaaccaaaa tctcaccaca cattgaaat tgctcatcaa 1080 accattgcaa acatgcaagc aaggttaat caaaagaag aagtattaa gaagtatca 1140 cgtctctctag aaaaagccag agagagca agagaattg tgagaaca tgaggac 1200 cttcatattc ttcacacag attagaacta caggctgata gttcactaaa taattcaa 1260 caaacggctt gggatttaat gaacagtct cccactccag ttcctaccaa caagcatttt 1320 attcgtctgg ctgagatgga acagacagta gcagaacaag atgactct ttcctcactc 1380 ttggtcaaac taaagaagt atcacagat ttggagac aagagaat cactgaatta 1440 aaagtaaag aatttgaaa tatcaatta cagctcaag aaaaccatga agatgaagtg 1500 aaaaaagtaa aagcggagt agaggatttta aagtatctctc tggaccagtc aaaaggag 1560 tcacagtgtt taaaatctga acttcaggct caaaagaag caattcaag agctccaaca 1620 actacaatga gaatctagt agaacggcta aagagccaat tagccttgaa ggagaaaca 1680 cagaaagcac ttagtcggggc acttttagaa ctcggggcag aaatgacagc agctgctgaa 1740 gaacgtatta ttctgcaac ttctcaaaa gaggcccatc tcaatgttca acaaatcgtt 1800 gatcgacata ctagagagct aagacacaa gttgagatt taaatgaaa tctttaaaa 1860 ttgaagaag cactaaac agtaaaac aggaaact cactaactga tatttgaat 1920 gacttaata atgaactgca aaagaaaaaaagcctata ataaatact tagagagaaa 1980 gaggaaattg atcagagaa tgatgaactg aaaggcaaa ttaaaagact aaccagtgga 2040 ttacaggggca aacccctgac agatataaa CAagtcTA ttgagaact ccaaggaaa 2100 gttaaaaaac tagagaacca attagaggga aaggtggagg aagtagacct aaaacctag 2160 aaagaaaaga atgctaaga agaatttatt aggtgggaag aaggtaaaa gtggcaagcc 2220 aaaatagaag gattcgaaa caagttaaaa gagaaaggg gggagtctt tactttaca 2280 aagcagttga atacttgaa ggatcttttt gccaaagccg ataagagaa acttactttg 2340 Casualty TV 2358 <210> 25 <211> 2745 <212> DNA <213> Humans (Homo sapiens) <400> 25 attaacaa aggaaatcaa taaacttgaa ttgaagatca gtgatttcct tgatgaaaat 60 gaggcactta gagagcgtgt gggccttgaa ccaaagacaa tgattgattt aactgaattt 120 agaatagca aacacttaaa acagcagcag tacagagctg aaaaccagat tcttttgaaa 180 gagattgaaa gtctagagga agaacgactt gatctgaaaa aaaaaattcg tcaaatggct 240 caagaaagag gaaaaagaag tgcaacttca ggattaacca ctgaggacct gaacctaact 300 gaaaacattt ctcaaggaga tagataagt gaaagaaaat tggatttatt gagcctcaaa 360 aatatgagtg aagcacaatc aaagaatgaa tttctttcaa gagaactaat tgaaaaagaa 420 agagatttag aaaggagtag gacagtgata gccaaatttc agaataaatt aaaagaatta 480 gttgaagaaa ataagcaact tgaagaaggt atgaaagaaa tattgcaagc aattaaggaa 540 atgcagaaag atcctgatgt taaaggagga gaaacatctc taattatccc tagccttgaa 600 agactagtta atgctataga atcaaagaat gcagaaggaa tctttgatgc gagtctgcat 660 ttgaaagccc aagttgatca gcttaccgga agaaatgaag aattaagaca ggagctcagg 720 gaatctcgga aagaggctat aaattattca cagcagttgg caaaagctaa tttaaagata 780 gaccatcttg aaaaagaaac tagtctttta cgacaatcag aggatcgaa tgttgttttt 840 aaaggaattg acttacctga tgggatagca ccatctagtg ccagtatcat taattctcag 900 aatgaatatt taatacattt gttacaggaa ctagaaaata aagaaaaaaa gttaaagaat 960 ttagaagatt ctcttgaaga ttacaacaga aaatttgctg taattcgtca tcaacaaagt 1020 ttgttgtata aagaatacct aagtgaaaag gagacctgga aaacagaatc taaaacaata 1080 aaagaggaaa agagaaaact tgaggatcaa gtccaacaag atgctataaa agtaaaagaa 1140 tataataatt tgctcaatgc tcttcagatg gattcggatg aaatgaaaaa aatacttgca 1200 acaactggca tgactgttga tcaggttttg ggaatacgag ctttggagtc agaaaaagaa 1260 ttggaagaat taaaaaagag aaatcttgac ttagaaaatg atatattgta tatgagggcc 1320 caccaagctc ttcctcgaga ttctgttgta gaagatttac atttacaaaa tagatacctc 1380 caagaaaaac ttcatgcttt agaaaaacag ttttcaaagg atacatattc taagccttca 1440 atttcaggaa tagagtcaga tgatcattgt cagagagaac aggagcttca gaaggaaaac 1500 ttgaagttgt catctgaaaa tattgaactg aaatttcagc ttgaacaagc aaataaaagat 1560 ttgccaagat taaagaatca agtcagagat ttgaaggaaa tgtgtgaatt tcttaagaaa 1620 gaaaaagcag aagttcagcg gaaacttggc catgttagag ggtctggtag aagtggaaag 1680 acaatcccag aactggaaaa aaccattggt ttaatgaaaa aagtagttga aaaagtccag 1740 aagaaaaatg aacagttgaa aaaagcatca ggaatattga ctagtgaaaa aatggctaat 1800 attgagcagg aaaatgaaaa attgaaggct gaattagaaa aacttaaagc tcatcttggg 1860 catcagttga gcatgcacta tgaatccaag accaaaggca cagaaaaaat tattgctgaa 1920 aatgaaaggc ttcgtaaaga acttaaaaaa gaaactgatg ctgcagagaa attacggata 1980 gcaaagaata atttagagat attaaatgag aagatgacag ttcaactaga agagactggt 2040 aagagattgc agtttgcaga aagcagaggt ccacagcttg aaggtgctga footagagc 2100 tggaaatcca ttgtggttac aagaatgtat gaaccaagt taaaagaatt ggaaactgat 2160 attgccaaaa aaatcaag cattactgac cttaaacagc ttgtaaaga agcaacag 2220 aggaaaaaaaaaaaxaaa gaccttgaac aahagaaa gattcttaa 2280 catgttcctg aaggtgctga gagagcaa ggccttaaac gggagcttca agttcttaga 2340 ttagctaatc atcagctgga taagagaaa gcagaattaa tccatcagat agaagctaac 2400 aaggaccaaa gtggagctga aaggaccata cctgatgctg atcactaaa ggaaaaaata 2460 aagatctag agacacagct caaatgtca gattagaaa agcagcattt gagaggaa 2520 aaagaagc tgaaaaaaga actggaaat ttgatcctt cattttttga agaattgaa 2580 gatcttagt atattacha gggagtg aagaata ttctcttaga aggaaggta 2640 aaaaaacttt cagaacaatt gggagttgaa ttaactagcc ctgttgctgc ttctgagag 2700 tttgaagatg agaagaaag tcctgttaat ttccccattt acta 2745 <210> 26 <211> 2655 <212> DNA <213> Humans (Homo sapiens) <400> 26 atattaacaa aggaaatcaa taaacttgaa ttgaagatca gtgatttcct tgatgaaaat 60 gaggcactta gagagcgtgt gggccttgaa ccaaagacaa tgattgattt aactgaattt 120 agaaatagca aacacttaaa acagcagcag tacagagctg aaaaccagat tcttttgaaa 180 gagattgaaa gtctagagga agaacgactt gatctgaaaa aaaaaattcg tcaaatggct 240 caagaaagag gaaaaagaag tgcaacttca ggattaacca ctgaggacct gaacctagag 300 tccctcagaa tgcaactgct agactatcag gcacagtctg atgaaaagtc gctcattgcc 360 aagttgcacc aacataatgt ctctcttcaa ctgagtgagg ctactgctct tggtaagttg 420 gagtcaatta catctaaact gcaagaagatg gaggcctaca acttgcgctt agagcagaaa 480 cttgatgaaa aagaacaggc tctctattat gctcgtttgg agggaagaaa cagagcaaaa 540 catctgcgcc aaacaattca gtctctacga cgacagttta gtggagcttt acccttggca 600 caacaggaaa agttctccaa aacaatgatt caactacaaa atgacaaact taagataatg 660 caagaaatga aaaattctca acaagaacat agaaatatgg agaacaaaac attggagatg 720 gattaaaat taaagggcct ggagaagtta ataagcactt taaaggatac caaaggagcc 780 caaaaggtaa tcaactggca tatgaaaaata gaagaacttc gtcttcaaga acttaaacta 840 aatcgggaat tagtcaagga taaagaagaa ataaaatt tgaataacat aatttctgaa 900 tatgaacgta caatcagcag tcttgaagaa gaaattgtgc aacagaacaa gtttcatgaa 960 gaagacaaa tggcctggga tcaaagagaa gttgacctgg aacgccaact agacatttt 1020 1080 atccctgacc ctagtttgcc ccttccaaat caacttgaga tcgctctaag gaaattaag 1140 gagaacattc gaataattct agaaacacgg gcaacttgca aatcactaga agaaacta 1200 aaagagaaag aatctgcttt aaggttagca gaacaaaata tactgtcaag agacaagta 1260 atcaatgaac tgaggcttcg attgcctgcc actgcaagaa gagaaagct catagctgag 1320 ctaggcagaa aagagatgga accaaaatct caccacacat tgaaaaattgc tcatcaaacc 1380 1440 cttctagaaa aagccagaga ggagcaaaga gaaattgtga agaaacatga ggaagacctt 1500 catattcttc atcacagatt agaactacag gctgatagtt cactaaataa attcaaacaa 1560 acggcttggg atttaatgaa acagtctccc actccagttc ctaccaacaa gcattttatt 1620 cgtctggctg agatggaaca gacagtagca gaacaagatg actctctttc ctcactcttg 1680 gtcaaactaa agaaagtatc acaagatttg gagagacaaa gagaatcac tgaattaaaa 1740 gtaaaagaat ttgaaaatat caaattacag cttcaagaaa accatgaaga tgaagtgaaa 1800 aaagtaaaag cggaagtaga ggatttaaag tatcttctgg accagtcaca aaaggagtca 1860 cagtgtttaa aatctgaact tcaggctcaa aaagaagcaa attcaagagc tccaacaact 1920 acaatgagaa atctagtaga acggctaaag agccaattag ccttgaagga gaaacaacag 1980 aaagcactta gtcgggcact tttagaactc cgggcagaaa tgacagcagc tgctgaagaa 2040 cgtattattt ctgcaacttc tcaaaaagag gcccatctca atgttcaaca aatcgttgat 2100 cgacatacta gagagctaaa gacacaagtt gaagatttaa atgaaaatct tttaaaaattg 2160 aaagaagcac ttaaaacaag taaaaacaga gaaaactcac taactgata tttgaatgac 2220 ttaataatg aactgcaaaaaaaaaaaa gcctataata aattacttag aggaagag 2280 gaattgaatc agagaatga tgaactgaa agcaatta aagaactaac cagtggatta 2340 cagggcaaac ccctgacaga taaaaaaa agtctaattg aagaactcca aaggaagtt 2400 aaaaaactag agaaccaatt agagggaaag gtgaggaag tagacctaa acctagaaa 2460 gaaaagaatg ctaagaga atttattagg tgggagag gtaaaagtg gcaagccaaa 2520 atagaaggaa ttcgaacaa gttaaagag aaagagggggg aagtctttac ttcaacaag 2580 cagttgaata ctttgaagga tcttttgcc aaagccgata agagaact tactttgcag 2640 Agata aaca 2655 <210> 27 <211> 2013 <212> DNA <213> Humans (Homo sapiens) <400> 27 attack aggaatca taaacttgaa tgagatca gtgatttcct tgatgaaat 60 gaggcactta gagagcgtgt gggccttgaa ccaagacaa tgattgatt aactgaattt 120 agaatagca aacacttaaa acagcagcag tacagagctg aaaaccagat tcttttgaaa 180 gagattgaaa gtctagagga agaacgactt gatctgaaaa aaaaaattcg tcaaatggct 240 caagaaagag gaaaaagaag tgcaacttca ggattaacca ctgaggacct gaacctaact 300 gaaaacattt ctcaaggaga tagataagt gaaagaaaat tggatttatt gagcctcaaa 360 aatatgagtg aagcacaatc aaagaatgaa tttctttcaa gagaactaat tgaaaaagaa 420 agagatttag aaaggagtag gacagtgata gccaaatttc agaataaatt aaaagaatta 480 gttgaagaaa ataagcaact tgaagaaggt atgaaagaaa tattgcaagc aattaaggaa 540 atgcagaaag atcctgatgt taaaggagga gaaacatctc taattatccc tagccttgaa 600 agactagtta atgctataga atcaaagaat gcagaaggaa tctttgatgc gagtctgcat 660 ttgaaagccc aagttgatca gcttaccgga agaaatgaag aattaagaca ggagctcagg 720 gaatctcgga aagaggctat aaattattca cagcagttgg caaaagctaa tttaaagata 780 gaccatcttg aaaaagaaac tagtctttta cgacaatcag aaggatcgaa tgttgttttt 840 aaaggaattg acttacctga tgggatagca ccatctagtg ccagtatcat taattctcag 900 aatgaatatt taatacattt gttacaggaa ctagaaaata aagaaaaaaa gttaaagaat 960 ttagaagatt ctcttgaaga ttacaacaga aaatttgctg taattcgtca tcaacaaagt 1020 ttgttgtata aagaatacct aagtgaaaag gagacctgga aaacagaatc taaaacaata 1080 aaagaggaaa agagaaaact tgaggatcaa gtccaacaag atgctataaa agtaaaagaa 1140 tataataatt tgctcaatgc tcttcagatg gattcggatg aaatgaaaaa aatacttgca 1200 cagtcacaaa aggagtcaca gtgtttaaaa tctgaacttc aggctcaaaa agaagcaaat 1260 tcaagagctc caacaactac aatgagaaat ctagtagaac ggctaaagag ccaattagcc 1320 ttgaaggaga aacaacagaa agcacttagt cgggcacttt tagaactccg ggcagaaatg 1380 acagcagctg ctgaagaacg tattatttct gcaacttctc aaaaagaggc ccatctcaat 1440 gttcaacaaa tcgttgatcg acatactaga gagctaaaga cacaagttga agatttaaat 1500 gaaaatcttt taaaattgaa agaagcactt aaaacaagta aaaacagaga aaactcacta 1560 actgaataatt tgaatgactt aaataatgaa ctgcaaaga aaaaaagc ctataataa 1620 attackgag agaagagg attgatca gagaatgatg aactgaaag gcaattaa 1680 agactacca gtggattaca gggcaaaccc ctgacagata ataaaaag tctattgaa 1740 gaactccaaa ggaagttaaaaactagag aaccaattag agggaaggt ggaggagta 1800 gacctaaac cttagaagaaagaatgct aaagaat taattaggtg ggaagggt 1860 aaaaagtggc aagccaaat agaggatt cgaaaaagt taaaagagaa agaggggga 1920 gtctttactt taacaagca gttgaatact ttgaaggatc ttttgccaa agccgataaa 1980 gagaaactta ctttgcagag gaaaaaaaa 2013 <210> 28 <211> 1716 <212> DNA <213> Humans (Homo sapiens) <400> 28 actgaaaaca tttctcagg agatagata agtgaaagaa aattggattt attgagccctc 60 aaaatatga gtgagcaca atcaagaat gatttctttt cavagaact attgaaaaa 120 gaagagatt tagaaggag taggacagtg atagccaat ttcagaata atttaaagaa 180 ttagttgaag aaaataagca acttgaagaa ggtatgaaag aaatattgca agcaattaag 240 gaaatgcaga aagatcctga tgttaaaagga ggagaaacat ctctaattat ccctagcctt 300 gaaagactag ttaatgctat agaatcaaag aatgcagaag gaatctttga tgcgagtctg 360 catttgaaag cccaagttga tcagcttacc ggagaaatg aagaattaag acaggagctc 420 agggaatctc ggaaagaggc tataaattat tcacagcagt tggcaaaagc taatttaaag 480 atagaccatc ttgaaaaaga aactagtctt ttacgacaat cagaaggatc gaatgttgtt 540 tttaaaggaa ttgacttacc tgatgggata gcaccatcta gtgccagtat cattaattct 600 cagaatgaat atttaataca tttgttacag gaactagaaa ataaagaaaa aaagttaaag 660 aatttagaag attctcttga agattacaac agaaaatttg ctgtaattcg tcatcaacaa 720 agtttgttgt ataaagaata cctaagtgaa aggagacct ggaaaacaga atctaaaaca 780 ataaagagg aaaagagaaa acttgaggat caagtccaac aagatgctat aaaagtaaaa 840 gaatataata atttgctcaa tgctcttcag atggattcgg atgaaatgaa aaaaatactt 900 gcacagtcac aaaaggagtc acagtgttta aaatctgaac ttcaggctca aaagaagca 960 aattcaagag ctccacaac tacaatgaga aatctagtag aacggctaaa gagccaatta 1020 gccttgaagg agaacaaca gaaagcactt agtcggcac ttttagaact cccggcagaa 1080 atgacagcag ctgctgaaga acgtattatt tctgcaactt ctcaaaaga ggcccactc 1140 aatgttcaac aaatcgttga tcgacatact aggagcta agacacaagt tgagattta 1200 aatgaaaatc ttttaaaatt gaaagaagca cttaaaaca gtaaaaacag agaaaactca 1260 ctaactgata atttgaatga cttaaataat gaactgcaa agaaacaaa agcctataat 1320 aaatactta gagagaaga ggaattgat cagagaatg atgaactga aaggcaatt 1380 aaagactaa ccagtggatt acagggcaaa cccctgacag ataataaca aagtctaatt 1440 gagaactcc aaaggaagt taaaaaaacta gagaaccaat taggaggaa ggtggaggaa 1500 gtagacctaa aacctagaa agaaagaat gctaagaag attattag gtgggaagaa 1560 ggtaaaagt ggcaagccaa atagaagga attcgaaca agttaaaaga gaaagagggg 1620 gaagtcttta ctttaacaa gcagttgaat actttgaagg atctttttgc caagccgat 1680 aagaaaaaaaaaaaaaaaaaaaaaaaaaaggcaaaaaaca. <210> 29 <211> 2406 <212> DNA <213> Humans (Homo sapiens) <400> 29 atgccaccta ataaactg gaaagaaata atgaagttg acccagatga cctgccccgt 60 caagagaac tggcagataa tttattgatt tccttatcca aggtggaagt aaatgagcta 120 aaaagtgaaa agcaagaaaa tgtgatacac ctttcagaa ttactcagtc actaatgaag 180 atgaaagctc agaagtgga gctggctttg gagaagtag aaaagctgg agagaacaa 240 gcaaatttg aaatcatt aaaaactaaa gtaatgaac tggaaatga actggagatg 300 gctcagcagt ctgcaggtgg acgagatact cggtttttac gtaatgaat ttgccaactt 360 gaaaaaacat tagaaaaa agatagagaa tggaggaca tggaaagga gttgagaaa 420 gagagaaag ttaatgagca attggctctt cgaatgagg aggcagaaaa tgaaaacagc 480 aaattaagaa gagagaacaa acgtctaaag aaaagaatg aaaaactttg tcaggatatt 540 attgactacc agaaacaaat agattcacag aaagaaacac tttatcaag aagagggggaa 600 actgaaaaca tttctcaagg agatagaata agtgaaagaa aattggattt attgagcctc 660 aaaaatatga gtgaagcaca atcaaagaat gaatttcttt caagagaact aattgaaaaa 720 gaaagagatt tagaaaggag taggacagtg atagccaaat ttcagaataa attaaaagaa 780 ttagttgaag aaaataagca acttgaagaa ggtatgaaag aaatattgca agcaattaag 840 gaaatgcaga aagatcctga tgttaaaagga ggagaaacat ctctaattat ccctagcctt 900 gaaagactag ttaatgctat agaatcaaag aatgcagaag gaatctttga tgcgagtctg 960 catttgaaag cccaagttga tcagcttacc ggagaaatg aagaattaag acaggagctc 1020 agggaatctc ggaaagaggc tataaattat tcacagcagt tggcaaaagc taatttaaag 1080 atagaccatc ttgaaaaaga aactagtctt ttacgacaat cagaaggatc gaatgttgtt 1140 tttaaaggaa ttgacttacc tgatgggata gcaccatcta gtgccagtat cattaattct 1200 cagaatgaat atttaataca tttgttacag gaactagaaa ataaagaaaa aaagttaaag 1260 aatttagaag attctcttga agattacac agaaatttg ctgtattcg tcatcaaca 1320 agtttgttgt aagaata cctaagtgaa aaggacct ggaaaacaga atctaaaaca 1380 aaaagagg aaagagaa acttgaggt caagtccaac aagatgctat aaagtaaa 1440 gatatata atttgctca tgctctcag atggattcgg atgaatgaa aaaatactt 1500 gcagaaaata gtaggaaaat tactgttttg caagtgaatg aaaaatcact tataaggcaa 1560 tatacaacct taggaatt ggcgaaaaaatgaaa gcaaagaat 1620 gattgttgt caatggaggc tgaagttttgt gaaaaatttg gttgtttgca aagatttaag 1680 gaaatggcca ttttcagat tgcagctctc caaaagttg tagatatag tgttttctttg 1740 tctgaactag aactggctaa taacagtac atgactga ctgctaagta caggcacatc 1800 ttgcaaaag atatatgct tgttcaaga acagtact tggacacct ggagtgtgaa 1860 aacatctcct taaagaca agtggagtct aaataag aactggagat taccaggaa 1920 aaacttcaca ctattgaca agcctgggaa caggaacta aattaggtaa tgaatctagc 1980 atggataagg caaagaaatc aataaccaac agtgacattg tttccatttc aaaaaaaata 2040 actatgctgg aaatgaagga attaaatgaa aggcagcggg ctgaacattg tcaaaaaatg 2100 tatgaacact tacggacttc gttaaagcaa atggaggaac gtaattttga attggaaacc 2160 aaatttgctg agcttaccaa aatcaatttg gatgcacaga aggtggaaca gatgttaaga 2220 gatgaattag ctgatagtgt gagcaaggca gtaagtgatg ctgataggca acggattcta 2280 gaattagaga agaatgaaat ggaactaaaa gttgaagtgt caaaactgag agagatttct 2340 gatattgcca gaagacaagt tgaaattttg aatgcacaac aacaatctag ggacaaggaa 2400 gtataa 2406 <210> 30 <211> 1316 <212> PRT <213> Homo sapiens <400> 30 Lys Asn Thr Cys Ile Ile Glu Asp Leu Lys Asn Glu Leu Gln Arg Asn 1 5 10 15 Lys Gly Ala Ser Thr Leu Ser Gln Gln Thr His Met Lys Ile Gln Ser 20 25 30 Thr Leu Asp Ile Leu Lys Glu Lys Thr Lys Glu Ala Glu Arg Thr Ala 35 40 45 Glu Leu Ala Glu Ala Asp Ala Arg Glu Lys Asp Lys Glu Leu Val Glu 50 55 60 Ala Leu Lys Arg Leu Lys Asp Tyr Glu Ser Gly Val Tyr Gly Leu Glu 65 70 75 80 Asp Ala Val Val Glu Ile Lys Asn Cys Lys Asn Gln Ile Lys Ile Arg 85 90 95 Asp Arg Glu Ile Glu Ile Leu Thr Lys Glu Ile Asn Lys Leu Glu Leu 100 105 110 Lys Ile Ser Asp Phe Leu Asp Glu Asn Glu Ala Leu Arg Glu Arg Val 115 120 125 Gly Leu Glu Pro Lys Thr Met Ile Asp Leu Thr Glu Phe Arg Asn Ser 130 135 140 Lys His Leu Lys Gln Gln Gln Tyr Arg Ala Glu Asn Gln Ile Leu Leu 145 150 155 160 Lys Glu Ile Glu Ser Leu Glu Glu Glu Arg Leu Asp Leu Lys Lys Lys 165 170 175 Ile Arg Gln Met Ala Gln Glu Arg Gly Lys Arg Ser Ala Thr Ser Gly 180 185 190 Leu Thr Thr Glu Asp Leu Asn Leu Thr Glu Asn Ile Ser Gln Gly Asp 195 200 205 Arg Ile Ser Glu Arg Lys Leu Asp Leu Leu Ser Leu Lys Asn Met Ser 210 215 220 Glu Ala Gln Ser Lys Asn Glu Phe Leu Ser Arg Glu Leu Ile Glu Lys 225 230 235 240 Glu Arg Asp Leu Glu Arg Ser Arg Thr Val Ile Ala Lys Phe Gln Asn 245 250 255 Lys Leu Lys Glu Leu Val Glu Glu Asn Lys Gln Leu Glu Glu Gly Met 260 265 270 Lys Glu Ile Leu Gln Ala Ile Lys Glu Met Gln Lys Asp Pro Asp Val 275 280 285 Lys Gly Gly Glu Thr Ser Leu Ile Ile Pro Ser Leu Glu Arg Leu Val 290 295 300 Asn Ala Ile Glu Ser Lys Asn Ala Glu Gly Ile Phe Asp Ala Ser Leu 305 310 315 320 His Leu Lys Ala Gln Val Asp Gln Leu Thr Gly Arg Asn Glu Glu Leu 325 330 335 Arg Gln Glu Leu Arg Glu Ser Arg Lys Glu Ala Ile Asn Tyr Ser Gln 340 345 350 Gln Leu Ala Lys Ala Asn Leu Lys Ile Asp His Leu Glu Lys Glu Thr 355 360 365 Ser Leu Leu Arg Gln Ser Glu Gly Ser Asn Val Val Phe Lys Gly Ile 370 375 380 Asp Leu Pro Asp Gly Ile Ala Pro Ser Ser Ala Ser Ile Ile Asn Ser 385 390 395 400 Gln Asn Glu Tyr Leu Ile His Leu Leu Gln Glu Leu Glu Asn Lys Glu 405 410 415 Lys Lys Leu Lys Asn Leu Glu Asp Ser Leu Glu Asp Tyr Asn Arg Lys 420 425 430 Phe Ala Val Ile Arg His Gln Gln Ser Leu Leu Tyr Lys Glu Tyr Leu 435 440 445 Ser Glu Lys Glu Thr Trp Lys Thr Glu Ser Lys Thr Ile Lys Glu Glu 450 455 460 Lys Arg Lys Leu Glu Asp Gln Val Gln Gln Asp Ala Ile Lys Val Lys 465 470 475 480 Glu Tyr Asn Asn Leu Leu Asn Ala Leu Gln Met Asp Ser Asp Glu Met 485 490 495 Lys Lys Ile Leu Ala Glu Asn Ser Arg Lys Ile Thr Val Leu Gln Val 500 505 510 Asn Glu Lys Ser Leu Ile Arg Gln Tyr Thr Thr Leu Val Glu Leu Glu 515 520 525 Arg Gln Leu Arg Lys Glu Asn Glu Lys Gln Lys Asn Glu Leu Leu Ser 530 535 540 Met Glu Ala Glu Val Cys Glu Lys Ile Gly Cys Leu Gln Arg Phe Lys 545 550 555 560 Glu Met Ala Ile Phe Lys Ile Ala Ala Leu Gln Lys Val Val Asp Asn 565 570 575 Ser Val Ser Leu Ser Glu Leu Glu Leu Ala Asn Lys Gln Tyr Asn Glu 580 585 590 Leu Thr Ala Lys Tyr Arg Asp Ile Leu Gln Lys Asp Asn Met Leu Val 595 600 605 Gln Arg Thr Ser Asn Leu Glu His Leu Glu Cys Glu Asn Ile Ser Leu 610 615 620 Lys Glu Gln Val Glu Ser Ile Asn Lys Glu Leu Glu Ile Thr Lys Glu 625 630 635 640 Lys Leu His Thr Ile Glu Gln Ala Trp Glu Gln Glu Thr Lys Leu Gly 645 650 655 Asn Glu Ser Ser Met Asp Lys Ala Lys Lys Ser Ile Thr Asn Ser Asp 660 665 670 Ile Val Ser Ile Ser Lys Lys Ile Thr Met Leu Glu Met Lys Glu Leu 675 680 685 Asn Glu Arg Gln Arg Ala Glu His Cys Gln Lys Met Tyr Glu His Leu 690 695 700 Arg Thr Ser Leu Lys Gln Met Glu Glu Arg Asn Phe Glu Leu Glu Thr 705 710 715 720 Lys Phe Ala Glu Leu Thr Lys Ile Asn Leu Asp Ala Gln Lys Val Glu 725 730 735 Gln Met Leu Arg Asp Glu Leu Ala Asp Ser Val Ser Lys Ala Val Ser 740 745 750 Asp Ala Asp Arg Gln Arg Ile Leu Glu Leu Glu Lys Asn Glu Met Glu 755 760 765 Leu Lys Val Glu Val Ser Lys Leu Arg Glu Ile Ser Asp Ile Ala Arg 770 775 780 Arg Gln Val Glu Ile Leu Asn Ala Gln Gln Gln Ser Arg Asp Lys Glu 785 790 795 800 Val Glu Ser Leu Arg Met Gln Leu Leu Asp Tyr Gln Ala Gln Ser Asp 805 810 815 Glu Lys Ser Leu Ile Ala Lys Leu His Gln His Asn Val Ser Leu Gln 820 825 830 Leu Ser Glu Ala Thr Ala Leu Gly Lys Leu Glu Ser Ile Thr Ser Lys 835 840 845 Leu Gln Lys Met Glu Ala Tyr Asn Leu Arg Leu Glu Gln Lys Leu Asp 850 855 860 Glu Lys Glu Gln Ala Leu Tyr Tyr Ala Arg Leu Glu Gly Arg Asn Arg 865 870 875 880 Ala Lys His Leu Arg Gln Thr Ile Gln Ser Leu Arg Arg Gln Phe Ser 885 890 895 Gly Ala Leu Pro Leu Ala Gln Gln Glu Lys Phe Ser Lys Thr Met Ile 900 905 910 Gln Leu Gln Asn Asp Lys Leu Lys Ile Met Gln Glu Met Lys Asn Ser 915 920 925 Gln Gln Glu His Arg Asn Met Glu Asn Lys Thr Leu Glu Met Glu Leu 930 935 940 Lys Leu Lys Gly Leu Glu Glu Leu Ile Ser Thr Leu Lys Asp Thr Lys 945 950 955 960 Gly Ala Gln Lys Val Ile Asn Trp His Met Lys Ile Glu Glu Leu Arg 965 970 975 Leu Gln Glu Leu Lys Leu Asn Arg Glu Leu Val Lys Asp Lys Glu Glu 980 985 990 Ile Lys Tyr Leu Asn Asn Ile Ile Ser Glu Tyr Glu Arg Thr Ile Ser 995 1000 1005 Serum Leu Glu Glu Glu Ile Val Gln Gln Asn Lys Phe His Glu Glu 1010 1015 1020 Arg Gln Met Ala Trp Asp Gln Arg Glu Val Asp Leu Glu Arg Gln 1025 1030 1035 Leu Asp Ile Phe Asp Arg Gln Gln Asn Glu Ile Leu Asn Ala Ala 1040 1045 1050 Gln Lys Phe Glu Glu Ala Thr Gly Ser Ile Pro Asp Pro Ser Leu 1055 1060 1065 Pro Leu Pro Asn Gln Leu Glu Ile Ala Leu Arg Lys Ile Lys Glu 1070 1075 1080 Asn Ile Arg Ile Ile Leu Glu Thr Arg Ala Thr Cys Lys Ser Leu 1085 1090 1095 Glu Glu Lys Leu Lys Glu Lys Glu Ser Ala Leu Arg Leu Ala Glu 1100 1105 1110 Gln Asn Ile Leu Ser Arg Asp Lys Val Ile Asn Glu Leu Arg Leu 1115 1120 1125 Arg Leu Pro Ala Thr Ala Glu Arg Glu Lys Leu Ile Ala Glu Leu 1130 1135 1140 Gly Arg Lys Glu Met Glu Pro Lys Ser His His Thr Leu Lys Ile 1145 1150 1155 Ala His Gln Thr Ile Ala Asn Met Gln Ala Arg Leu Asn Gln Lys 1160 1165 1170 Glu Glu Val Leu Lys Lys Tyr Gln Arg Leu Leu Glu Lys Ala Arg 1175 1180 1185 Glu Glu Gln Arg Glu Ile Val Lys Lys His Glu Glu Asp Leu His 1190 1195 1200 Ile Leu His His Arg Leu Glu Leu Gln Ala Asp Ser Ser Leu Asn 1205 1210 1215 Lys Phe Lys Gln Thr Ala Trp Asp Leu Met Lys Gln Ser Pro Thr 1220 1225 1230 Pro Val Pro Thr Asn Lys His Phe Ile Arg Leu Ala Glu Met Glu 1235 1240 1245 Gln Thr Val Ala Glu Gln Asp Asp Ser Leu Ser Ser Leu Leu Val 1250 1255 1260 Lys Leu Lys Lys Val Ser Gln Asp Leu Glu Arg Gln Arg Glu Ile 1265 1270 1275 Thr Glu Leu Lys Val Lys Glu Phe Glu Asn Ile Lys Leu Gln Leu 1280 1285 1290 Gln Glu Asn His Glu Asp Glu Val Lys Lys Val Lys Ala Glu Val 1295 1300 1305 Glu Asp Leu Lys Tyr Leu Leu Asp 1310 1315 <210> 31 <211> 514 <212> PRT <213> Homo sapiens <400> 31 Thr Thr Gly Met Thr Val Asp Gln Val Leu Gly Ile Arg Ala Leu Glu 1 5 10 15 Ser Glu Lys Glu Leu Glu Glu Leu Lys Lys Arg Asn Leu Asp Leu Glu 20 25 30 Asn Asp Ile Leu Tyr Met Arg Ala His Gln Ala Leu Pro Arg Asp Ser 35 40 45 Val Val Glu Asp Leu His Leu Gln Asn Arg Tyr Leu Gln Glu Lys Leu 50 55 60 His Ala Leu Glu Lys Gln Phe Ser Lys Asp Thr Tyr Ser Lys Pro Ser 65 70 75 80 Ile Ser Gly Ile Glu Ser Asp Asp His Cys Gln Arg Glu Gln Glu Leu 85 90 95 Gln Lys Glu Asn Leu Lys Leu Ser Ser Glu Asn Ile Glu Leu Lys Phe [[ID=4Gln Leu Glu Gln Ala Asn Lys Asp Leu Pro Arg Leu Lys Asn Gln Val 115 120 125 Arg Asp Leu Lys Glu Met Cys Glu Phe Leu Lys Lys Glu Lys Ala Glu 130 135 140 Val Gln Arg Lys Leu Gly His Val Arg Gly Ser Gly Arg Ser Gly Lys 145 150 155 160 Thr Ile Pro Glu Leu Glu Lys Thr Ile Gly Leu Met Lys Lys Val Val 165 170 175 Glu Lys Val Gln Arg Glu Asn Glu Gln Leu Lys Lys Ala Ser Gly Ile 180 185 190 Leu Thr Ser Glu Lys Met Ala Asn Ile Glu Gln Glu Asn Glu Lys Leu 195 200 205 Lys Ala Glu Leu Glu Lys Leu Lys Ala His Leu Gly His Gln Leu Ser 210 215 220 Met His Tyr Glu Ser Lys Thr Lys Gly Thr Glu Lys Ile Ile Ala Glu 225 230 235 240 Asn Glu Arg Leu Arg Lys Glu Leu Lys Lys Glu Thr Asp Ala Ala Glu 245 250 255 Lys Leu Arg Ile Ala Lys Asn Asn Leu Glu Ile Leu Asn Glu Lys Met 260 265 270 Thr Val Gln Leu Glu Glu Thr Gly Lys Arg Leu Gln Phe Ala Glu Ser 275 280 285 Arg Gly Pro Gln Leu Glu Gly Ala Asp Ser Lys Ser Trp Lys Ser Ile 290 295 300 Val Val Thr Arg Met Tyr Glu Thr Lys Leu Lys Glu Leu Glu Thr Asp 305 310 315 320 Ile Ala Lys Lys Asn Gln Ser Ile Thr Asp Leu Lys Gln Leu Val Lys 325 330 335 Glu Ala Thr Glu Arg Glu Gln Lys Val Asn Lys Tyr Asn Glu Asp Leu 340 345 350 Glu Gln Gln Ile Lys Ile Leu Lys His Val Pro Glu Gly Ala Glu Thr 355 360 365 Glu Gln Gly Leu Lys Arg Glu Leu Gln Val Leu Arg Leu Ala Asn His 370 375 380 Gln Leu Asp Lys Glu Lys Ala Glu Leu Ile His Gln Ile Glu Ala Asn 385 390 395 400 Lys Asp Gln Ser Gly Ala Glu Ser Thr Ile Pro Asp Ala Asp Gln Leu 405 410 415 Lys Glu Lys Ile Lys Asp Leu Glu Thr Gln Leu Lys Met Ser Asp Leu 420 425 430 Glu Lys Gln His Leu Lys Glu Glu Ile Lys Leu Lys Lys Glu Leu 435 440 445 Glu Asn Phe Asp Pro Ser Phe Phe Glu Glu Ile Glu Asp Leu Lys Tyr 450 455 460 Asn Tyr Lys Glu Glu Val Lys Asn Ile Leu Leu Glu Glu Lys Val 465 470 475 480 Lys Lys Leu Ser Glu Gln Leu Gly Val Glu Leu Thr Ser Pro Val Ala 485,490,495 Ala Ser Glu Glu Phe Glu Asp Glu Glu Glu Ser Pro Val Asn Phe Pro 500 505 510 The Tyr <210> 32 <211> 1545 <212> DNA <213> Humans (Homo sapiens) <400> 32 acaactggca tgactgttga tcaggtttg ggaatacgag ctttggagtc agaaaaagaa 60 ttggaagaat taaaaagag aaatcttgac ttagaaatg atatattgta tatgaggcc 120 caccaagctc ttcctcgaga ttctgttgta gaagattac atttacaaaa tagataccctc 180 caagaaaaac ttcatgcttt agaaaaacag ttcaagg attackatattc taagccttca 240 atttcaggaa tagagtcaga tgatcattgt cagagagaac aggagcttca gaaggaaaac 300 ttgaagttgt catctgaaaa tattgaactg aaatttcagc ttgaacaagc aaataaaagat 360 ttgccaagat taaagaatca agtcagagat ttgaaggaaa tgtgtgaatt tcttaagaaa 420 gaaaaagcag aagttcagcg gaaacttggc catgttagag ggtctggtag aagtggaaag 480 acaatcccag aactggaaaa aaccattggt ttaatgaaaa aagtagttga aaaagtccag 540 aagaaaaatg aacagttgaa aaaagcatca ggaatattga ctagtgaaaa aatggctaat 600 attgagcagg aaaatgaaaa attgaaggct gaattagaaa aacttaaagc tcatcttggg 660 catcagttga gcatgcacta tgaatccaag accaaaggca cagaaaaaat tattgctgaa 720 aatgaaaggc ttcgtaaaga acttaaaaaa gaaactgatg ctgcagagaa attacggata 780 gcaaagaata atttagagat attaaatgag aagatgacag ttcaactaga agagactggt 840 aagagattgc agtttgcaga aagcagaggt ccacagcttg aaggtgctga footagagc 900 tggaaatcca ttgtggttac aagaatgtat gaaccaagt taaaagaatt ggaaactgat 960 attgccaaaa aaatcaag cattactgac cttaaacagc tgtaaaga agcaacag 1020 aggaaaaaaaaaaaacaaa gaccttgaaaaaaaaa gattcttaa 1080 catgttcctg aaggtgctga agamgagcaa ggccttaac gggagcttca agttcttaga 1140 ttagctaatc atcagctgga taagagaaa gcagaattaa tccatcagat agaagctaac 1200 aaggaccaaa gtggagctga aaggaccata cctgatgctg atcactaaa ggaaaaata 1260 aaagatctag agacacagct caaatgtca gattagaaa agcagcattt gagaggaa 1320 aaagaagc tgaaaaaaga actggaaat ttgatcctt catttttga agaaattgaa 1380 gatcttagt atattacha ggaagtg aagaata ttctcttag aggaggta 1440 aaaaaacttt cagaacaatt gggagttgaa ttaactagcc ctgttgctgc tctgagag 1500 tttgaagatg agaagaaag tcctgttaat ttccccattt acta 1545 <210> 33 <211> 3948 <212> DNA <213> Humans (Homo sapiens) <400> 33 aagaatactt gtattattga agatttgaaa aatgagctcc aaagaaacaa aggtgcttca 60 accctttctc aacagactca tatgaaaatt cagtcaacgt tagacatttt aaaagagaaa 120 actaaagagg ctgagagaac agctgaactg gctgaggctg atgctaggga aaaggataaa 180 gaattagttg aggctctgaa gaggttaaaa gattatgaat cgggagtata tggtttagaa 240 gatgctgtcg ttgaaataaa gaattgtaaa aaccaaatta aaataagaga tcgagagatt 300 gaaatattaa caaaggaaat caataaactt gaattgaaga tcagtgattt ccttgatgaa 360 aatgaggcac ttagagagcg tgtgggcctt gaaccaaaga caatgattga tttaactgaa 420 tttagaaata gcaaacactt aaaacagcag footcagag ctgaaaacca gattcttttg 480 aaagagattg aaagtctaga ggaagaacga cttgatctga aaaaaaaaat tcgtcaaatg 540 gctcaagaaa gaggaaaaag aagtgcaact tcaggattaa ccactgagga cctgaaccta 600 actgaaaaca tttctcaagg agatagaata agtgaaagaa aattggattt attgagcctc 660 aaaaatatga gtgaagcaca atcaaagaat gaatttcttt caagagaact aattgaaaaa 720 gaaagagatt tagaaaggag taggacagtg atagccaaat ttcagaataa attaaaagaa 780 ttagttgaag aaaataagca acttgaagaa ggtatgaaag aaatattgca agcaattaag 840 gaaatgcaga aagatcctga tgttaaaagga ggagaaacat ctctaattat ccctagcctt 900 gaaagactag ttaatgctat agaatcaaag aatgcagaag gaatctttga tgcgagtctg 960 catttgaaag cccaagttga tcagcttacc ggagaaatg aagaattaag acaggagctc 1020 agggaatctc ggaaagaggc tataaattat tcacagcagt tggcaaaagc taatttaaag 1080 atagaccatc ttgaaaaaga aactagtctt ttacgacaat cagaaggatc gaatgttgtt 1140 tttaaaggaa ttgacttacc tgatgggata gcaccatcta gtgccagtat cattaattct 1200 cagaatgaat atttaataca tttgttacag gaactagaaa ataaagaaaa aaagttaaag 1260 aatttagaag attctcttga agattacaac agaaaatttg ctgtaattcg tcatcaacaa 1320 agtttgttgt ataaagaata cctaagtgaa aggagacct ggaaaacaga atctaaaaca 1380 ataaagagg aaaagagaaa acttgaggat caagtccaac aagatgctat aaaagtaaaa 1440 gatatata atttgctca tgctctcag atggattcgg atgaatgaa aaaatactt 1500 gcagaaaata gtaggaaaat tactgttttg caagtgaatg aaaaatcact tataaggcaa 1560 tatacaacct taggaatt ggcgaaaaaatgaaa gcaaagaat 1620 gattgttgt caatggaggc tgaagttttgt gaaaaatttg gttgtttgca aagatttaag 1680 gaaatggcca ttttcagat tgcagctctc caaaagttg tagatatag tgttttctttg 1740 tctgaactag aactggctaa taacagtac atgactga ctgctaagta caggcacatc 1800 ttgcaaaag atatatgct tgttcaaga acagtact tggacacct ggagtgtgaa 1860 aacatctcct taaagaca agtggagtct aaataag aactggagat taccaggaa 1920 aaacttcaca ctattgaca agcctgggaa caggaacta aattaggtaa tgaatctagc 1980 atggatagg aaagaaatc aaaccaac agtgacattg tttccattc aaaaaaata 2040 actatgctgg aaatgaagga attaaatgaa aggcagcggg ctgaacattg tcaaaaatg 2100 tatgacact tacggactc gttaaagcaa atggaggac gtattttga attggaacc 2160 aaatttgctg agcttaccaa aatcaatttg gatgcacaga aggtggaaca gatgttaaga 2220 gatgaattag ctgatagtgt gagcaaggca gtaagtgatg ctgataggca acggattcta 2280 gaattagaga agaatgaaat ggaactaaaa gttgaagtgt caaaactgag agagatttct 2340 gatattgcca gaagacaagt tgaaattttg aatgcacaac aacaatctag ggacaaggaa 2400 gtagagtccc tcagaatgca actgctagac tatcaggcac agtctgatga aaagtcgctc 2460 attgccaagt tgcaccaaca taatgtctct cttcaactga gtgaggctac tgctcttggt 2520 aagttggagt caattacatc taaactgcag aagatggagg cctacaactt gcgcttagag 2580 cagaaacttg atgaaaaaga acaggctctc tattatgctc gtttggaggg aagaaacaga 2640 gcaaaacatc tgcgccaaac aattcagtct ctacgacgac agtttagtgg agctttaccc 2700 ttggcacaac aggaaaagtt ctccaaaaca atgattcaac tacaaaatga caaacttaag 2760 ataatgcaag aaatgaaaaa ttctcaacaa gaacatagaa atatggagaa caaaacattg 2820 gagatggaat taaaattaaa gggcctggaa gagttaataa gcactttaaa ggataccaaa 2880 ggagcccaaa aggtaatcaa ctggcatatg aaaatagaag aacttcgtct tcaagaactt 2940 aaactaaatc gggaattagt caaggataa gaagaataa aatatttgaa taacataatt 3000 tctgaatatg aacgtacaat cagcagtctt gaagaaa ttgtgcaaca gaacaagttt 3060 catgaaaa gacaaatggc ctgggatcaa agagaagttg acctggaacg ccaactagac 3120 atttttgacc gtcagcaaaa tgaaatacta aatgcggcac aaaagtttga agaagctaca 3180 ggatcaatcc ctgaccctag tttgcccctt ccaaatcaac ttgagatcgc tctaaggaaa 3240 attaaggaga acattcgaat aattctagaa acacgggcaa cttgcaaatc actagaagag 3300 aaactaaaag agaaagaatc tgctttaagg ttagcagaac aaaatatact gtcaagagac 3360 3420 gctgagctag gcagaaaaga gatggaacca aaatctcacc acacattgaa aattgctcat 3480 aaaccattg aaacatgca agcaaggtta aatcaaaaag aagaagtatt aaagagtat 3540 caacgtcttc tagaaaaagc cagagaggag caaagagaaa ttgtgaaa acatgaggaa 3600 gaccttcata ttctcatca cagattagaa ctacaggctg atagttcact aataaattc 3660 aaacaaacgg cttgggatt aatgaacag tctcccactc cagttcctac siacaagcat 3720 tttattcgtc tggctgagat ggaacagaca gtagcagaac aagatgactc tctttcctca 3780 ctcttggtca aactaagaa agtatcacaa gatttggaga gawagaga aatcactgaa 3840 ttaaagtaa aagaatttga aaatcaaa ttacagctc aagaaacca tgaagaatgaa 3900 gtgaaaaaag taaaagcgga agtagaggat ttaaagtatc ttctggac 3948 <210> 34 <211> 2406 <212> DNA <213> Humans (Homo sapiens) <400> 34 atgccaccta ataaactg gaaagaaata atgaagttg acccagatga cctgccccgt 60 caagagaac tggcagataa tttattgatt tccttatcca aggtggaagt aaatgagcta 120 aaaagtgaaa agcaagaaaa tgtgatacac ctttcagaa ttactcagtc actaatgaag 180 atgaaagctc agaagtgga gctggctttg gagaagtag aaaagctgg agagaacaa 240 gcaaatttg aaatcatt aaaaactaaa gtaatgaac tggaaatga actggagatg 300 gctcagcagt ctgcaggtgg acgagatact cggtttttac gtaatgaat ttgccaactt 360 gaaaaaacat tagaaaaa agatagagaa tggaggaca tggaaagga gttgagaaa 420 gagagaaag ttaatgagca attggctctt cgaatgagg aggcagaaaa tgaaaacagc 480 aaattaagaa gagagaacaa acgtctaaag aaaagaatg aaaaactttg tcaggatatt 540 attgactacc agaaacaat agattcacag aagaaacac ttttatcag agagggaa 600 actgaaaaca ttctcagg agatagata agtgaaagaa attggattt attgagccctc 660 aaaatatga gtgagcaca atcaagaat gatttctttt caagaact attgaaaaa 720 gaagagatt tagaaggag taggacagtg atagccaat ttcagaata attaaagaa 780 ttagttgaag aaataagca acttgaagaa ggtatgaag aaatattgca agcaattaag 840 gaatgcaga aagatcctga tgttaaagga ggagaaacat ctctattat ccctagcctt 900 gaagactag ttaatgctat agaatcaag atgcagag gatctttga tgcgagtctg 960 catttgaaag cccaagttga tcagcttacc ggagaaatg aagaattaag acaggagctc 1020 agggaatctc ggaaagaggc tataaattat tcacagcagt tggcaaaagc taatttaaag 1080 atagaccatc ttgaaaaaga aactagtctt ttacgacaat cagaaggatc gaatgttgtt 1140 tttaaaggaa ttgacttacc tgatgggata gcaccatcta gtgccagtat cattaattct 1200 cagaatgaat atttaataca tttgttacag gaactagaaa ataaagaaaa aaagttaaag 1260 aatttagaag attctcttga agattacaac agaaaatttg ctgtaattcg tcatcaacaa 1320 agtttgttgt ataaagaata cctaagtgaa aggagacct ggaaaacaga atctaaaaca 1380 ataaagagg aaaagagaaa acttgaggat caagtccaac aagatgctat aaaagtaaaa 1440 gaatataata atttgctcaa tgctcttcag atggattcgg atgaaatgaa aaaaatactt 1500 gcagaaaata gtaggaaaat tactgttttg caagtgaatg aaaaatcact tataaggcaa 1560 tatacaacct tagtagaatt ggagcgaacaa cttagaaaag aaaatgagaa gcaaaagaat 1620 gaattgttgt caatggaggc tgaagtttgt gaaaaaattg ggtgtttgca aagatttaag 1680 gaaatggcca ttttcaagat tgcagctctc caaaaagttg tagataatag tgtttctttg 1740 tctgaactag aactggctaa taaacagtac aatgaactga ctgctaagta cagggacatc 1800 ttgcaaaaag ataatatgct tgttcaaaga acaagtaact tggaacacct ggagtgtgaa 1860 aacatctcct taaaagaaca agtggagtct ataaataaag aactggagat taccaaggaa 1920 aaacttcaca ctattgaaca agcctgggaa caggaaacta aattaggtaa tgaatctagc 1980 atggataagg caaagaaatc aataaccaac agtgacattg tttccatttc aaaaaaata 2040 actatgctgg aaatgaagga attaaatgaa aggcagcggg ctgaacattg tcaaaaaatg 2100 tatgaacact tacggacttc gttaaagcaa atggaggaac gtaatttga attggaaacc 2160 aaatttgctg agcttaccaa aatcaatttg gatgcacaga aggtggaaca gatgttaaga 2220 gatgaattag ctgatagtgt gagcaaggca gtaagtgatg ctgataggca acggattcta 2280 gaattagaga agaatgaaat ggaactaaaa gttgaagtgt caaaactgag agagatttct 2340 gatattgcca gaagacaagt tgaaatttg aatgcacaac aacaatctag ggacaaggaa 2400 gtataa 2406 <210> 35 <211> 2946 <212> DNA <213> Humans (Homo sapiens) <400> 35 atgcccccaa accaacctg gaagagatt atgaagtgg accctgacga cctgcctaga 60 caggaagaac tggctgacaa cctgctgatc agcctgtcca aggtggaagt gatgagctg 120 aagtctgaga agcaggagaa cgtgatccac ctgttcagaa tcaccagag cctgatgaag 180 atgaggcac aggaggtgga gctggccctg gaggaggtgg agaggcagg agaggcagg 240 gccaagttcg agaatcagct gagaccaaa gtgatgaagc tggaacga gctggagatg 300 gcacagcagt ccgccggagg caggtaca cgctttctgc ggaacgagat ctgccagctg 360 gagaagcagc tggaggagaa ggacagggag ctggaggata tggagaagg gctggagaag 420 gagaagaagg tgaacgagca gctggccctg cgcaatgagg aggccgagaa tgagaatagc 480 aagctgcgga gagaacaa gcggctgaag aagagaacg agcagctgtg ccaggacatc 540 atcgattacc agaagcagat cgactcccag aggagacac tgctgagcag gagggagag 600 gactccgatt atcgcagcca gctgtccaag aagaattacg agctgatcca gtatctggat 660 gagatccaga ccctgacaga ggccaacgag aagatcgagg tgcagaacca ggagatgaga 720 aagaatctgg aggagtccgt gcaggagatg gagagaatga ccgacgagta caacaggatg 780 aaggccatcg tgcaccagac agacaatgtg atcgatcagc tgaagaagga gaacgaccac 840 tatcagctgc aggtgcagga gctgaccgat ctgctgaagt ccaagaatga ggaggacgat 900 cccatcatgg tggccgtgaa cgccaaggtg gaggagtgga agctgatcct gagctccaag 960 gacgatgaga tcatcgagta ccagcagatg ctgcacaacc tgcgcgagaa gctgaagaat 1020 gcccagctgg acgccgataa gagcaatgtg atggcactgc agcagggaat ccaggagagg 1080 gactcccaga tcaagatgct gaccgagcag gtggagcagt ataccaagga gatggagaag 1140 acagagaaca tctctcaggg cgacagaatc agcgagagga agctggatct gctgtccctg 1200 aagaacatgt ccgaggccca gtctaagaat gagttcctgt cccgcgagct gatcgagaag 1260 gagcgggacc tggagcggag ccggacagtg atcgccaagt ttcagaataa gctgaaggag 1320 ctggtggagg agacaagca gctggaggag ggcatgaagg agatcctgca ggccatcaag 1380 gagatgcaga aggacccaga tgtgaagggc ggcgagacaa gcctgatcat cccctctctg 1440 gagcgcctgg tgaacgccat cgagagcaag atgccgagg gcatctttga cgcctccctg 1500 cacctgagg cccaggtgga tcagctgaca ggcgcaatg aggagctgcg gcaggagctg 1560 1620 atcgaccacc tggaagga ggaagcctg ctgcggcagt ctgagggcag caacgtggtg 1680 ttcaagggaa tcgacctgcc agatggaatc gcaccttcta gcgccagcat catcactcc 1740 cagaatgagt acctgatcca cctgctgcag gagctgaga aaggaga gaagctgaag 1800 aatctggagg actctctgga ggattaat agaagtttg ccgtgatcag gcaccagcag 1860 tccctgctgt acaggagta tctgtctgag aaggacat ggagacaga gagcagacc 1920 atchaggagg wagggaag gctggaggac caggtgcagc agggaggc waggtgag 1980 gagtacaaca atctgctgaa cgccctgcag atggactctg atgagatgaa gagatccctg 2040 gccgagaata gcagaaagat cacagtgctg caggtgaacg agaagtccct gatcaggcag 2100 tataccacac tggtggagct ggagcgccag ctgcggaagg agaacgagaa gcagaagaat 2160 gagctgctgt ctatggaggc cgaggtgtgc gagagaatcg gctgtctgca gagattcaag 2220 gagatggcca tctttaagat cgccgccctg cagaaggtgg tggacaattc tgtgagcctg 2280 tccgagctgg agctggccaa caagcagtac aatgagctga ccgccaagta tcgcgacatc 2340 ctgcagaagg ataacatgct ggtgcagcgg acaagcaatc tggagcacct ggagtgcgag 2400 aacatcagcc tgaaggagca ggtggagtcc atcaacaagg agctggagat caccaaggag 2460 aagctggcaca caatcgagca ggcctgggag caggagacaa agctgggcaa tgagtcctct 2520 atggacaagg ccaagaagtc tatcaccaac agcgatatcg tgtctatcag caagaagatc 2580 acaatgctgg agatgaagga gctgaatgag aggcagcgcg ccgagcactg tcagaagatg 2640 tacgagcacc tgagaacatc cctgaagcag atggagaga ggaatttcga gctggagaca 2700 aagtttgccg agctgacaaa gatcaacctg gacgcccaga aggtggagca gatgctgaga 2760 gacgagctgg ccgattccgt gtctaaggcc gtgagcgacg ccgatcggca gagaatcctg 2820 gagctggaga agaacgagat ggagctgaag gtggaggtgt ccaagctgag ggagatctct 2880 gatatcgctc ggcggcaggt ggagattctg aacgcacagc agcagtcacg ggacaaggaa 2940 gtctga 2946 <210> 36 <211> 981 <212> PRT <213> Homo sapiens <400> 36 Met Pro Pro Asn Ile Asn Trp Lys Glu Ile Met Lys Val Asp Pro Asp 1 5 10 15 Asp Leu Pro Arg Gln Glu Glu Leu Ala Asp Asn Leu Leu Ile Ser Leu 20 25 30 Ser Lys Val Glu Val Asn Glu Leu Lys Ser Glu Lys Gln Glu Asn Val 35 40 45 Ile His Leu Phe Arg Ile Thr Gln Ser Leu Met Lys Met Lys Ala Gln 50 55 60 Glu Val Glu Leu Ala Leu Glu Glu Val Glu Lys Ala Gly Glu Glu Gln 65 70 75 80 Ala Lys Phe Glu Asn Gln Leu Lys Thr Lys Val Met Lys Leu Glu Asn 85 90 95 Glu Leu Glu Met Ala Gln Gln Ser Ala Gly Gly Arg Asp Thr Arg Phe 100 105 110 Leu Arg Asn Glu Ile Cys Gln Leu Glu Lys Gln Leu Glu Gln Lys Asp 115 120 125 Arg Glu Leu Glu Asp Met Glu Lys Glu Leu Glu Lys Glu Lys Lys Val 130 135 140 Asn Glu Gln Leu Ala Leu Arg Asn Glu Glu Ala Glu Asn Glu Asn Ser 145 150 155 160 Lys Leu Arg Arg Glu Asn Lys Arg Leu Lys Lys Lys Asn Glu Gln Leu 165 170 175 Cys Gln Asp Ile Ile Asp Tyr Gln Lys Gln Ile Asp Ser Gln Lys Glu 180 185 190 Thr Leu Leu Ser Arg Arg Gly Glu Asp Ser Asp Tyr Arg Ser Gln Leu 195 200 205 Ser Lys Lys Asn Tyr Glu Leu Ile Gln Tyr Leu Asp Glu Ile Gln Thr 210 215 220 Leu Thr Glu Ala Asn Glu Lys Ile Glu Val Gln Asn Gln Glu Met Arg 225 230 235 240 Lys Asn Leu Glu Glu Ser Val Gln Glu Met Glu Lys Met Thr Asp Glu 245 250 255 Tyr Asn Arg Met Lys Ala Ile Val His Gln Thr Asp Asn Val Ile Asp 260 265 270 Gln Leu Lys Lys Glu Asn Asp His Tyr Gln Leu Gln Val Gln Glu Leu 275 280 285 Thr Asp Leu Leu Lys Ser Lys Asn Glu Glu Asp Asp Pro Ile Met Val 290 295 300 Ala Val Asn Ala Lys Val Glu Glu Trp Lys Leu Ile Leu Ser Ser Lys 305 310 315 320 Asp Asp Glu Ile Ile Glu Tyr Gln Gln Met Leu His Asn Leu Arg Glu 325 330 335 Lys Leu Lys Asn Ala Gln Leu Asp Ala Asp Lys Ser Asn Val Met Ala 340 345 350 Leu Gln Gln Gly Ile Gln Glu Arg Asp Ser Gln Ile Lys Met Leu Thr 355 360 365 Glu Gln Val Glu Gln Tyr Thr Lys Glu Met Glu Lys Thr Glu Asn Ile 370 375 380 Ser Gln Gly Asp Arg Ile Ser Glu Arg Lys Leu Asp Leu Leu Ser Leu 385 390 395 400 Lys Asn Met Ser Glu Ala Gln Ser Lys Asn Glu Phe Leu Ser Arg Glu 405 410 415 Leu Ile Glu Lys Glu Arg Asp Leu Glu Arg Ser Arg Thr Val Ile Ala 420 425 430 Lys Phe Gln Asn Lys Leu Lys Glu Leu Val Glu Glu Asn Lys Gln Leu 435 440 445 Glu Glu Gly Met Lys Glu Ile Leu Gln Ala Ile Lys Glu Met Gln Lys 450 455 460 Asp Pro Asp Val Lys Gly Gly Glu Thr Ser Leu Ile Ile Pro Ser Leu 465 470 475 480 Glu Arg Leu Val Asn Ala Ile Glu Ser Lys Asn Ala Glu Gly Ile Phe 485 490 495 Asp Ala Ser Leu His Leu Lys Ala Gln Val Asp Gln Leu Thr Gly Arg 500 505 510 Asn Glu Glu Leu Arg Gln Glu Leu Arg Glu Ser Arg Lys Glu Ala Ile 515 520 525 Asn Tyr Ser Gln Gln Leu Ala Lys Ala Asn Leu Lys Ile Asp His Leu 530 535 540 Glu Lys Glu Thr Ser Leu Leu Arg Gln Ser Glu Gly Ser Asn Val Val 545 550 555 560 Phe Lys Gly Ile Asp Leu Pro Asp Gly Ile Ala Pro Ser Ser Ala Ser 565 570 575 Ile Ile Asn Ser Gln Asn Glu Tyr Leu Ile His Leu Leu Gln Glu Leu 580 585 590 Glu Asn Lys Glu Lys Lys Leu Lys Asn Leu Glu Asp Ser Leu Glu Asp 595 600 605 Tyr Asn Arg Lys Phe Ala Val Ile Arg His Gln Gln Ser Leu Leu Tyr 610 615 620 Lys Glu Tyr Leu Ser Glu Lys Glu Thr Trp Lys Thr Glu Ser Lys Thr 625 630 635 640 Ile Lys Glu Glu Lys Arg Lys Leu Glu Asp Gln Val Gln Gln Asp Ala 645 650 655 Ile Lys Val Lys Glu Tyr Asn Asn Leu Leu Asn Ala Leu Gln Met Asp 660 665 670 Ser Asp Glu Met Lys Lys Ile Leu Ala Glu Asn Ser Arg Lys Ile Thr 675 680 685 Val Leu Gln Val Asn Glu Lys Ser Leu Ile Arg Gln Tyr Thr Thr Leu 690 695 700 Val Glu Leu Glu Arg Gln Leu Arg Lys Glu Asn Glu Lys Gln Lys Asn 705 710 715 720 Glu Leu Leu Ser Met Glu Ala Glu Val Cys Glu Lys Ile Gly Cys Leu 725 730 735 Gln Arg Phe Lys Glu Met Ala Ile Phe Lys Ile Ala Ala Leu Gln Lys 740 745 750 Val Val Asp Asn Ser Val Ser Leu Ser Glu Leu Glu Leu Ala Asn Lys 755 760 765 Gln Tyr Asn Glu Leu Thr Ala Lys Tyr Arg Asp Ile Leu Gln Lys Asp 770 775 780 Asn Met Leu Val Gln Arg Thr Ser Asn Leu Glu His Leu Glu Cys Glu 785 790 795 800 Asn Ile Ser Leu Lys Glu Gln Val Glu Ser Ile Asn Lys Glu Leu Glu 805 810 815 Ile Thr Lys Glu Lys Leu His Thr Ile Glu Gln Ala Trp Glu Gln Glu 820 825 830 Thr Lys Leu Gly Asn Glu Ser Ser Met Asp Lys Ala Lys Lys Ser Ile 835 840 845 Thr Asn Ser Asp Ile Val Ser Ile Ser Lys Lys Ile Thr Met Leu Glu 850 855 860 Met Lys Glu Leu Asn Glu Arg Gln Arg Ala Glu His Cys Gln Lys Met 865 870 875 880 Tyr Glu has Arg Thr Ser Leu Lys Gln with Glu Glu Arg Asn Phe 885,890,895 Glu Leu Glu Thr Lys Phe Ala Glu Leu Thr Lys Ile Asn Leu Asp Ala 900 905 910 Gln Lys Val Glu Gln Met Leu Arg Asp Glu Leu Ala Asp Ser Val Ser 915,920,925 Lys Ala Val Ser Asp Ala Asp Arg Gln Arg With Glu With Glu Lys 930,935,940 Asn Glu Met Glu Leu Lys Val Glu Val Ser Lys Leu Arg Glu Ile Ser 945 950 955 960 Asp With Arg Only Gln Gln Val Val Glu With Leu Asn Only Gln Gln Gln Ser 965,970,975 Arg Asp Lys Glu Val 980 <210> 37 <211> 973 <212> DNA <213> Chicken (Rooster domesticus) <400> 37 gtgagcgggc gggacggccc ttctcctccg ggctgtaatt agcgcttggt ttaatgacgg 60 cttgttctt tctgtggct gcgtgaaagc cttgaggggc tccggggg ccctttgtgc 120 ggggggagcg gctcgggggg tgcgtgcgtg tgtgtgtgcg tggggagcgc cgcgtgcggc 180 tccgcgctgc ccggcggctg tgagcgctgc gggcgcggcg cggggctttg tgcgctccgc 240 agtgtgcgcg aggggagcgc ggccgggggc ggtgccccgc ggtgcggggg gggctgcgag 300 gggaacaaag gctgcgtgcg gggtgtgtgc gtgggggggt gagcaggggg tgtgggcgcg 360 tcggtcgggc tgcaaccccc cctgcacccc cctccccgag ttgctgagca cggcccggct 420 tcgggtgcgg ggctccgtac ggggcgtggc gcggggctcg ccgtgccggg cggggggtgg 480 cggcaggtgg gggtgccggg cggggcgggg ccgcctcggg ccggggaggg ctcgggggag 540 gggcgcggcg gcccccggag cgccggcggc tgtcgaggcg cggcgagccg cagccattgc 600 cttttatggt aatcgtgcga gagggcgcag ggacttcctt tgtcccaaat ctgtgcggag 660 ccgaaatctg ggaggcgccg ccgcaccccc tctagcgggc gcggggcgaa gcggtgcggc 720 gccggcagga aggaaatggg cggggagggc cttcgtgcgt cgccgcgccg ccgtcccctt 780 ctccctctcc agcctcgggg ctgtccgcgg ggggacggct gccttcgggg gggacggggc 840 agggcggggt tcggcttctg gcgtgtgacc ggcggctcta gagcctctgc taaccatgtt 900 catgccttct tctttttcct acagctcctg ggcaacgtgc tggttattgt gctgtctcat 960 cattttggca aag 973 <210> 38 <211> 172 <212> DNA <213> Artificial Sequence <220> <223> Synthetic polynucleotide <400> 38 gaactgaaaa accagaaagt taactggtaa gtttagtctt tttgtctttt atttcaggtc 60 ccggatccgg tggtggtgca aatcaaagaa ctgctcctca gtggatgttg cctttacttc 120 taggcctgta cggaagtgtt acttctgctc taaaagctgc ggaattgtac cc 172 <210> 39 <211> 384 <212> DNA <213> Unknown <220> <223> MBL intron <400> 39 tcagatcgcc tggagacgcc atccacgctg ttttgacctc catagaagac accgggaccg 60 atccagcctc cgcggccggg aacggtgcat tggaacgcgg attccccgtg ccaagagtga 120 cgtaagtacc gcctatagag tctataggcc cacccccttg gcttcttatg catgctatac 180 tgtttttggc ttggggtcta tacacccccg cttcctcatg tttgctgccc gtgaccagca 240 cgtcaacgat tttgtgggca cgggcgacac cgcagtgtag tctgagcagt actcgttgct 300 gccgcgcgcg ccaccagaca taatagctga cagactaaca gactgttcct ttccatgggt 360 cttttctgca gtcaccgtcg ccgc 384
Claims
1. An isolated nucleic acid comprising a transgene, wherein the transgene comprises a nucleic acid sequence encoding a CEP290 fragment operably linked to a promoter, wherein the CEP290 fragment consists of the amino acid sequence shown in SEQ ID NO:
19. 2 . The isolated nucleic acid according to claim 1 , wherein the CEP290 fragment is encoded by a nucleic acid consisting of the sequence shown in SEQ ID NO: 29 or 34. 3 .
3. The isolated nucleic acid of claim 1, wherein the promoter is a CB6 promoter, a CBA promoter or a tissue-specific promoter.
4. The isolated nucleic acid of claim 3, wherein the tissue-specific promoter is an eye-specific promoter.
5. The isolated nucleic acid of claim 4, wherein the eye-specific promoter is a retinoschisis promoter, a K12 promoter, a rhodopsin promoter, a rod-specific promoter, a cone-specific promoter, a rhodopsin kinase promoter, or an interphotoreceptor retinoid binding protein proximal (IRBP) promoter.
6. The isolated nucleic acid of claim 5, wherein the rhodopsin kinase promoter is the GRK1 promoter.
7. The isolated nucleic acid of any one of claims 1 to 6, wherein the transgene is flanked by adeno-associated virus (AAV) inverted terminal repeats (ITRs).
8. The isolated nucleic acid of claim 7, wherein the ITR is an AAV2 ITR.
9. A vector comprising the isolated nucleic acid of any one of claims 1 to 8.
10. The vector according to claim 9, wherein the vector is a plasmid.
11. A host cell comprising the isolated nucleic acid of any one of claims 1 to 8, or the vector of claim 9 or 10.
12. A recombinant adeno-associated virus (rAAV), comprising: (i) capsid protein; and, (ii) The isolated nucleic acid according to any one of claims 1 to 8.
13. The rAAV according to claim 12, wherein the capsid protein is an AAV8 capsid protein or an AAV5 capsid protein.
14. The rAAV of claim 12, wherein the capsid protein is an AAV2, AAV3, AAV4, AAV6, AAV7, AAVrh8, AAV9 or AAV10 capsid protein.
15. The rAAV according to claim 13, wherein the capsid protein comprises the sequence shown in SEQ ID NO:
9.
16. The rAAV of any one of claims 12 to 15, wherein the rAAV is a self-complementary AAV (scAAV).
17. The rAAV of any one of claims 12 to 15, wherein the rAAV is formulated for delivery to the eye.
18. A composition comprising the rAAV of any one of claims 12 to 17, and a pharmaceutically acceptable excipient.
19. Use of a therapeutically effective amount of the isolated nucleic acid of any one of claims 1 to 8, the rAAV of any one of claims 12 to 17, or the composition of claim 18 in the preparation of a medicament for treating an ocular ciliopathy in a subject in need thereof.
20. The use according to claim 19, wherein the ocular ciliopathy is associated with a mutation of the CEP290 gene of the subject or a deletion of the CEP290 gene of the subject.
21. The use according to claim 20, wherein mutation or deletion of the CEP290 gene leads to retinal degeneration, photoreceptor degeneration, retinal dysfunction, retinal pigment epithelial degeneration / dysfunction and / or vision loss.
22. The use according to claim 19, wherein the ocular ciliary disease is Leber's congenital amaurosis (LCA), Joubert syndrome, Bardet-Biedl syndrome, Meckel syndrome, Usher syndrome, nephronophthisis or syndrome.
23. The use according to claim 22, wherein the ocular ciliary disease is Leber's congenital amaurosis (LCA).
24. Use according to claim 23, wherein the LCA is LCA10.
25. The use according to claim 20, wherein the mutation in the CEP290 gene is an intron mutation, a nonsense mutation, a frameshift mutation, a missense mutation or any combination thereof.
26. The use according to claim 25, wherein the subject is a human and the mutation occurs at position c.2991+1655.
27. Use according to claim 26, wherein the mutation is A1655G.
28. The use of any one of claims 19 to 27, wherein administration of the medicament results in delivery of the isolated nucleic acid or rAAV to the eye of the subject.
29. The use according to any one of claims 19 to 27, wherein the medicament is administered via injection.
30. The use according to any one of claims 19 to 27, wherein the medicament is administered subretina of the subject's eye.
31. The use according to any one of claims 19 to 27, wherein the effective amount results in an improvement in photoreceptor (PR) function compared to PR function prior to administration of the medicament.
32. The use according to claim 31, wherein the improvement in PR function is measured by ERG.
33. The use according to claim 32, wherein the ERG comprises scotopic or photopic measurement.
34. A recombinant adeno-associated virus (rAAV) vector comprising an expression cassette comprising a nucleic acid encoding a CEP290 fragment consisting of the amino acid sequence shown in SEQ ID NO: 19, which is operably linked to a promoter, wherein the expression cassette is flanked by adeno-associated virus 2 (AAV2) inverted terminal repeat sequences (ITRs).
35. The rAAV vector according to claim 34, wherein the nucleic acid encoding the CEP290 fragment consists of the sequence shown in SEQ ID NO: 29 or 34.
36. The rAAV vector according to claim 34 or 35, wherein the expression cassette comprises an intron located between the promoter and the nucleic acid sequence encoding the CEP290 fragment consisting of the amino acid sequence shown in SEQ ID NO:
19.
37. The rAAV vector of claim 36, wherein the intron comprises a chicken β-actin intron, a synthetic intron, or an MBL intron.
38. A recombinant adeno-associated virus (rAAV), comprising: (i) a nucleic acid encoding a CEP290 fragment consisting of the amino acid sequence shown in SEQ ID NO: 19 operably linked to a promoter, wherein the expression cassette is flanked by adeno-associated virus 2 (AAV2) inverted terminal repeats (ITRs); and (ii) one or more AAV capsid proteins.
39. The rAAV of claim 38, wherein the one or more AAV capsid proteins are AAV8 capsid proteins or AAV5 capsid proteins.
40. The rAAV of claim 39, wherein the promoter is a rhodopsin kinase (RK) promoter or a chicken β-actin promoter.
41. The rAAV according to any one of claims 38 to 40, further comprising an intron located between the promoter and the nucleic acid sequence encoding the CEP290 fragment consisting of the amino acid sequence shown in SEQ ID NO:
19.
42. The rAAV of claim 41, wherein the intron comprises a chicken β-actin intron, a synthetic intron, or an MBL intron.
